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General Introduction
SOLID ORGAN TRANSPLANTATION
Since the late 50’s, transplantation of
solid organs has become an increasingly
successful therapy for patients suffering
from end-stage organ failure. In the year
2000, more than 13.000 kidneys, almost
5.000 livers, more than 2.000 hearts, and
almost 1.000 lungs were transplanted in
the USA
1. In the Netherlands, 346 cadav-
eric kidneys, 95 livers, 43 hearts and 17
lungs were transplanted in the year 19992.
The short-term results of organ transplan-
tation have significantly increased over
the last decades. This improvement is pri-
marily due to the introduction of new,
more effective, immunosuppressive
agents. Especially the introduction of
cyclosporine A (CsA) in the late 70’s
caused an enormous decrease in morbid-
ity and mortality after solid organ trans-
plantation3,4. Moreover, improved HLA
tissue-typing assays and surgical tech-
niques as well as advances made in do-
nor-organ preservation contributed to the
decreased morbidity and mortality after
solid organ transplantation5-7.
ALLOGRAFT REJECTION
After transplantation of allogeneic
solid organs, grafts can be rejected result-
ing in graft loss in three different ways:
hyperacutely, acutely, and chronically.
Grafts will be hyperacutely rejected if pre-
existing circulating anti-donor-HLA an-
tibodies are present in the recipient at the
time of transplantation. Binding of these
antibodies to HLA-antigens expressed on
donor-endothelium results in severe dam-
age of the graft endothelial cells (EC’s),
and platelet aggregation and complement
activation occurs8. Today, however, po-
tential transplant recipients placed on
waiting-lists are frequently panel-tested
for the presence of circulating anti-HLA
antibodies before transplantation, thereby
minimizing the risk of hyperacute rejec-
tion after transplantation.
Unlike hyperacute rejection, which is an-
tibody-mediated, acute rejection is a cell-
mediated pathological inflammatory re-
sponse, which occurs most frequently in
the first months after transplantation9.
Acute rejection occurs when HLA-mis-
matches between donor and recipient are
present. Because of limitations in the time
of donor-organ preservation as well as the
shortage of donor-organs, prospective
HLA-typing of the donor is not possible
except for kidney grafts. Therefore, the
presence of HLA-mismatches between
donor and recipient can not be prevented,
thereby increasing the risk of acute rejec-
tion. To date, however, acute rejection
episodes can be adequately treated since
new immunosuppressive agents have be-
come available (e.g., CsA and FK506).
Despite the use of these new drugs, how-
ever, it has become clear that clinical
transplantation has not achieved its goals
as a long-term treatment. Long-term suc-
cess has remained at the same level as in
the pre-cyclosporine era, and sofar no
drugs are available that can further extend
graft survival time. Chronic graft dysfunc-
tion (CTD) is now recognized as the pri-
mary cause of allograft loss after the first
year after transplantation10.
CHRONIC TRANSPLANT
DYSFUNCTION
As mentioned above, CTD has be-
come today’s most important cause of late
(>1 year post transplantation) graft fail-12
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ure11,12. In its clinical context, CTD can
be defined as the progressive irreversible
loss of graft function that occurs late in
the post transplant period (months to years
after transplantation)13. Formerly, CTD
was also known as ‘chronic rejection’.
The term ‘rejection’, however, implies the
alloimmune response of the recipient
against the graft to be the basis for the
deterioration in graft function. However,
data have been reported indicating that
also non-alloimmune associated factors
involved in organ transplantation can
cause similar functional and histopatho-
logical changes. Referring the whole pro-
cess to as chronic rejection is therefore
not satisfactory, and as long as the pro-
gressive deterioration in graft function can
not exclusively be attributed to an allo-
immune mediated pathway it is recom-
mended to name the process CTD, leav-
ing any causative factor as yet out of con-
sideration14.
The incidence of CTD after transplan-
tation depends on the type of organ
grafted. Five years after kidney transplan-
tation, 30%-50% of the grafts are lost due
to CTD15,16. After cardiac and lung trans-
plantation, the incidence of CTD is more
than 50% and more than 70%, respec-
tively, five years after transplantation17-21.
In liver transplantation, CTD seems to be
less of a problem compared to kidney,
cardiac, and lung allografts. Five years
after transplantation, the incidence of
CTD after liver transplantation varies
from 3% to 26% depending on the trans-
plant center22-24.
The clinical presentation of CTD de-
pends on the transplanted organ15. CTD
in kidney grafts presents as a progressive
decline in the glomerular filtration rate in
conjunction with increasing plasma crea-
tinine concentrations, proteinuria and ar-
terial hypertension25. In cardiac allografts,
CTD presents itself with myocardial in-
farction, arrhythmia’s and sudden death26-
28, and in liver transplants CTD is clini-
cally characterized by elevation of liver
enzymes and bilirubin in blood29. Finally,
CTD in the transplanted lung is charac-
terized by a decline in pulmonary func-
tion, referred to as bronchiolitis obliter-
ans syndrome (BOS)30.
CHRONIC TRANSPLANT DYSFUNC-
TION ASSOCIATED HISTOPATHO-
LOGY
The histopathological characteristics
associated with CTD depend on the or-
gan that has been transplanted15. CTD in
kidney allografts is characterized by in-
flammation, excessive interstitial fibrosis,
tubular atrophy and glomerular sclerosis,
whereas in cardiac transplants CTD is
characterized by inflammation, fibrosis
and an aggressive form of coronary ar-
tery disease (coronary allograft vasculo-
pathy), that limits survival after transplan-
tation25,28. In liver allografts, CTD is his-
tologically characterized by inflammation
and disappearance of bile ducts and arthe-
ritis (vanishing bile duct syndrome)31,
whereas in lung allografts the presence of
fibroproliferative obliteration of bronchi-
oles (obliterative bronchiolitis) is indica-
tive of CTD32.
The common histomorphological feature
of CTD in solid organ transplants (kid-
ney, heart, and lung) is the development
of transplant vascular sclerosis or trans-
plant arteriosclerosis (TA)9,15, which is,
however, most prominent in cardiac al-13
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lografts17,18. TA is characterized by vas-
cular lesions in the graft that consist of
concentric myointimal proliferation re-
sulting in the development of an occlu-
sive neointima in the arterial structures
of the graft13. The neointima primarily
consists of α-actin positive vascular
smooth muscle (VSM) cells which are
believed to be derived from the vessel
media15. This progressive blood vessel
occlusion could lead to downstream is-
chemic tissue damage and disruptive fi-
brosis, and has therefore generally been
accepted as the main cause of progressive
deterioration in graft function (CTD).
Other findings coinciding with TA include
a persistent focal perivascular inflamma-
tion (perivasculitis), endothelial swelling,
disruption of the internal elastic lamina,
focal myocyte necrosis, foam cell accu-
mulation in the neointima, and presence
of macrophages and T lymphocytes in the
neointimal lesion33,34. In contrast to ordi-
nary atherosclerosis, which is usually fo-
cal and eccentric, the common form of
TA is concentric and generalized. Figure
1 shows a typical example of the histo-
pathological characteristics of CTD in a
cardiac allograft i.e., luminal occlusion
and perivascular inflammation.
Coronary artery
healthy (normal)
A
M
IEL
Coronary artery
transplant arteriosclerosis
B
IEL
NI
MC
IC
Figure 1. Microphotographs of a normal coronary artery (A) and a coronary artery with severe trans-
plant arteriosclerosis (B) in normal rat cardiac tissue and a rat cardiac allograft, respectively. Note the
presence of severe neointima formation containing α-actin positive vascular smooth muscle (VSM)
cells, and perivascular inflammation. Double staining for elastin (internal elastic lamina) and VSM cell
α-actin. Abbreviations: IC, inflammatory cells; IEL, internal elastic lamina; M, media; MC, myocar-
dium; NI, neointima. Magnification x200.14
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ETIOLOGY OF CHRONIC TRANS-
PLANT DYSFUNCTION
The presence of persistent perivascu-
lar inflammation in TA suggests that an
allogeneic injury to the graft vessels is the
prime cause for development of TA. In
1963, Porter et al. already showed pres-
ence of TA in kidney allografts from pa-
tients who had experienced early episodes
of acute rejection35. These results indeed
suggest that the process of TA develop-
ment can evolve from early acute cellu-
lar infiltration of the graft (acute rejec-
tion) to a more chronic inflammatory pro-
cess, eventually resulting in the develop-
ment of TA. However, the etiology of TA
is still poorly defined, and the precise
mechanism(s) of the development of this
vasculopathy still remain obscure. The
pathogenesis of TA seems to be multifac-
torial and both an ongoing alloimmune
response of the host and non-alloantigen
driven tissue-damage of the graft seem to
contribute to the development of TA. Sev-
eral risk factors for the development of
TA have been identified which can rough-
ly be divided in alloantigen dependent
factors (i.e., donor-recipient combina-
tion), donor-related factors, recipient-re-
lated factors, and viral infections.
COMPONENTS INVOLVED IN TRANS-
PLANT ARTERIOSCLEROSIS
Alloantigen dependent risk factors (do-
nor-recipient combination)
Transplant arteriosclerosis is charac-
terized by interstitial and persistent
perivascular inflammation, suggesting
that alloreactivity of host immune cells
against the MHC-incompatible graft plays
an important role in the development of
TA. Several factors supporting the con-
tribution of an alloimmunologic mecha-
nism in the development of TA have been
identified.
Histoincompatibility. The presence of
HLA-disparities between donor and re-
cipient is associated with rejection of the
graft, and long-term graft survival ap-
peared to be strongly correlated with the
presence of HLA-incompatibility be-
tween the donor and the recipient6,36-39.
However, a clear association between the
number of HLA mismatches and the de-
velopment of TA remains a matter of con-
troversy40: studies have been reported
describing a clear association37,41 whereas
others do not42. Using experimental trans-
plant models it has been shown that in the
absence of mismatches (isografts) these
grafts develop no or minor TA after trans-
plantation, suggesting that HLA-incom-
patibility indeed plays a role in the devel-
opment of TA43-45. It is, however, unclear
whether matching of donor and recipient
HLA directly affects the development of
TA  or whether this results from a de-
creased incidence of acute rejection epi-
sodes46,47.
Acute rejection. Although no direct asso-
ciation between the number of HLA-mis-
matches and the development of TA is
observed, one of the most important risk
factors for the development of TA is the
onset, frequency, and severity of acute
rejection episodes after transplantation.
This effect has been demonstrated in
many retrospective studies analyzing all
types of organ transplants42,48-53. These
clinical data have been confirmed by ex-
perimental studies using animal transplant15
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models in rats and rabbits54-56. However,
the occurrence of acute rejection episodes
early after transplantation is not an abso-
lute prerequisite for the development of
TA since development of TA without prior
acute rejection episodes has also been
described in some studies57-59.
Inadequate immunosuppression. Since
acute rejection is associated with the de-
velopment of TA, one might expect that
inadequate immunosuppression to treat
acute rejection episodes is also related to
the development of TA. In several clini-
cal studies it indeed has been shown that
a low dose of maintenance CsA was as-
sociated with CTD38,60,61, whereas in oth-
ers it was not62. Studying human renal al-
lografts, Isoniemi et al. showed that pa-
tients receiving triple-drug immunosup-
pression developed less pronounced CTD
related pathology compared to patients
that received double-drug immunosup-
pression63. These results support the role
of inadequate immunosuppression in the
development of TA. Moreover, in rat stud-
ies it has been shown that high dose CsA
treatment prevents or inhibits develop-
ment of TA after allogeneic aorta trans-
plantation64-67. Although very effective in
rats, in man it would be impossible to
maintain high doses of CsA for prolonged
periods of time because of the nephrotoxic
side-effects68. (See also paragraph Preven-
tion of chronic transplant dysfunction).
Non-compliance of patients may result in
inadequate immunosuppression, and in-
deed it has been shown that also non-com-
pliance is associated with late deteriora-
tion in graft-function69,70.
Anti-donor antigen antibodies. Although
many patients develop antibodies reactive
with donor-HLA antigens and other do-
nor-tissue antigens after transplantation,
a clear correlation between antibodies and
the development of CTD is, however, not
consistently found71-74. After experimen-
tal kidney transplantation in rats, antibod-
ies reactive with glomerular and tubular
basement membranes, mesangial cells
and endothelial cells (EC’s) were found
in sera of allograft recipients75,76. Also af-
ter allogeneic aorta transplantation, donor
reactive antibodies have been found77,78.
The exact role of donor reactive antibod-
ies in the pathogenesis of TA has to be
further explored.
Donor- and recipient-related risk fac-
tors
Although alloreactivity of the host
against the graft appears to be the most
important factor contributing to the de-
velopment of TA, also alloantigen inde-
pendent factors seem to be associated with
the pathogenesis of TA. In the late 60’s it
has been shown that kidney isografts
transplanted between identical twins de-
veloped glomerular and vascular lesions79,
and today several alloantigen independent
risk factors for the development of TA
have been identified80,81.
Donor-related risk factors
Ischemia. Whether or not ischemia plays
an important role in the development of
CTD and TA is still unclear, since both
studies favoring6,82 and discounting83,84 the
effect of ischemia have been described.
In experimental kidney and aorta trans-
plant models in rats, it has been shown
that prolonged ischemic time induces the
development of TA in isografts81,85,86.16
Chapter 1
Moreover, the severity of the vascular le-
sions seems to correlate with the duration
of the ischemic period87,88. Although a
clear effect of ischemia on the develop-
ment of TA in isografts has been de-
scribed, it is less clear whether the length
of the ischemic period plays a role in the
development of TA in allografts.
Brain death. Over the last years it has been
shown that recipients of kidney allografts
from brain dead donors show decreased
long-term graft survival compared to
grafts obtained from living-related and
unrelated donors89. It has been hypothe-
sized that brain death increases the
cytokine induced expression of surface
molecules on peripheral organs, and in
experimental models it has been shown
that brain death indeed activates EC’s and
increases the influx of inflammatory cells
several hours after the induction of brain
death90,91. Moreover, accelerated acute
rejection of kidney and cardiac allografts
in rats has been observed after transplan-
tation of grafts from brain dead donors91,92.
Whether brain death also accelerates the
development of TA has still to be proven.
Donor age. Kidney and cardiac allografts
obtained from older donors have been
found to be associated with poorer sur-
vival rates and show an earlier onset of
CTD18,93.
Recipient-related risk factors
Cytokine gene polymorphisms. Among
organ recipients, transplanted with simi-
lar HLA-incompatible grafts and receiv-
ing similar immunosuppression, variation
exists in both the rejection rate and long-
term outcome. This variation has not been
fully explained, but data indicate that the
immune response to an allograft varies
from one individual to another. In gen-
eral, from an immunological point of
view, different individuals might display
different responses upon stimulation (dif-
ferent responder status). This individual
variation is, at least in part, due to genetic
variation in the regulation of cytokine
gene expression94. High and low cytokine
responses in vitro for TNF-α, TGF-β,
IFN-γ, and IL-10 can be predicted from
an individual’s cytokine genotype95.
Acute rejection of kidney and liver al-
lografts has been shown to correlate with
the presence of the high TNF-α produc-
tion genotype96,97. Also the high IFN-γ and
IL-10 production genotypes have been
correlated with increased acute rejection
after kidney transplantation, however,
also controversial results have been re-
ported96-99.
Also CTD and TA have been shown to
correlate with cytokine genotypes. In sev-
eral studies, presence of the high TGF-β
production genotype has been correlated
with accelerated onset of TA in cardiac
allografts100,101. Also in lung transplanta-
tion, the high TGF-β production genotype
has been shown to be a risk factor for the
development of obliterative bronchioli-
tis102. Taken together, these studies indi-
cate that it might be possible to identify
high and low responders to allografts, and
to predict who will suffer from acute re-
jection and CTD.
Hypertension and hyperlipidemia.
In clinical kidney and heart transplanta-
tion, systemic hypertension has been
shown to be associated with CTD103,104.
Moreover, in experimental kidney trans-
plantation systemic hypertension acceler-17
General Introduction
ates CTD, whereas antihypertensive drugs
inhibit or reduce TA and CTD after kid-
ney and aorta transplantation105-107. Also
hyperlipidemia has been identified as a
risk factor for CTD108, however its role
remains controversial.
Gender and race. Male recipients are
more vulnerable to CTD compared to fe-
male recipients18. This gender effect might
reflect a role for oestrogen, as it has been
shown that oestradiol effectively inhibits
TA after allogeneic aorta transplantation
in rats109. Moreover, long-term graft sur-
vival of cardiac and kidney allografts
seem to be related to race18,110.
Viral infections
Cytomegalovirus (CMV). Studying hu-
man cardiac allografts, Grattan et al. in
1989 for the first time showed a positive
correlation between the presence of cy-
tomegalovirus (positive serology, CMV
inclusion bodies, and positive CMV cul-
ture) and graft atherosclerosis111. Subse-
quently, similar results have been reported
by others112. Also in human kidney, liver,
and lung transplants CMV has been
shown to be related to CTD53,113-115. On the
other hand, also data have been described
indicating that CMV does not contribute
to enhanced CTD after solid organ trans-
plantation116-119. It would be interesting to
investigate whether these different clini-
cal outcomes might be related to differ-
ences in antiviral treatment regimens (e.g.,
prophylactic treatment with antiviral
drugs).
Also in several experimental transplant
models in rats (heart, kidney, liver, and
trachea), using Rat Cytomegalovirus
(RCMV),  data have been collected that
indicate that viral infection accelerates the
development of CTD related pathology120-
123. In the aortic transplant model in rats,
it has been shown that RCMV infection
results in enhancement of both the
perivascular inflammatory response124-126
and neointima formation44,45,126-128. Inhibi-
tion of viral replication and inflammation
using antiviral45,127 and immunosuppres-
sive drugs129, respectively, prevent RCMV
enhanced development of TA, indicating
that CMV indeed may affect the process
of TA development. The exact mechanism
by which CMV is involved in the devel-
opment of TA and CTD is still unclear.
PREVENTION OF CHRONIC TRANS-
PLANT DYSFUNCTION
The standard therapy to prevent acute
rejection in cardiac transplantation is
triple therapy, consisting of cyclosporineA
(CsA), azathioprine, and prednisone130.
CsA is a small fungal peptide that inter-
feres with the synthesis of a variety of
cytokines, particularly IL-2, which is criti-
cal for T cell maturation and clonal ex-
pansion (proliferation), and IFN-γ, which
is critical for macrophage activation131.
Azathioprine is a purine antagonist and
inhibits cell proliferation132. Prednisone is
a corticosteroid and among others influ-
ences the transcription of several genes
thereby inhibiting T cell proliferation133.
This triple therapy is very effective in
treatment of acute rejection episodes,
however CsA therapy has some serious
side-effects. CsA induces severe nephro-
toxicity, and even at minimal effective
concentrations of CsA evidence of ne-
phrotoxicity may be present131. Moreover,
CsA therapy does not prevent develop-
ment of CTD which might be attributed18
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to the fact that CsA directly upregulates
fibrogenic cytokines such as TGF-β134.
Over the last decade, several new immu-
nosuppressive drugs have been developed
of which some are now being used in
clinical practice. FK506 (Tacrolimus) is
more potent than CsA, but has the same
mode of action. Compared to CsA, un-
fortunately FK506 has not been found to
prolong long-term graft survival after kid-
ney transplantation135. Mycophenolate
mofetil (MMF) and Rapamycin (Siroli-
mus) are newly approved immunosup-
pressive drugs both inhibiting T cell pro-
liferation136-138. These new immunosup-
pressive drugs also have side-effects and
appear not to prevent or control CTD.
Several studies in rats have been reported,
however, indicating that treatment of al-
lograft recipients with CsA, rapamycin,
or other immunosuppressive agents can
block the development of CTD related
vasculopathy13.
In addition to immunosuppressive drugs,
polyclonal antibodies specific to T cells,
such as anti-thymocyte globin (ATG) and
anti-CD3 (OKT3), are mainly used as res-
cue therapy resulting in functional T cell
blockade.
Since alloreactive T cells seem to play
an important role in the development of
CTD-related histopathology, it has been
suggested that the key to preventing CTD
involves inducing immunologic tolerance
to the graft139. The creation of  transplan-
tation tolerance would obviate the need
for long-term immunosuppression and
theoretically could prevent CTD. Block-
ade of T cell costimulation pathways not
only results in suppression of the immune
response, but has also been shown to be
effective in inducing antigen-specific
transplantation tolerance in rodents139.
Optimal T cell activation requires both
antigen-specific signals (signal 1, inter-
action TCR-MHC/peptide complex) and
non-antigen-specific, costimulatory, sig-
nals (signal 2)140. The best understood co-
stimulatory pathway is provided through
the T cell surface molecule CD28 and its
ligands CD80 (B7-1) and CD86 (B7-2)
on antigen-presenting-cells (APC’s)141.
Blockade of this costimulatory CD28-B7
pathway early after transplantation by
using CTLA4-Ig fusion protein has been
shown to ameliorate development of TA
and other, graft specific, histopathologi-
cal findings of CTD in cardiac and kid-
ney allografts in rodents142,143. Even block-
ing CD28-B7 mediated T cell costimul-
atory activation late after transplantation,
after initial graft injury, has been shown
to prevent progression of CTD related
histopathology144,145. When CTLA4-Ig
treatment was suboptimal, and antidonor
reactivity (partly) remained, the develop-
ment of TA could not be prevented146-148.
Another T cell costimulatory pathway is
mediated through CD40, expressed on a
variety of cell types including APC’s, B
cells and EC’s), and its ligand CD154
which is expressed on activated T cells139.
Although blockade of the CD40-CD154
pathway using monoclonal antibodies
prolonged graft survival, its effect on the
development of CTD related histopathol-
ogy remains controversial149-151. More-
over, cardiac allografting in CD154-/-
knock-out mice did not reduce the devel-
opment of TA152.
Although both treatment with new
immunosuppressive drugs and blockade
of costimulatory pathways might be (part-
ly) effective in the amelioration of TA,19
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one should remember that in most animal
studies the development of TA is analyzed
several weeks to months after transplan-
tation. Since TA is primarily caused by
alloreactive T cells, it is predictable that
suppressing T cell alloreactivity inhibits
the development of TA. However, in clini-
cal practice, transplant recipients need
long-term treatment with immunosup-
pressive drugs. So far, it is not known
whether the new immunosuppressive
drugs and costimulation blockers only
prevent development of TA on the short-
term, and therefore TA deceleration
should not be confused with TA elimina-
tion13.
Probably all protocols, which do not eli-
minate alloreactivity completely but ra-
ther suppress the immune response
against the graft, will fail to prevent the
eventual development of TA. According
to this view, only those interventions in
which antidonor reactivity is completely
blocked or deleted (i.e., ‘true tolerance’),
e.g., the creation of donor bone marrow
chimeras153-157, will prevent the develop-
ment TA.
PATHOPHYSIOLOGY OF TRANS-
PLANT ARTERIOSCLEROSIS
Although the exact pathogenesis of TA
is unknown, data from clinical and experi-
mental studies suggest that its develop-
ment is an immune-mediated process
modified by nonimmunologic features15.
Despite discrepancies in histopathology
between ordinary atherosclerosis and TA,
the ‘response-to-injury’ paradigm appli-
cable to atherosclerosis and originally
proposed by Ross et al.158,159 has been ac-
cepted widely for the development of TA.
This paradigm proposes that transplant-
related trauma (alloantigen-dependent
and independent) causes activation and
damage of EC’s along the graft arterial
system. Important insults leading to EC
damage may include preservation/is-
chemia injury, reperfusion injury, acute
rejection episodes (i.e., activation allo-
reactive T cells), antibody deposition, and
complement fixation160. The thus dam-
aged and activated endothelium subse-
quently initiates a generalized vascular
repair process that is coordinated by pro-
inflammatory and histogenic factors pro-
duced by the activated EC’s itself as well
as vessel wall parenchymal cells and in-
flammatory cells. Moreover, the immune
response characterized by perivascular
inflammation induces further low-grade
damage to the vascular endothelium. This
cascade of events eventually results in
replication of VSM cells in the vascular
wall, influx of VSM cells from the media
into the subendothelial space (intima), and
generation of the neointimal lesion15. So,
according to this working hypothesis graft
endothelium seems to be one of the key
players in the development of TA.
Activation of graft endothelium
Endothelial cells play an impor-
tant role in recruiting lymphocytes into
sites of inflammation by molecular adhe-
sion events. Upon stimulation, graft en-
dothelium upregulates the expression of
adhesion molecules, thereby increasing
interactions between polymorphonuclear
neutrophils (PMN’s) and lymphocytes,
and EC’s. Important adhesion molecules
expressed by activated EC’s are E-selec-
tin, P-selectin, VCAM-1 and ICAM-1161..
Moreover, several chemokines produced
by both endothelium and interstitial cells20
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(e.g., interleukin (IL)-8, MCP-1, MIP-1α,
MIP-1β, and RANTES) can promote the
binding of lymphocytes and macrophages
to endothelium162,163.
The initial damage to the graft endothe-
lium, caused by alloantigen independent
factors (such as ischemia/reperfusion in-
jury and brain death, resulting in infiltra-
tion of free-oxygen radical producing
PMN’s), may be followed by influx of ma-
crophages into the subendothelial space
which may subsequently be activated by
IFN-γ. Activated macrophages produce a
number of inflammatory mediators in-
cluding IL-1, IL-6, IFN-γ, TNF-α and the
chemokines IL-8, MCP-1, MIP-1α, MIP-
1β. These cytokines and chemokines in
turn further activate the graft endothelium
and increase the expression of adhesion
molecules, thereby attracting more mac-
rophages and lymphocytes in a positive
feedback loop164. Thus, as a result of the
transplant procedure, a complete network
of cytokines is already activated, even
before the allogeneic reactions develop.
In addition to its capability to attract
and activate macrophages, graft endothe-
lium can activate alloreactive T cells by
the direct  allorecognition pathway of an-
tigen presentation. Nominal antigens are
recognized as peptides, presented to (self-
restricted) T cells by self-MHC molecules
(indirect pathway)165. However, direct
allorecognition implies that a T cell rec-
ognizes foreign MHC molecules per se
independent of the peptide present in the
groove of this MHC molecule166. In vitro
studies have demonstrated that EC’s ex-
press both MHC class I and II antigens
upon stimulation with IFN-γ and are able
to directly stimulate allogeneic T cells167-
169. In addition to MHC molecules, EC’s
also express costimulatory molecules
which are necessary to induce full T cell
activation. The best defined of these mol-
ecules is LFA-3, which interacts with T
cell CD2170,171. Once activated, T cells pro-
duce leukotrienes and several cytokines
including IL-1, IL-4, IFN-γ, TNF-α, and
TGF-β, which increases the expression of
E-selectin, ICAM-1 and VCAM-1 on
graft endothelium172,173. Moreover, TNF-
α and IFN-γ further increase the expres-
sion of MHC class I and II on graft EC’s.
This cross-talk between lymphocytes and
EC’s suggests that a positive feedback
loop may be established.
One central element of the TA para-
digm is that smooth muscle cells from the
vessel media are the progenitors of the
neointima, i.e. medial VSM cells are sup-
posed to migrate from the media to the
intima in response to activation by cyto-
kines and growth factors15. The ongoing
perivascular response induces persistent
low-grade damage to the graft endothe-
lium, which in turn begins to secrete
growth factors to repair the damage. Upon
activation, EC’s have been shown to pro-
duce multiple growth factors such as
PDGF, IGF-1, bFGF, and TGF-β as well
as pro-thrombotic molecules (tissue fac-
tor and plasminogen activator inhibitor)
and metabolic products such as prostag-
landins, nitric oxide, and low-density li-
poproteins15,159. Also activated T cells
and macrophages produce a range of these
factors. The ‘response-to-injury’ para-
digm now implies that these factors to-
gether induce migration of VSM cells to
the intima, during which they transform
their phenotype from ‘contractile’ to
‘secretory’ and the cells become capable
of replication159.21
General Introduction
DONOR VS. RECIPIENT ORIGIN OF
NEOINTIMAL CELLS IN TRANS-
PLANT ARTERIOSCLEROSIS
Transplant arteriosclerosis consists of
progressive concentric intimal thickening
coinciding with ongoing perivascular in-
flammation. Current thinking on the pro-
cess of TA holds that in response to
cytokines, growth factors and other in-
flammatory mediators produced by in-
flammatory cells and damaged/activated
graft endothelium, donor-derived medial
vascular smooth muscle (VSM) cells of
affected arteries start to proliferate and
migrate from the media into the suben-
dothelial space just beneath the endothe-
lial cell layer174-176. According to this con-
cept, neointimal EC’s and VSM cells in
TA originate from graft tissue and there-
fore should be donor-derived. Figure 2
shows a schematic representation of the
hypothetical migration of donor medial
VSM cells into the subendothelial space
in response to the ongoing perivascular
inflammation, resulting in obliteration of
the vascular lumen eventually.
 However, if the neointimal EC’s and
VSM cells do indeed originate from the
donor, they should  demonstrably be graft
derived. Already in the early 60’s, Wood-
ruff177 and Medawar178 proposed that re-
placement of graft endothelium with host-
derived EC’s might be the reason why
long-term allograft survivors experience
relatively few rejection episodes (i.e.,
graft adaptation). Since then, several
groups studied whether EC’s covering the
luminal surface of the graft vessels after
transplantation are indeed of donor-ori-
gin or had been replaced by host-derived
EC’s. Donor-origin of the graft vessels
endothelium is supported by findings re-
ported by several groups179-182. However,
also repopulation of graft vessels by host-
derived EC’s has been reported183-187, sug-
inflammatory cells
vascular smooth muscle cells (VSM cells)
endothelial cells (EC's)
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Figure 2. Current paradigm on the development of intimal hyperplasia in transplant arteriosclerosis.22
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gesting heterogeneity of the underlying
processes.
Only few studies have addressed the
question whether the neointimal VSM
cells in TA are indeed graft-derived. Do-
nor-origin of neointimal VSM cells has
been described in human solid organ
transplants, favoring the current paradigm
that neointimal VSM cells are derived
from the graft’s media182,188. Alternatively,
data exist indicating that also the host
might give rise to α-actin positive VSM
cells which are derived from the blood-
stream. Studying Dacron-hubs implanted
in the aorta of young pigs, Stump et al.
showed that these hubs were covered with
EC’s and VSM-like cells which originated
from cells in the blood189. Moreover, im-
plantation of biodegradable compliant
vascular grafts in rats show development
of new vascular wall structures, includ-
ing a neomedia (with α-actin positive
VSM cells) and a neointima (with
EC’s)190-192. In the Dacron-hubs as well as
the synthetic biodegradable vascular
grafts, the EC’s and VSM cells should by
definition be host-derived, indicating that
EC’s and VSM cells can originate from
the host. Some data have been reported
suggesting that host-derived VSM cells
also contribute in the process of neointima
formation after organ transplantation.
Plissonnier et al. showed that neointimal
VSM cell proliferation and medial VSM
cell disappearance in rat aortic allografts
start at the same time. According to the
TA paradigm, the medial VSM cells now
migrate to the intima, resulting in an acel-
lular media and the formation of a neo-
intima. Légaré et al. demonstrated that
there is a striking loss of medial VSM
cells by apoptotic cell death even before
the development of a neointima193. It
seems therefore at least a bit contradic-
tory that the VSM cells proliferate at one
side (neointima) and die by apoptosis at
another, nearby, side. Moreover, if migra-
tion should be the only mechanism by
which medial VSM cells disappear from
the media, one could wonder why all
medial VSM cells migrate to the intima
since then a dramatic loss of vascular wall
function is warranted.
So, a major role for the media-derived
VSM cells in the process of neointima
formation seems unlikely. In their study,
Plissonnier et al. indeed showed by FACS
analysis using allo-antisera the neointimal
VSM cells to be of host-origin and not of
donor-origin77. However, neointimal
VSM cells and neointima infiltrating host-
derived inflammatory cells could not be
distinguished due to the procedure they
used.
Based on the observations that new
vascular wall structures develop after
implantation of biodegradable vascular
grafts, as well as the notion that medial
VSM cells disappear before neointimal
VSM cells appear, we hypothesized that,
analogous to the development vascular
wall structures in biodegradable grafts, the
development of TA in allogeneic grafts is
in principal the same implying that
neointimal EC’s and VSM cells are host-
derived194.
Although some data on the origin of
neointimal cells have become available
in the past years, no conclusive results
have been described on the origin of EC’s
and VSM cells after solid organ transplan-
tation so far.23
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AIM OF THE THESIS
Chronic transplant dysfunction (CTD)
has become today’s most important cause
of late  graft failure and cannot be pre-
vented by current immunosuppressive
protocols. CTD can be defined as the pro-
gressive irreversible loss of graft function
that occurs months to years after trans-
plantation. Irrespective of the organ
grafted (kidney, heart, liver, lung), graft
vessels eventually develop so-called
transplant arteriosclerosis (TA) consisting
of concentric intimal thickening (neoin-
tima formation) coinciding with ongoing
perivascular inflammation. Pathogenesis
of TA seems to be multifactorial, but pre-
cise mechanisms involved in the devel-
opment of this remodeling process still
remain obscure. Both alloantigen-depen-
dent factors (e.g. histoincompatibility,
acute rejection, and inadequate immuno-
suppression) as well as alloantigen-inde-
pendent factors (e.g. ischemia, brain death
and cytomegalovirus infection) have been
identified as probable risk factors for the
development of TA.
Current thinking on the process of TA
holds that in response to cytokines,
growth factors and other inflammatory
mediators produced by activated endo-
thelium and inflammatory cells, donor-
derived medial VSM cells start to prolife-
rate and migrate into the subendothelial
space. This response-to-injury with time
results in occlusion of the vascular lumen,
eventually leading to progressive deterio-
ration of graft function.
The introduction of this thesis (Chap-
ter 1) presents the clinical and histopatho-
logical hallmarks of CTD after solid or-
gan transplantation. Moreover, risk fac-
tors for the development of CTD are de-
scribed. The current paradigm of the de-
velopment of TA is discussed and the cas-
cade of pathological events leading to TA
is presented.
In the subsequent chapters of this the-
sis a series of experiments is described in
which several aspects of the pathophysi-
ology of TA after allogeneic organ trans-
plantation are addressed. First we intro-
duced and validated several experimen-
tal transplant models in rats, and analyzed
their applicability to study development
of TA (Chapters 2, 3, and 4).
Alloreactivity of the host immune system
against the graft seems to be one of the
key factors in the pathogenesis of TA.
Theoretically, inducing transplant toler-
ance, and thereby abolishing alloreac-
tivity against the graft, might be a pos-
sible strategy to prevent the development
of TA. Intrathymic (IT) immune modula-
tion has been shown to significantly pro-
long graft survival of MHC-incompatible
cardiac allografts in rats. In Chapter 2 we
studied whether induction of hyporespon-
sivess by IT immune modulation prevents
the development of TA after allogeneic
heart transplantation in rats.
Since transplantation of a vascular cardiac
allograft is a rather complicated and time-
consuming operational technique, we ana-
lyzed in Chapter 3 whether a more sim-
plified model could be used to study IT
immune modulation in rats after alloge-
neic organ transplantation. Therefore,
neonatal cardiac tissue was transplanted
subcutaneously in the ear-pinnae of adult
recipient rats. Moreover, development of
vascular lesions in neonatal cardiac allo-
grafts transplanted in the ear-pinnae of IT
immune modulated rats was analyzed.
In Chapter 4 we describe a series of expe-24
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riments in which we used the aortic trans-
plant model in rats which is a well-de-
scribed and reproducible model to study
development of TA. We studied the ef-
fect of several risk factors for the devel-
opment of TA. In clinical organ transplan-
tation variation exists in both the rejec-
tion rate and long-term outcome among
organ recipients transplanted with simi-
lar HLA-incompatible grafts and receiv-
ing similar immunosuppression. Data in-
dicate that the immune response to an al-
lograft varies from one individual to an-
other, and these variations might be in-
volved in the different long-term outcome.
We  therefore analyzed the severity and
kinetics of TA development in several rat
strain combinations, representing recipi-
ents with different immune responses to
an allograft.
Cytomegalovirus (CMV) appears to be a
risk factor for the development of accel-
erated and enhanced TA. Using Rat CMV
(RCMV), we analyzed whether additional
RCMV infection after allogeneic aorta
transplantation in different strain combi-
nations enhanced the development of TA.
Moreover, the effect of timing of RCMV
infection of the donor or recipient on the
development of TA was analyzed.
Since considerable differences exist in the
kinetics of the development of TA in dif-
ferent rat strains (Chapter 4), we further
analyzed which factors might be respon-
sible for this observation. Using MHC-
congenic rat strains we therefore studied
in Chapter 5 the kinetics of the develop-
ment of TA after aortic transplantation. In
addition, we used bone marrow chimeric
rats to study whether allogeneic bone
marrow transplantation between high and
low TA responders altered the severity
of TA development in aortic allografts.
According to the current paradigm of
the development of TA, the neointimal
EC’s and VSM cells originate from graft
tissue and therefore should be donor-de-
rived. Sufficient experimental evidence
supporting this paradigm is, however,
lacking, and we hypothesized that the
neointimal EC’s and VSM cells are not
donor but recipient-derived194. Knowing
the exact origin of these neointimal cells
might have implications for the develop-
ment of new strategies to prevent or ame-
liorate TA. To test this hypothesis, a se-
ries of experiments in which we studied
the origin of neointimal EC’s and VSM
cells was performed and results are des-
cribed the second part of this thesis (Chap-
ters 6, 7 and 8).
We analyzed the origin of neointimal
EC’s and VSM cells in aortic and cardiac
allografts (Chapters 6 and 7). The origin
of EC’s was determined using MHC class
I haplotype specific immunohistochem-
istry, whereas the origin of neointimal
VSM cells was determined using a PCR
based analysis which was sufficiently sen-
sitive to detect host-derived cells at the
single cell level.
Since we showed that the neointimal EC’s
and VSM cells are of host-origin and not
of donor-origin, the question remained
what the anatomical origin of the host-
derived EC’s and VSM cells is: ingrowth
from the recipient side of anastomosis or
derived from recirculating, possibly bone
marrow derived, progenitor cells. To ad-
dress this question, we analyzed in Chap-
ter 8 the anatomical origin (bone marrow
vs. non-bone marrow) of the host-derived
EC’s in TA in aortic allografts transplanted
in bone marrow chimeric rats using con-
focal laserscanning microscopy (CLSM).
In Chapter 9, all data are discussed in25
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their context and a concluding view on
the development of TA is given.
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Abstract
Background.  We showed previously that our intrathymic immune modulation proto-
col induces virtually permanent graft survival of simultaneously transplanted cardiac
allografts in MHC-incompatible rat strain combinations. It is, however, unknown
whether this procedure prevents the development of graft arterial disease (GAD).
Methods.  Male AO recipient rats were intrathymically inoculated with 2.5x107 PVG
splenocytes immediately followed by heterotopic transplantation of a PVG cardiac
allograft (day 0). Immunosuppression consisted of 1 ml of antilymphocyte serum i.p.
(day 0) and cyclosporine i.m. (15 mg/kg body weight) on days 1, 2, and 3
posttransplantation. Histological analysis, mixed lymphocyte reactions, and intragraft
cytokine mRNA expression were performed at several time points after engraftment.
Results. Histological analysis revealed that GAD was already present 14 days after
transplantation. At 200 days, virtually all vessels were affected and over 80% of the
vessels showed severe intimal lesions. Infiltrate analysis displayed massive paren-
chymatous infiltrates (CD8+ cells and ED1+ macrophages) 2 weeks after transplanta-
tion. At later time points, infiltrates became epicardial and/or blood vessel associated
and mainly consisted of CD4+, CD8+,  and B cells. Mixed lymphocyte reactions showed
non-specifically decreased responses at 60 days but complete restoration of these
responses at later time points (120 to 280 days). Intragraft cytokine mRNA expres-
sion showed decreased interleukin-2/interferon-γ and sustained interleukin-10 expres-
sion 2 weeks after transplantation. Transforming growth factor-β mRNA expression
was increased >200 days after transplantation.
Conclusions. Intrathymic immune modulation does not abolish alloreactivity, and
despite induction of long-lasting graft survival, this procedure does not prevent and
may even facilitate the development of GAD.41
Intrathymic immune modulation and transplant arteriosclerosis
Introduction
Despite the use of potent immunosuppres-
sive agents and the fact that nowadays
clinical organ transplantation has almost
become a routine procedure, the devel-
opment of chronic transplant dysfunction
(CTD) is the most common cause of long-
term allograft loss1,2. Three years after
transplantation, 4% to 17% of liver trans-
plants, 20% to 50% of renal transplants,
30% to 40% of cardiac transplants, and
>50% of lung transplants show functional
deterioration and histologic changes char-
acteristic of CTD3,4. The most important
risk factor in the pathogenesis of CTD is
histoincompatibility between donor and
recipient, which leads to alloreactivity
directed against the graft5. However, sev-
eral other risk factors in the pathogenesis
of CTD have been identified, e.g., pro-
longed cold ischemia time and cytome-
galovirus infection2. The most remarkable
feature of CTD is the development of graft
arterial disease (GAD), also referred to
as transplant arteriosclerosis. This form
of vasculopathy is characterized by peri-
vascular inflammation, thinning of the
vascular media (myocyte necrosis), focal
breaks in the internal elastic lamina (IEL),
and a generalized concentric intimal
thickening, consisting of vascular smooth
muscle (VSM) cells intermingled with T
cells and macrophages2.
Because alloreactivity directed against the
graft is the most important contributing
factor in the development of CTD, induc-
tion of specific hyporesponsiveness to
donor antigens would be the obvious so-
lution to overcome the problems associ-
ated with this pathology. Specific hypo-
responsiveness to allografts can be ob-
tained by intrathymic (IT) inoculation of
donor-type lymphoid cells. After Posselt
et al.6 showed for the first time that IT
inoculation of islets of Langerhans medi-
ates the acceptance of transplanted islets
120 days later under the kidney capsule,
several other groups demonstrated that
this procedure could also be used to in-
duce hyporesponsiveness to cardiac7,
liver8, renal9, and small bowel allografts10
in rats and mice. In all of these protocols,
a time lag between IT inoculation and the
actual transplantation was needed. With
a modification of the protocols described
above, we were able to start induction of
functional tolerance, i.e., prolonged graft
survival, and perform transplantation on
the same day. This protocol results in
long-lasting graft survival of cardiac al-
lografts in the MHC-incompatible PVG
to AO rat strain combination11. So, IT in-
oculation of donor-derived antigens pre-
vents (acute) rejection and prolongs graft
survival.
However, most studies in which IT im-
mune modulation protocols have been
used to prolong graft survival do not re-
port on the effect of IT inoculation on the
development of CTD and/or GAD after
allografting. As a result, few data are
available describing the inhibitory effect
of IT induction of donor-specific hypo-
responsiveness on the development of
GAD12-14. These studies have been per-
formed in the Lewis (Lew) to F344 rat
strain combination, which is an estab-
lished rat model, to study the pathogene-
sis of CTD and GAD after cardiac and
renal allografting. In this model, only
short-term treatment with CsA is needed
to prevent acute rejection of the allografts,
and vascular lesions characteristic of CTD
develop spontaneously15,16. Although the
authors claim that in this model GAD can42
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be prevented by IT induction of donor-
specific hyporesponsiveness, note that the
Lew and F344 strains are MHC compat-
ible and only differ in minor histocom-
patibility antigens.
In this study, we investigated the effect of
IT immune modulation on the develop-
ment of GAD in a fully MHC-incompati-
ble rat strain combination. Our results
clearly show that despite induction of vir-
tually permanent graft survival, IT inocu-
lation of donor splenocytes does not pre-
vent, and may even facilitate, the devel-
opment of CTD-related vasculopathy in
the MHC-disparate PVG to AO rat strain
combination.
Materials and Methods
Animals
Specific pathogen-free male AO (RT-1u)
and female PVG (RT-1c) rats were ob-
tained from the Central Animal Facility
of the faculty of Medical Sciences of the
University of Groningen. PVG and AO
rats were age matched, 7 to 10 weeks of
age, and used as donors and recipients,
respectively. Rats were maintained under
clean conventional conditions and fed
with standard rat chow and acidified wa-
ter ad libitum. All animals received hu-
mane care in compliance with the Prin-
ciples of Laboratory Animal Care (Na-
tional Institutes of Health, publication
No.86-23, revised 1985) and the Dutch
law on experimental animal care.
Cardiac Transplantation and IT Immune
Modulation
Cardiac transplantation and IT immune
modulation were accomplished by a pro-
tocol developed in our laboratory as de-
scribed elsewhere11. Briefly, under hal-
othane inhalation anesthesia, partial
sternotomy was performed, and 2.5x107
PVG splenocytes were injected into the
recipient’s (AO) thymus. Subsequently,
the PVG heart was heterotopically trans-
planted into the right side of the neck.
Total ischemic time was consistently less
than 20 minutes, during which time the
graft was kept on ice. All grafts started
beating promptly after revascularization,
and graft function was assessed regularly
by palpation. Graft rejection was defined
as complete cessation of palpable ven-
tricular contraction.
Immunosuppression
Immediately after cardiac transplantation
(day 0) 1 ml of rabbit anti-rat lympho-
cyte serum (ALS, Accurate Chemical
Corp., Westbury, NY) was injected intra-
peritoneally. Cyclosporine (CsA, Sandoz
Pharma AG, Basel, Switzerland) was in-
jected intramuscularly on days 1, 2, and
3 posttransplantation (15 mg/kg body
weight).
Experimental Design
Rats with a beating graft were killed at
several timepoints after transplantation to
sequentially investigate the histological
changes in cardiac transplants after IT in-
oculation of donor splenocytes. Control
animals consisted of rats that received a
cardiac isograft (only ALS and CsA treat-
ment, no IT inoculation) and rats that re-
ceived an allograft without further treat-
ment (acute rejection). The control rats
were killed 250 days (isografts) and 4
days posttransplantation (acute rejection).
Also, control grafts were beating at the
time of removal. The experimental groups
are listed in Table 1. In addition to evalua-43
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tion of cardiac histology, intragraft cyto-
kine mRNA expression was determined
in some of the grafts with semi-quantita-
tive reverse transcriptase-polymerase
chain reaction (RT-PCR) analysis. In ad-
dition, one-way mixed lymphocyte reac-
tions (MLR) using peripheral blood
mononuclear cells (PBMC) were per-
formed at two timepoints (60 days and
120 to 280 days) after IT inoculation to
assess sustained alloreactivity against
donor antigens in vitro.
Histological Analyses
At the time of euthanization, explanted
grafts were divided into four parts, two
were fixed in Bouin’s fixative and embed-
ded in paraffin and the other two were
embedded in Tissue-Tek (OCT com-
pound, Miles Inc., Elkhart, IN), snap-fro-
zen in liquid nitrogen, and stored at -80￿C
until analysis. In addition, a tissue sample
of some grafts was immediately frozen
in liquid nitrogen and stored at -80￿C un-
til RNA isolation and cytokine RT-PCR
was performed.
Presence of graft-infiltrating leukocytes
was determined with a routine hematoxy-
lin and eosin staining on paraffin sections.
Furthermore, the distribution of different
leukocyte subsets was determined with an
indirect immunoperoxidase-staining tech-
nique on cryostat sections. A panel of dif-
ferent monoclonal antibodies (Table 2)
was used to differentiate between the vari-
ous leukocyte subsets. Cryosections were
acetone fixed (10 min, room temperature),
air dried, and incubated with phosphate-
buffered saline (PBS) (0.05M, pH 7.6)
that contained 2% bovine serum albumin
for 10 min. Sections were rinsed in wash-
ing buffer (PBS/0.1% Tween 20) and in-
cubated with the primary antibody for 60
minutes. Subsequently, sections were
rinsed in washing buffer and incubated
with a second-step horseradish peroxi-
dase-conjugated rabbit anti-mouse anti-
body (DAKO A/S, Glostrup, Denmark)
for 30 min. After several rinses in wash-
ing buffer, the chromogen 3-amino-9-
ethyl carbazole (AEC) was applied for 30
min. Sections were counterstained with
Mayer’s hematoxylin, and coverslipped
with Kaiser’s glycerol gelatin (Merck,
Darmstadt, Germany).
To identify T and B cells in cardiac tissue
Table 1. Experimental groups used for histological evaluation of cardiac grafts for the
presence of graft-infiltrating cells and GAD
Group Graft Recipient ALS CsA IT N Euthanization
donor (days post-Tx)
1 PVG AO - - - 3 4
2A O A O ++-3 250
3 PVG AO + + + 3 14
4 PVG AO + + + 12 30 - 200
5 PVG AO + + + 10 > 200
(ALS: rabbit-anti-rat lymphocyte serum; CsA: Cyclosporin A; IT: intrathymic inocula-
tion of 2.5x107 donor-type splenocytes; N: number of animals, Tx: transplantation)44
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simultaneously, a double-staining tech-
nique was performed with alkaline phos-
phatase and horseradish peroxidase-con-
jugated isotype-specific goat anti-mouse
antibodies (Southern Biotechnology
Assoc., Inc., Birmingham, AL). OX19
(IgG1)-positive T cells stained blue (fast
blue), whereas HIS24 (IgG2b)-positive B
cells stained red (AEC). The staining pro-
cedure was similar to the one described
for single staining. Double-stained sec-
tions were not counterstained with
Mayer’s hematoxylin. After immunohis-
tochemical staining, the number of posi-
tively stained graft-infiltrating cells was
scored in a semiquantitative fashion. Of
each graft, several tissue sections were
evaluated and the overall impression was
given a value that ranged from - to +++
(- = no infiltration; – = few infiltration;
+ = mild infiltration; ++ = moderate infil-
tration; and +++ = severe infiltration).
Evaluation of GAD
GAD in the coronary system of cardiac
transplants was evaluated on paraffin sec-
tions stained with orcein (Gurr, BDH
Chemicals Ltd., UK) for elastin. Orcein
stains the IEL and permits easy detection
of cells at the luminal side of the vessel.
A double-staining technique was per-
formed to detect VSM cells at the lumi-
nal side of the arterioles (i.e. GAD).
Briefly, paraffin sections were deparaf-
finized, rehydrated, and incubated in
Lawson solution (Klinipath, Duiven, The
Netherlands) to stain the IEL. Subse-
quently, sections were stained immuno-
histochemically (as described above) with
a monoclonal antibody directed against
VSM cell α-actin17,18. Sections were
counterstained with Mayer’s hematoxy-
lin, and coverslipped with Kaiser’s glyce-
rol gelatin. Severity of GAD was scored
semiquantitatively, using a method de-
scribed by Adams et al.19. The different
grades of arterial damage varied from 0
(normal artery) to 5 (circumferential inti-
mal thickening, with more than 80% lu-
minal compromise).
All elastin-positive vessels of varying
sizes within an orcein stained section were
counted, and severity of GAD was ana-
lyzed as mentioned above. From each tis-
sue section, the percentage of affected
(grades 1 to 5) vessels of the total num-
ber of vessels counted was calculated. In
addition, the percentage of arteriosclerotic
vessels (i.e. grade >2; circumferential in-
timal thickening) was calculated. From
each cardiac graft, two different parts
were processed and analyzed histologi-
cally, and the mean of both parts was cal-
culated. The sections were scored in a
blind fashion, i.e., without prior knowl-
edge to which study group each section
belonged.
Semiquantitative Cytokine RT-PCR
Semiquantitative RT-PCR was used to
assess the intragraft expression of
interleukin (IL)-2, IL-4, IL-10, transform-
ing growth factor (TGF)-β, and interferon
(IFN)-γ mRNA 14 days and >200 days
after IT inoculation/ transplantation. To-
tal RNA was isolated from 100 to 200 mg
of homogenized cardiac tissue with
TRIzol Reagent (Gibco BRL, Life Tech-
nologies B.V., Breda, The Netherlands).
The isolated RNA was precipitated,
washed, and finally dissolved in 100 ￿l
of diethylpyrocarbonate (DEPC)-MilliQ.
An 11-￿l volume of the RNA was reverse
transcribed into cDNA using Super-
script™ II reverse transcriptase (Gibco
BRL, Life Technologies B.V., Breda, The45
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Netherlands). The cDNA products were
amplified using primers specific for
IL-2, IL-4 20, IL-10 21, TGF-β  22, and
IFN-γ 23. In addition, rat β-actin primers
were used to amplify  β-actin cDNA24. As
a constitutively expressed gene, β-actin
expression was used to control for the to-
tal amount of cDNA present in each
sample. The amplification reactions were
performed in a 25-￿l mixture that con-
tained 1.25 U Taq polymerase, 2 mM
dNTP, 0.6 ￿M of each of the two primers
(forward and reverse), and 1.5 mM MgCl2
in PCR buffer (Gibco BRL, Life Tech-
nologies B.V., Breda, The Netherlands).
All amplifications involved an initial 3
min at 95￿C denaturating step, followed
by 30 cycles, each consisting of 1 min at
94￿C, 1 min at 55￿C (IL-4 and IL-10),
58￿C (β-actin), or 60￿C (IL-2, TGF-β and
IFN-γ), and 1.2 min at 72￿C. The ampli-
fications ended with a step of 7 min at
72￿C. Amplifications were performed on
an Amplitron II Thermolyne thermocycler
(Barnstead/ Thermolyne, Dubuque, Iowa,
USA). The PCR amplifications were per-
formed on serial 2-fold dilutions of car-
diac cDNA samples and cytokine standard
cDNA. (IL-2, IL-10, TGF-β, IFN-γ, and
β-actin cDNA standards were obtained
from in vitro phorbol myristate acetate/
ionomycin-stimulated splenocytes,
whereas the IL-4 standard was obtained
from a rat IL-4 producing Chinese Ham-
ster Ovary cell line). All samples were
subjected to electrophoresis on a 1.2%
agarose gel and visualized by ethidium
bromide. Intensity of the visualized bands
that corresponded to the specific PCR
products was quantified using Leica Qwin
software (Leica, Cambridge, UK). Refe-
rence curves were constructed from the
standard β-actin and cytokine cDNA di-
lution series data, relating band intensity
to cDNA concentrations in arbitrary units
(AU). The standard curves were used to
calculate the concentration (in AU) of
β-actin and cytokine cDNA present in car-
diac samples. Finally, the amount of
cytokine cDNA was related to the amount
of β-actin for each tissue sample. This
type of analysis allows semiquantitative
comparison of mRNA transcript expres-
sion of one cytokine between different
samples but not of different cytokines
within one sample.
One-Way MLR
To evaluate the recipient (AO) PBMC’s
capacity to respond to donor-type (PVG)
and third-party (BN) splenocytes, in vitro
proliferative responses were measured
using a one-way MLR at two timepoints
(60 days and 120 to 280 days) after IT
inoculation/transplantation. Responder
cells (AO) were isolated from buffy coats.
Remaining erythrocytes were lysed with
NH4Cl buffer, after which PBMC’s were
washed in culture medium (RPMI 1640,
Gibco BRL, Life Technologies B.V.,
Breda, The Netherlands) supplemented
with 5x10-5 M β-mercaptoethanol, 2 mM
glutamine, 1 mM sodiumpyruvate, 40 ￿g/
ml gentamycin, and 10% fetal calf serum
(Gibco BRL, Life Technologies B.V.,
Breda, The Netherlands). Finally, cells
were resuspended in culture medium at a
final concentration of 2x106 cells/ml.
Single-cell suspensions of stimulator cells
were prepared by teasing a spleen through
a 60-￿m brass grid using scissors, after
which the cell suspension was filtered
over nylon gauze. Single cells were 50-
Gy γ-irradiated (137Cs, CIS Bio Interna-
tional IBL 673) and resuspended in cul-
ture medium at a final concentration of46
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4x106 cells/ml. Responder cells (2x105)
and stimulator cells (4x105) were mixed
in 96-well round bottom culture plates
(Nalge Nunc Int., Denmark) in quadru-
plicate and cultured at 37￿C and 5% CO2
atmosphere for 4 days. Proliferation was
determined by adding 0.5 ￿Ci of 3H-Thy-
midine to each well for the final 16 hr of
culture. Incorporation was measured on
a liquid-scintillation counter (Canberra
Packard), and results were obtained as
disintegrations per minute (dpm).
Statistical Analysis
Differences in graft survival rates were
analyzed statistically using the Student’s
t-test. Development of GAD and prolif-
erative responses were analyzed for sta-
tistical significance using the Kruskal-
Wallis test (One-way ANOVA). Post tests
(Dunn’s multiple comparisons test) were
performed if ANOVA reached signifi-
cance. All tests were performed using
GraphPad Instat, GraphPad software. Dif-
ferences with P<0.05 were considered
statistically significant.
Figure 1.  Cardiac allograft survival after IT inoculation of donor splenocytes [   ]. PVG allografts were
heterotopically transplanted to AO recipient rats. Nontreated animals [   ] and AO isografts [   ] served as
controls. IT inoculation resulted in significant prolongation (P<0.0001) of the graft survival (MST >150
days) compared to nontreated animals (MST 8 days).47
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Results
Graft Survival
Simultaneous transplantation and IT in-
oculation of donor splenocytes resulted
in significant prolongation of graft sur-
vival (median survival time [MST] >150
days, P<0.0001) compared to untreated
animals (MST 8 days). IT immune modu-
lation induces functional tolerance to
MHC-incompatible allografts because
survival rates at 150 days (indefinite graft
survival) are 90% (Fig. 1). Cardiac al-
lografts that did not survive indefinitely
were mostly rejected at timepoints com-
parable with animals treated with CsA and
ALS only (<25 days, not shown). AO
isografts (only ALS and CsA treatment;
no IT inoculation) showed indefinite graft
survival (MST >150 days, Fig.1) in all
animals.
GAD After IT Immune Modulation
Approximately 90% of the cardiac al-
lografts transplanted after IT inoculation
survived indefinitely (Fig. 1). In this
study, we investigated whether this pro-
tocol could also prevent the development
of GAD in these long-term surviving al-
lografts. Therefore, severity of arterial
lesions present in cardiac allografts at dif-
ferent timepoints after IT inoculation/
transplantation was analyzed as described
in Materials and Methods.
First, the percentage of affected (grades
1 to 5) elastin-positive vessels was deter-
mined. As shown in Figure 2A, up to 80%
of the vessels in rejecting cardiac al-
lografts (group 1, 4 days posttransplanta-
tion) were affected. The pathology con-
sisted mainly of mononuclear cell infil-
tration of the intima (high nuclear den-
sity). In most cases, this coincided with a
Figure 2.  Development of CTD-related vasculo-
pathy (GAD) at different timepoints after IT in-
oculation/transplantation. All grafts were beating
at time of removal and processed for histological
analysis. Analysis was performed semiquantita-
tively on elastin-stained tissue sections. (A) Per-
centage of affected vessels (grades 0 to 5). Four-
teen days after IT inoculation (group 3), up to 80%
of the vessels were affected, which was similar to
the control groups (1 and 2). At later timepoints,
the percentage of affected vessels showed a slight
increase. (B) Percentage of arteriosclerotic vessels
(GAD). In group 3, up to 20% of the vessels showed
arteriosclerotic lesions (similar to the control
groups). At later timepoints, the percentage of ar-
teriosclerotic lesions increased significantly
(* P<0.01 vs. controls [1 and 2] and groups 3 and
4). Group 1: acute rejection (n=3; 4 days); group
2: AO isografts (n = 3; 250 days); group 3: 14 days
after IT inoculation (n = 3); group 4: 30 to 200
days after IT inoculation (n = 12); and group 5:
>200 days after IT inoculation (n = 10).48
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perivascular infiltrate consisting of CD8+
and ED1+ cells. Most of the elastin-posi-
tive vessels were only slightly damaged
(grades 1 and 2), and  few vessels (up to
10%) showed intimal thickening (grades
3 to 5, Fig. 2B) in which VSM cells were
barely present (as determined by absence
of α-actin-positive cells). Moreover, in
most vessels, the IEL was fragmented,
indicating severe vascular rejection (Fig.
3B).
In AO isografts (group 2), which were
explanted 250 days after transplantation,
up to 70% of the elastin positive vessels
were affected. However, the number of
intima-infiltrating cells and adhering
mononuclear cells to the vascular endo-
thelium was less pronounced compared
to acutely rejecting allografts. Up to 20%
of the elastin-positive vessels in AO
isografts showed intimal thickening (Fig.
2B). In contrast to rejecting allografts,
isografts contained more α-actin-positive
VSM cells in the intimal lesions, resem-
bling CTD-related vasculopathy (not
shown).After IT inoculation, the first
analysis was performed at 14 days after
transplantation (group 3). At this time
point approximately 80% of all elastin-
positive vessels counted were affected
(Fig. 2A). Again, most of the vessels were
only slightly affected (grades 1 and 2)
which was similar to rejecting grafts and
isografts. At this timepoint, 18% of the
vessels showed moderate intimal thick-
ening, which is similar to the percentages
observed in rejecting grafts (day 4, group
1) and isografts (day 250, group 2). At
later timepoints after transplantation, an
increase in the number of vessels that
showed moderate to severe intimal thick-
ening (grades 3 to 5) was observed (Fig.
2B). In group 4 (30 to 200 days), up to
36% of the elastin-positive vessels show-
ed moderate to severe intimal thickening,
which was not statistically different from
group 3 and the control groups (1 and 2).
However, the grafts in group 5 (>200
days) showed a dramatic increase in the
number of vessels that showed moderate
to severe intimal thickening. Virtually all
vessels were affected, and over 80% of
the vessels showed the presence of severe
intimal lesions. This increase differed sig-
nificantly from groups 3 and 4 and the
control groups (1 and 2) (P<0.01).
Figure 3.  (facing page) Photomicrographs of GAD (double staining for VSM cell α-actin and elastin)
(A to D), and infiltration of T and B lymphocytes (double staining for T cells [MRC-OX19, blue color]
and B cells [HIS24, red color]) (E to H) in normal cardiac tissue and tissue obtained from acutely
rejecting allografts (group 1, 4 days posttransplantation) and grafts from intrathymically inoculated rats
(group 3, 14 days after IT inoculation, and group 5, >200 days after IT inoculation).
In normal (nontransplanted) cardiac tissue, no blood vessel pathology or infiltrating T and B cells were
present (A and E). Acutely rejecting allografts were heavily infiltrated and showed severe vascular
rejection with complete disruption of the vascular media and IEL (B). The parenchymatous infiltrates
mainly consisted of T cells (blue color) and only few B cells (red color) were present (F). Two weeks
after IT inoculation, mild GAD (grade 3) was observed in 18% of the elastin-positive vessels (C). At this
early timepoint after IT inoculation, a parenchymatous, T-cell dominated infiltrate was present (G). At
later timepoints after IT inoculation (>200 days), the vast majority of the blood vessels showed severe
GAD (grade 5) with (nearly) complete luminal occlusion (D). At this timepoint, the grafts were charac-
terized by pericardial infiltrates, which predominantly consisted of B cells (H). (Abbreviations: B: B
cell; IEL: internal elastic lamina; M: media; NI: neo-intima; and T: T cell). Immunoperoxidase staining,
magnification x400.50
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In contrast to the intimal lesions at earlier
timepoints (groups 3 and 4), most of the
arteries in group 5 showed complete lu-
minal occlusion (grade 5) by intimal
thickening that contained large numbers
of α-actin-positive VSM cells. In addition,
fragmentation of the IEL was often ob-
served and sometimes the elastin fibers
(belonging to the IEL) had completely
disappeared. Figure 3, A to D, shows rep-
resentative micrographs of intimal thick-
ening observed at different timepoints
after IT inoculation and in nontrans-
planted cardiac tissue and acutely rejec-
ting allografts.
One-Way MLR
To evaluate recipient PBMC’s capacity to
respond to donor-type (PVG) antigens
after IT inoculation of donor splenocytes,
one-way MLR’s were performed at vari-
ous timepoints (60 days [rats 4 to 6], and
120 days [rat 7], and 280 days [rats 8 and
9]) after transplantation. Proliferative re-
sponses of intrathymically inoculated ani-
mals were compared to responses of na-
ive rats (rats 1 to 3). Representative re-
sults of three individual rats in their re-
spective groups are shown in Figure 4.
At the first timepoint, 60 days after IT in-
oculation, all animals showed a decreased
Figure 4.  Proliferative responses of PBMC’s, as determined by a one-way MLR, against donor-type
(PVG) stimulator cells. Responses were measured at two timepoints after IT inoculation: 60 days (rats 4
to 6) and 120 days (rat 7) and 280 days (rats 8 to 9). The responses of the inoculated animals were
compared to the proliferative responses of naive rats (rats 1 to 3). Representative data from 3 individual
rats in respective groups are shown. Responses are expressed as dpm. A relatively short time after IT
inoculation, there is a significant decrease in the proliferative responses against donor-type stimulator
cells (P<0.001). However, the responses have been restored to naive levels at later timepoints after IT
inoculation. Medium control consists of the mean proliferative responses of all individual rats against
medium alone. NS=not significant.51
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Figure 5.  Phenotypic analysis of graft-infiltrating cells in normal (nontransplanted) cardiac tissue,
acutely rejecting allografts (group 1), and after IT inoculation. Intrathymically inoculated animals were
divided in two different groups: early (group 3) and late (group 5), which were killed 14 days and >200
days after IT inoculation, respectively. In normal cardiac tissue, no infiltrated leukocytes were present.
Only some ED2+ (resident) macrophages resided amidst the parenchymal cells (A, E, I, and M)). In
acutely rejecting allografts, massive parenchymatous infiltrates were observed, mainly consisting of
ED1+ macrophages and CD8+ (OX8) cells. Only a few ED2+ macrophages and CD4+ (OX35) cells were
detected within the parenchymatous infiltrates (B, F, J, and N). Two weeks after IT inoculation, acute
rejection like parenchymatous infiltrates were present, consisting of ED1+ macrophages and CD8+ (OX8)
cells. However, the frequency of these cells was obviously less compared to infiltrates in acutely reject-
ing grafts (C, G, K, and O). Late (>200 days) after IT inoculation, the infiltrates were mainly concen-
trated at the peripheral sides of the graft. Compared to early timepoints, the absolute numbers of infil-
trating leukocytes had increased (especially the CD4+ [OX35] and CD8+ [OX8] cells) (D, H, I, and P).
Arrowheads indicate positively stained cells. Abbreviations: PC: pericardium; MC: myocardium.
Immunoperoxidase staining; magnification x400.52
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T
able 2.
Semi-quantitative analysis of graft infiltrating leukocyte subsets after hematoxylin and eosin and immunohistochemical
staining of tissue sections at dif
ferent timepoints after intrathymic inoculation of donor splenocytes.
         Staining
   Specificity
non
acute
isograft
14 days
30-200 days
>200 days
transplanted
rejection
(group 2)
(group 3)
(group 4)
(group 5)
(group 1)
Mononuclear
Hematoxylin and eosin
-
+++
–
++
+
++
cell infiltrate
mAb MRC-OX19 
58
T cells (CD5)
-
+++
nd
++
+
+
+
mAb MRC-OX35 
59
CD4
-
–
nd
+
+
++
mAb MRC-OX8 
60
CD8 (
α
-chain)
-
+++
nd
++
+
+
+
mAb HIS24 
61
B cells (CD45R)
-
–
nd
–
++
+++
mAb ED1 
62
Macrophages
-
+++
nd
++
+
+
+
Resident (mature)
mAb ED2 
62
–
+n
d
+
+
+
+
macrophages
Semiquantitative analysis of graft-infiltrating leukocytes: - = no infiltration; 
–
 = few infiltrating cells; + = mild infiltration;
++ = moderate infiltration; +++ = severe infiltration. (mAb: monoclonal antibody
, nd: not determined)53
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proliferative response against donor-type
splenocytes compared to naive rats
(P<0.001). Responses against third-party
antigens were also decreased (P<0.001,
not shown). At later timepoints after IT
inoculation, however, proliferative re-
sponses against donor and third-party an-
tigens were restored towards levels of
naive rats (no significant differences). In
animals that acutely rejected their graft,
proliferative responses against donor-type
antigens were significantly elevated com-
pared to naive rats (not shown). By con-
trast, proliferative responses against third-
party antigens were not increased. The
results indicate that there is a non-specific
decrease in proliferative responsiveness
at 60 days after IT inoculation/transplan-
tation. At later timepoints, the allore-
sponse has been restored, indicating that
donor-reactive T cells are still present long
term after IT inoculation of donor spleno-
cytes.
Infiltration of Cardiac Allografts
In addition to the histological presence of
GAD, we determined the presence of
graft-infiltrating cells in control groups (1
and 2) and at different timepoints after IT
inoculation (groups 3, 4, and 5). General
morphology of cardiac tissue and the pres-
ence of infiltrates were evaluated by
hematoxylin and eosin staining (groups
1 to 5). Immunohistochemical staining
was performed to characterize the infil-
trating cells phenotypically in nontrans-
planted cardiac tissue, acutely rejecting
allografts (group 1) and different time-
points after IT inoculation (groups 3, 4,
and 5). The number of positively stained
infiltrating leukocytes was scored semi-
quantitatively as described in Materials
and Methods. In normal (nontransplanted)
cardiac tissue, no infiltrating leukocytes
could be observed. The only leukocytes
present were ED2+ macrophages, which
resided amidst the cardiac parenchymal
cells (Fig. 5E).
In contrast to AO isografts (group 2), in
which few infiltrating inflammatory cells
were present, rejecting allografts (group
1) were characterized by massive paren-
chymatous infiltrates, i.e., infiltrating cells
localized amidst the cardiac myocytes.
Immunohistochemical analysis revealed
that these infiltrates mainly consisted of
CD8+ cells (MRC-OX8) and ED1+ macro-
phages. Another subset of macrophages
stained positively for ED2, a marker
among others present on resident mac-
rophages. In contrast to ED1+ macro-
phages, ED2+ macrophages were local-
ized mostly at the periphery of the grafts.
Some CD4+ cells (MRC-OX35) were
present in rejecting allografts, although
these CD4+ cells were relatively few in
number compared to the number of CD8+
cells. According to their morphology,
many of the CD4+ cells present were pro-
bably not T cells but macrophages, which
were present in high numbers (as shown
by ED1 staining) (Fig. 5 B, F, J, and N).
Anti-CD45R staining (HIS24) revealed a
virtual absence of B cells in rejecting al-
lografts (Fig. 3F), whereas a monoclonal
antibody directed against IgM (HIS40)
sometimes showed IgM depositions on
endothelial cells in capillaries and along
the blood vessels, which indicated vas-
cular damage (not shown).
After IT inoculation, the first analysis was
performed 14 days after transplantation
(group 3). At this timepoint, the infiltrates
present were mostly parenchymatous and,
with the exception of lower absolute num-
bers of infiltrating cells, were qualitatively54
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virtually indistinguishable from the infil-
trates observed in rejecting grafts. In ad-
dition, inoculated animals contained rela-
tively more CD4+ cells than the infiltrates
in rejecting animals. Again, similar to
acutely rejecting allografts, ED2+ macro-
phages were mostly localized at the pe-
riphery of the grafts, whereas ED1+ ma-
crophages were observed frequently in the
parenchymatous infiltrates (Fig. 5C, G, K,
and O).
At later timepoints (30 to 200 days) after
IT inoculation (group 4), the initially par-
enchymatous infiltrate had disappeared.
The most striking difference with group
3 (14 days) was a decrease in the abso-
lute numbers of infiltrating cells and the
appearance of peripheral and/or blood
vessel-associated infiltrates, which con-
tained relatively few T cells (equal num-
bers of CD4+ and CD8+ cells) and macro-
phages but did contain considerable num-
bers of B cells. Few T cells and ED1+
macrophages were present amidst the
graft parenchymal cells compared to the
numbers found in the graft periphery (not
shown).
In group 5 (> 200 days posttransplanta-
tion), the peripheral infiltrate increased in
size with a tendency to locally “spill over”
into the cardiac parenchyma. Double
staining for B and T cells revealed that
the peripheral infiltrates were now domi-
nated by B cells instead of T cells (Fig.
3H). CD4+  and CD8+  cells and ED1+
macrophages were still present and
seemed to infiltrate the graft parenchyma
again. The ED2+ macrophages remained
localized at the peripheral sides of the
grafts (Fig. 5D, H, L, and P). Results of
the semiquantitative analysis of numbers
of infiltrating leukocytes are represented
in Table 2. Figure 5 shows representative
β-actin
IFN-γ
IL-2
IL-10
normal
acute rejection
IT 14 days
IT >200 days
TGF-β
Figure 6.  Intragraft expression of cytokine mRNA
after IT inoculation as determined by RT-PCR. The
amounts of intragraft cytokine mRNA present were
expressed in AU, and were calculated using
cytokine standards and normalized against β-ac-
tin. IL-2 expression was observed only in acutely
rejecting allografts and was undetectable after IT
inoculation and in normal cardiac tissue. IFN-γ ex-
pression was present in acutely rejecting allografts
and in grafts obtained from inoculated animals.
Early after IT inoculation (group 3, 14 days), a re-
duction in IFN-γ expression was observed com-
pared to acutely rejecting allografts. Late after IT
inoculation (group 5, >200 days), the intragraft
expression of IFN-γ had dramatically increased
compared to the 14 days group. Although clear
trends were observed in IFN-γ expression between
the experimental groups, statistical significance was
not reached because of the small number of samples
(acute rejection vs. 14 days P=0.012; >200 days
vs. 14 days and acute rejection P=0.083; Mann-
Whitney test). Expression of IL-10 mRNA was
similar in acutely rejecting allografts and at differ-
ent timepoints after IT inoculation. Expression of
TGF-β was increased in group 5 (>200 days) com-
pared to the other groups. Although clear trends
were observed in TGF-β expression between the
experimental groups, statistical significance was
not reached because of the small number of samples
(>200 days vs. 14 days P=0.248; >200 days vs.
acute rejection and normal P=0.083; Mann-
Whitney test).55
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micrographs of infiltrating leukocytes at
different timepoints after IT immune
modulation.
Semiquantitative Cytokine RT-PCR
Intragraft cytokine gene expression was
analyzed with a semiquantitative RT-PCR
as described in detail in Materials and
Methods. Representative results of RT-
PCR for IL-2, IFN-γ, IL-10 and TGF-β
are shown in Figure 6. Because IL-4 ex-
pression was not detected in any of the
experimental groups tested, no IL-4 data
are shown. Cytokine gene expression was
analyzed in normal (nontransplanted) car-
diac tissue, acutely rejecting allografts
(group 1), 14 days after IT inoculation
(group 3), and >200 days after IT inocu-
lation (group 5). Normal cardiac tissue
showed undetectable levels of IL-2 and
IFN-γ expression, whereas little expres-
sion of IL-10 and TGF-β was observed
(possibly produced by resident macro-
phages and endothelial cells, respec-
tively). Acutely rejecting allografts (group
1) showed clearly detectable levels of
IL-2, IFN-γ, and IL-10 mRNA expression,
whereas TGF-β expression was not al-
tered compared to normal cardiac tissue.
In contrast to acute rejection, grafts ex-
planted 14 days (group 3) after IT inocu-
lation had undetectable levels of IL-2 and
decreased expression of IFN-γ compared
to acutely rejecting allografts. IL-10 and
TGF-β expression, however, was similar
compared to acutely rejecting grafts. In
group 5 (>200 days after IT inoculation),
IL-2 expression was still undetectable,
whereas the IFN-γ and TGF-β expression
showed a remarkable increase compared
to acutely rejecting allografts and IT in-
oculation after 14 days. Although clear
trends were observed in IFN-γ  and TGF-
β expression between the different groups,
statistical significance was not reached
because of the small number of samples
(n = 2 to 3/ group; IFN-γ expression: acute
rejection vs. 14 days P=0.012, and >200
days vs. 14 days and acute rejection P=
0.083; TGF-β expression: >200 days vs.
14 days P=0.248 and 200 days vs. acute
rejection/normal P=0.083, Mann-Whit-
ney test). Expression of IL-10 mRNA was
similar to the expression observed in
acutely rejecting grafts and 14 days after
IT inoculation. The absence of IL-2
mRNA and decreased expression of
IFN-γ mRNA, together with sustained
IL-10 expression 14 days after IT inocu-
lation, suggest a down regulation of a
Th1-type cytokine response.
Discussion
Nowadays, CTD is the most significant
problem in clinical organ transplantation
after the first postoperative year1,2. Be-
cause histoincompatibility between donor
and recipient, and thereby alloreactivity
directed against the graft, is the major
contributing factor in the pathogenesis of
CTD5, induction of specific nonrespon-
sive-ness to donor antigens would be the
obvious solution to prevent the develop-
ment of this pathology.
Donor-specific hyporesponsiveness to
various organs can be induced by IT in-
oculation of donor lymphoid cells7-10 or
synthetic MHC allopeptides25. In all of
these studies, an interval between the in-
duction of hyporesponsiveness and the
actual transplantation was needed, ham-
pering clinical use of the protocol. There-
fore, we developed a method that allowed
the transplantation of a cardiac allograft56
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simultaneous with the IT inoculation of
donor splenocytes. This procedure, as pre-
sented in our previous reports11,26 and in
this study, results in virtual permanent
acceptance (i.e., functional tolerance) of
cardiac allografts in >90% of the recipi-
ents in MHC-incompatible strain combi-
nations.
The present study was designed to evalu-
ate whether our IT immune modulation
protocol also prevents the development
of CTD-related vasculopathy, referred to
as GAD. Therefore, histological analyses
at different timepoints after IT inocula-
tion/transplantation were performed.
Also, in vitro proliferative responses of
inoculated/transplanted rats were mea-
sured to determine residual alloreactivity
against donor-type and third-party anti-
gens. In addition, intragraft cytokine ex-
pression was determined using RT-PCR.
Histological analysis revealed that 14
days after inoculation, the vast majority
(up to 80%) of the blood vessels showed
mononuclear cell infiltration of the intima
and adherence of leukocytes to the vas-
cular endothelium. At later timepoints,
comparable percentages of affected ves-
sels were observed. However, the pathol-
ogy at later timepoints differed qualita-
tively from the pathology observed at 14
days. The percentage of vessels that
showed GAD, and also the severity of
GAD, dramatically increased at later
timepoints. In addition, the cellular com-
position of the arteriosclerotic lesions was
different at early and later timepoints. Two
weeks after IT inoculation, the lesions
showed a high neointimal nuclear density
and contained only few a α-actin-positive
cells. This was similar to the lesions ob-
served in acutely rejecting grafts. At later
timepoints, however, the lesions con-
tained fewer cells (lower neointimal nu-
clear density and less inflammation), but
the number of α-actin-positive cells was
higher, indicating the presence of GAD.
Also isografts, which were explanted 250
days after transplantation, showed some
GAD. Development of chronic rejection
after isografting was reported previously
by Tullius et al.27 and is probably caused
by ischemia and reperfusion injury2.
Thus, despite the induction of virtual per-
manent acceptance of allogeneic grafts
through IT immune modulation, this pro-
cedure does not prevent the subsequent
development of GAD in our fully MHC-
incompatible model. Similar findings
have been reported by Shirwan et al.28
after IT inoculation with donor class I
allopeptides in the congenic PVG.R8 to
PVG.1U rat strain combination, which
differs at the MHC class I locus. Orloff et
al.13 and Blom et al.14, on the other hand,
showed that IT inoculation of donor bone
marrow cells in the Lew-to-F344 CTD
model prevented the development of
GAD (evaluated 120 days after IT inocu-
lation). However, these rat strains are
MHC compatible and only differ at the
level of non-MHC loci. Shin et al.12 re-
ported that even treatment with ALS
alone, without additional IT inoculation
of donor-type antigens, prevented the de-
velopment of GAD in the Lew-to-F344
strain combination. Results so far indicate
that the development of GAD cannot be
prevented by IT immune modulation in
fully or partial MHC-incompatible trans-
plant combinations.
It is intriguing to note that IT immune
modulation, on one hand, is capable in
preventing acute rejection, whereas, on
the other hand, the process of chronic re-
jection seems to be unaffected, although57
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both are believed to be primarily alloan-
tigen driven. We, therefore, analyzed the
nature of the residual alloreactivity after
IT immune modulation and transplanta-
tion to attempt to understand this ambi-
guity in alloresponsiveness.
The mechanism by which IT inoculation
in our protocol results in prolonged graft
survival is not completely understood, but
we hypothesized that it is mediated
through the induction of donor-specific
hyporesponsiveness because third-party
allografts are rejected within 20 days29.
However, in vitro experiments, described
in this study, revealed that IT inoculation
does not result in donor-specific unre-
sponsiveness. Sixty days after IT inocu-
lation, a non-specific decrease in prolif-
erative responses against donor and third-
party antigens was observed. However, at
later timepoints, the responses had been
restored to levels of naive animals. Ito et
al.30 and Chowdhury et al.31 also observed
suppressed proliferative responses after IT
inoculation, with complete long term res-
toration. The non-specific downregulation
of proliferative responses after IT inocu-
lation of donor splenocytes, which was
also noted in other studies32,33, might be
explained by the persistence of ALS-in-
duced immunosuppression. However, af-
ter the injection of 1 ml of ALS, T-cell
numbers returned to 30% of the initial
numbers and back to normal levels after
50 days and 120 days, respectively34.
Thus, despite induction of functional tol-
erance (i.e., prolonged graft survival), IT-
inoculated animals clearly had a prolif-
erative response to donor antigens, which
argues against clonal deletion and favors
immune deviation as the underlying
mechanism. This view is supported by our
findings that IT inoculation results in the
generation of recirculating allospe-cific
suppressor/regulatory CD4+ T cells,
which are able to adoptively transfer func-
tional tolerance35. In addition, transplan-
tation of a donor-specific skin graft 60 to
150 days after primary cardiac allograf-
ting and IT inoculation results in signifi-
cantly prolonged skin graft survival, sug-
gesting induction of a regulatory mecha-
nism by IT immune modulation29. Al-
though we only retransplanted skin grafts,
and could therefore only observe pro-
longed graft survival and were not able
to study the development of GAD, we
expect that after transplantation of a sec-
ond cardiac allograft, the development of
GAD would be ameliorated compared to
the primary graft. This is strengthened by
the observation reported by Tullius et al.
that, using a different retransplant model,
transplantation of a second (cardiac) al-
lograft resulted in diminished severity of
GAD in this second graft36.
The notion that immune deviation, and not
immune depletion, might be instrumen-
tal after IT inoculation is also strength-
ened by immunohistochemical analysis of
the cardiac allografts. At 14 days after IT
inoculation, grafts were heavily infiltrated
with mainly CD8+ cells and ED1+ cells
and were virtually indistinguishable from
the parenchymatous infiltrates present in
acutely rejecting cardiac allografts. Sur-
prisingly, the infiltrates caused little dam-
age to the cardiac tissue, as shown by the
presence of NADH-reductase activity in
healthy cardiac myocytes (not shown).
Other groups have also reported that the
composition of infiltrates present in al-
lografts early after induction of donor-
specific hyporesponsiveness is similar to
that observed after acute rejection23,37. At
later timepoints after IT inoculation (3058
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to 200 days), the infiltrates were mostly
pericardially located and/or blood vessel
associated. Eventually (>200 days), pe-
ripheral infiltrates were still present and
seemed to spill over into the cardiac
parenchyma. A remarkable observation at
this stage was the presence of B cell domi-
nated pericardial infiltrates, whereas the
infiltrates at earlier timepoints were domi-
nated by T cells and macrophages. Thus,
not only in vitro but also in vivo, clear
signs of residual donor-directed allore-
activity can be observed after IT immune
modulation. The nature and localization
of the graft-infiltrating cells, however,
clearly differs in IT-treated rats as com-
pared to untreated (rejecting) recipients,
again supporting immune deviation as a
major element in the mechanism under-
lying long-term graft acceptance after IT
inoculation.
It has been suggested that successful ac-
ceptance of an allograft is dependent upon
immune deviation of CD4+ T cells to-
wards a Th2-type cytokine response (e.g.,
IL-4, IL-5, IL-10, and IL-13) and away
from the Th1-type cytokine response (e.g.,
IL-2 and IFN-γ)38. We, therefore, studied
intragraft cytokine mRNA expression at
different timepoints after IT inoculation/
transplantation.
Acutely rejecting cardiac allografts in
nontreated rats expressed detectable lev-
els of IL-2 and IFN-γ mRNA transcripts.
In addition, detectable levels of IL-10
were present, which might be produced
by macrophages that were abundantly
present in acutely rejecting allografts. RT-
PCR analysis revealed decreased Th1-
type (IL-2 and IFN-γ) and sustained Th2-
type (IL-10 and TGF-β) type cytokine
expression 14 days after IT inoculation
(compared to acutely rejecting allografts).
Long-surviving allografts expressed in-
creased levels of IL-10, IFN-γ, and
TGF-β, whereas IL-2 expression was still
undetectable. Increased expression of
IFN-γ in long-surviving allografts after IT
immune modulation was also recently re-
ported by Shirwan et al.22. Our cytokine
data thus strongly support immune devia-
tion as a major element that contributes
to the virtual permanent acceptance of
allografts after IT inoculation. At the same
time, however, this deviation and the as-
sociated change in cytokine profile may
be extremely detrimental to the graft39.
TGF-β has been linked to fibrotic pro-
cesses associated with chronic inflamma-
tory conditions, such as the development
of GAD40,41. In addition, in recent experi-
ments it has been shown that IFN-γ42 and
IL-1043 augment the development of GAD
after cardiac transplantation in mice.
Hancock et al.44 suggested that immune
deviation towards a Th2-type response
may be involved in the induction of hypo-
responsiveness to allografts but thereby
might enhance the development of CTD.
Indeed, Larsen et al.45 showed in their
model that long-term acceptance of al-
lografts and prevention of CTD requires
silencing of both Th1 and Th2 cytokine
programs.
Probably all tolerance-inducing protocols,
which do not eliminate alloreactivity com-
pletely but rather alter the immune re-
sponse against the graft instead (such as
our model), will fail to prevent the even-
tual development of GAD. According to
this view, only those interventions in
which antidonor reactivity is completely
blocked or deleted, e.g., the creation of
donor bone marrow chimeras46-50 or opti-
mal T-cell stimulation blockade using
CTLA4-Ig fusion protein51-53, are likely59
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to prevent the development of GAD after
solid organ transplantation. When
CTLA4-Ig treatment is suboptimal and
antidonor reactivity (partly) remains, the
development of GAD will not be pre-
vented54-56. To quote Sayegh and Carpen-
ter57: “The term “tolerance” should be
reserved to states where long-term survi-
ving grafts have normal function and do
not develop changes of chronic rejection.”
Taken together, our data show that IT in-
oculation of donor splenocytes prevents
acute rejection and results in significantly
prolonged graft survival rates of cardiac
allografts. However, the development of
GAD is not prevented by this treatment,
which is probably due to sustained
alloreactivity against the graft after IT ino-
culation (as shown by in vitro measured
alloreactivity and presence of lymphocyte
infiltrates). In addition, down-regulation
of Th1-type cytokine expression was ob-
served, suggesting a shift towards a Th2-
type cytokine response. This observation
is supported by the presence of massive
B cell dominated pericardial infiltrates.
Whether GAD is actually facilitated after
IT inoculation due to a shift to Th2- or
Tr1-type intragraft cytokine responses
remains to be elucidated.
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Abstract
To date, transplant arteriosclerosis (TA), the histologic counterpart of chronic trans-
plant dysfunction, is the most important problem in clinical organ transplantation.
Recently we showed in rats that intrathymic (IT) immune modulation substantially
prolonged graft survival of MHC-incompatible, heterotopic vascularized cardiac al-
lografts. Although acute rejection was prevented, eventually TA was found to devel-
op. In this study, we analyzed the efficacy of IT immune modulation in two other,
more simple, transplant models in which we transplanted tissues instead of whole
organs: allogeneic skin transplantation and allogeneic neonatal heart-in-ear trans-
plantation.
Results indicate that IT immune modulation does not prolong graft survival of allo-
geneic skin grafts. Tissue specific antigens present on the skin grafts may account for
this. Graft survival of neonatal cardiac allografts transplanted subcutaneously in the
ear-pinnae of recipient rats was significantly prolonged following IT immune modu-
lation. In long-term surviving neonatal allografts, neo-angiogenesis of graft myocar-
dial tissue was observed which was characterized by the appearance of cavernous-
like vascular structures. IT immune modulation is effective in inducing prolonged
graft survival after allogeneic cardiac tissue transplantation, whereas graft survival of
allogeneic skin grafts is not prolonged. In contrast to vascularized cardiac allografts,
development of TA was not observed in transplanted neonatal heart tissue, most pro-
bably as a result of lack of appropriate vascular structures (functional coronary  arte-
ries).67
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Introduction
Despite the fact that, to date, clinical or-
gan transplantation has almost become a
routine procedure, it is still complicated
by the problems associated with the long-
term use of systemic immunosuppressive
agents. Moreover, the development of
chronic transplant dysfunction (CTD) has
become the most serious cause of long-
term allograft loss1,2. Depending on the
type of organ grafted (liver, heart, kind-
ney, and lung), three years after transplan-
tation 4 to >50% of the transplants show
functional deterioration and histologic
changes characteristic of CTD3-5. The de-
velopment of CTD seems to be multifac-
torial, and both alloantigen-dependent and
alloantigen-independent factors seem to
contribute to the development of CTD.
However, the most important risk factor
in the pathogenesis of CTD in the clini-
cal setting appears to be histoincompati-
bility between donor and recipient, lead-
ing to alloreactivity directed against the
graft6.
The most characteristic feature of CTD
is the development of transplant arterio-
sclerosis (TA), also referred to as graft
arterial disease (GAD). This form of vas-
culopathy is characterized by perivascu-
lar inflammation, thinning of the vascu-
lar media (due to media necrosis), focal
breaks in the internal elastic lamina (IEL),
and a generalized concentric intimal
thickening, consisting of vascular smooth
muscle (VSM) cells intermingled with T
cells and macrophages2.
Because alloreactivity directed against the
graft appears to be the most important
contributing factor in the development of
CTD, induction of specific hyporespon-
siveness to donor antigens would be a
possible solution to overcome the prob-
lems associated with this pathology. Spe-
cific hyporesponsiveness to allografts can
be obtained by intrathymic (IT) inocula-
tion of donor-type lymphoid cells (IT
immune modulation). IT immune modu-
lation has been shown to be effective to
prolong survival of pancreatic islet, car-
diac, liver, kidney, and small bowel al-
lografts in rats and mice7-11. In all of these
protocols, a time lag between IT inocula-
tion and the actual transplantation was
needed.
Several years ago, we developed a meth-
od to induce donor-specific unresponsive-
ness and transplant a cardiac allograft,
simultaneously. Briefly, this protocol con-
sists of intrathymic inoculation of donor-
type splenocytes, intraperitoneal (i.p.) in-
jection of rabbit anti-rat lymphocyte se-
rum (ALS) on day 0, and treatment with
cyclosporine A (CsA) injected intramus-
cularly (i.m.) on days 1, 2, and 3 post
transplantation12. Our results show that it
is possible to induce functional tolerance
(i.e., continuous beating of the graft) af-
ter IT immune modulation in the (fully
MHC incompatible) PVG to AO rat strain
combination. However, we recently
showed that although induction of func-
tional tolerance was achieved, IT immune
modulation did not prevent the develop-
ment of TA13.
Transplantation of a cardiac allograft re-
quires connection of the graft and recipi-
ent vasculature via the graft’s pulmonary
artery and aorta in order to get perfusion.
This is a rather complicated and time-con-
suming technique and a more simple
transplantation model to study IT immune
modulation is therefore desirable. In this
paper, we investigated whether IT im-
mune modulation could also prevent acute68
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rejection and induce prolonged graft sur-
vival of MHC-incompatible non-vascu-
larized tissue grafts, and therefore allo-
geneic skin grafting and transplantation
of neonatal cardiac tissue was performed.
Neonatal cardiac tissue was transplanted
subcutaneously in the ear-pinnae of re-
cipient rats.
Results showed that IT immune modula-
tion did not prolong survival of MHC-in-
compatible skin grafts. However, sur vival
time of allogeneic neonatal cardiac tissue
transplanted in the ear-pinnae of recipi-
ent rats was significantly prolonged.
Long-term surviving neonatal allografts
were characterized by the appearance of
cavernous-like vascular structures. Immu-
nohistochemical analysis revealed that the
endothelium of those vessels was of graft
origin, suggesting neo-angiogenesis (pro-
liferation of pre-existing vasculature) to
be the underlying mechanism of new
blood vessel formation. TA was not ob-
served in the neonatal cardiac allografts,
most likely due to lack of suitable vessels
(functional coronary arteries [CA’s]) for
TA to develop in.
In conclusion, also after allogeneic car-
diac tissue transplantation IT immune
modulation prolongs graft survival. In
contrast to vascularized cardiac allografts,
TA did not develop in transplanted neo-
natal cardiac tissue. Nevertheless, con-
tractile activity of cardiac tissue disap-
peared eventually, most probably as a re-
sult of ongoing alloreactivity.
Materials and Methods
Animals
Specific-pathogen free, female PVG (RT-
1c) and male AO (RT-1u) rats differing at
the MHC-locus were obtained from the
Central Animal Facility of the Faculty of
Medical Sciences of the University of
Groningen. PVG and AO rats were used
as donors and recipients, respectively, and
were maintained under conventional con-
ditions and fed with regular rat chow and
acidified water ad libitum. All transplan-
tations were carried out under halothane
inhalation anesthesia.
Skin transplantation
Orthotopic allogeneic skin transplantation
was performed by transplanting circular
full thickness PVG skin grafts to AO re-
cipients. Both the donors and recipients
were 7-10 weeks of age. The dermal side
of the skin graft was cleared of all adher-
ent material (blood vessels, muscle etc.)
after which the graft was sutured into
place with 10 to 14 separate sutures (silk
5-0) on the recipient rat (from which first
a circular piece of skin had been excised).
The graft was inspected regularly and re-
jection was defined as macroscopic ap-
pearance of graft necrosis.
Neonatal heart-in-ear transplantation
A modified procedure of the transplanta-
tion of cardiac tissue into the mouse ear,
as originally described by Fulmer et al.14,
was used. Briefly, a subcutaneous pouch
was prepared on the dorsal surface of the
recipient’s (7-10 week old male AO rats)
ear-pinna using fine forceps. Subsequent-
ly, cardiac grafts obtained from neonatal
PVG donors (less than 4 days of age) were
rapidly transferred into the pouch using
cotton tips. The pouch was closed with
2-3 separate sutures (Monosof 8-0), and
the grafts were inspected regularly by vi-
sual inspection for pulsatile activity. Re-
jection was defined as complete cessation69
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of visible pulsatile activity.
Vascularized cardiac transplantation
The heart of an age-matched PVG rat (7
to 10 weeks of age) was heterotopically
transplanted into the right side of recipi-
ent’s neck, as described in detail else-
where12. Graft function was assessed reg-
ularly by palpation, and rejection was
defined as complete cessation of ventric-
ular contraction.
Intrathymic immune modulation
Intrathymic immune modulation was ac-
complished by a protocol developed in
our lab and described in detail else-
where12. Briefly, partial sternotomy was
performed, and 2.5x107 PVG splenocytes
were injected into the recipient’s (AO)
thymus.
Immunosuppression
Immediately after transplantation 1 ml
rabbit anti-rat lymphocyte serum (ALS,
Accurate Chemical Corp., Westbury, NY)
was injected (i.p.). CsA (Sandoz Pharma
AG, Basel, Switzerland) was injected i.m.
on days 1, 2, and 3 post transplantation
(15 mg/kg body weight).
Experimental setup
To investigate the efficacy of  IT immune
modulation in various tissue transplant
models in the rat, allogeneic skin trans-
plantation as well as transplantation of
neonatal heart tissue were performed as
listed in Table 1. Graft survival of trans-
planted tissues was compared to the graft
survival of vascularized cardiac allografts.
Allogeneic skin grafts were transplanted
following IT immune modulation (group
3). Control groups consisted of rats re-
ceiving no treatment at all (group 1) and
rats receiving only ALS and CsA (group
2) after skin grafting. Allogeneic neona-
tal cardiac allografts were transplanted
subcutaneously into a pouch on the dor-
sal side of the recipient’s ear following
IT immune modulation (group 6). Con-
trol groups again consisted of rats receiv-
ing no treatment at all (group 4), rats re-
ceiving only ALS and CsA (group 5), and
rats receiving an AO isograft (group 7).
Vascularized cardiac allografts were trans-
planted following IT immune modulation
as described previously12 (group 10). Con-
trol groups consisted of rats receiving no
treatment at all (group 8), rats receiving
only ALS and CsA (group 9), and rats re-
ceiving an AO isograft (group 11).
Histological analyses
To analyze vascular structures in long-
term surviving neonatal cardiac tissue
transplanted in the ear-pinnae of recipi-
ent rats, ear tissue including the graft was
removed at the time of sacrifice. Tissues
were either fixed in Bouin’s fixative and
embedded in paraffin or immediately fro-
zen in liquid nitrogen and stored at -80￿C
for cryostat sections. For general histolo-
gy, hematoxylin and eosin staining was
performed on paraffin cross sections (7
￿m). To analyze intimal hyperplasia in
long-term surviving neonatal cardiac al-
lografts, an indirect immunohistochemi-
cal staining for VSM cell α-actin was
performed using mAb asm-115,16 (Roche
Molecular Biochemicals, Almere, The
Netherlands). Incubation with the prima-
ry antibody was followed by incubation
with a second-step horseradish peroxi-
dase-conjugated rabbit anti-mouse anti-
body (DAKO A/S, Glostrup, Denmark).
Subsequently, the chromogen diami-
nobenzidine (DAB) was applied, fol-70
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lowed by counterstaining with Mayer’s
hematoxylin and coverslipping in Depex
mounting medium (BDH Laboratory Sup-
plies, Poole, United Kingdom).
Since neonatal cardiac tissue was trans-
planted subcutaneously whithout anasto-
mosing the graft vessels to the recipient’s
vasculature, we analyzed whether in-
growth of newly formed blood vessels
from the periphery of recipient tissue oc-
curs. To discriminate between donor
(PVG) and recipient (AO) derived cells
and tissues, MHC class I haplotype spe-
cific staining was performed on 7-￿m cry-
ostat sections as described above using
the following mAb’s: OX-18 (pan-class
I)17, OX-27 (PVG [RT-1c] class I)18 and
U9F4 (AO [RT-1u] class I)19. To detect
endothelial cells, mAb RECA-1 was
used20.
Statistics
All data are presented as median survival
times (MST) and were evaluated for sta-
Table 1. Survival of PVG neonatal cardiac tissue, skin grafts, and vascularized
cardiac grafts after intrathymic immune modulation in AO recipient rats
Treatment                Graft survival (days)
Group N a Graft P-value a
ALS CsA IT MST range
19 --- skin allograft 8 6 - 10 -
21 0+ +- skin allograft 24 12 - 47 <0.0001 b
31 0+ ++ skin allograft 24 20 - 26 NS c
43 --- neonatal cardiac
 allograft 13 11 - 13 -
56 ++- neonatal cardiac
allograft 20 11 - 26 NS b
65 +++ neonatal cardiac
allograft >125 22 - >125 0.007 c
73 --- neonatal cardiac
isograft >125 >125 0.0002 c
89 --- cardiac allograft 8 6 - 10 -
98 ++- cardiac allograft 20 18 - 24 <0.0001 b
10 25 + + + cardiac allograft >125 23 - >125 <0.0001 c
11 3 --- cardiac isograft >125 >125 <0.0001 c
Abbreviations: IT, intrathymic inoculation with 2.5x107 PVG splenocytes; ALS, rabbit-
anti-rat lymphocyte serum; CsA, cyclosporin A; MST, median survival time; NS, not sig-
nificant; a P<0.05 is considered statistically significant (Student t-test); b compared to the
non-treated group; c compared to the ALS + CsA treated group71
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tistical significance by the Student’s t-test
using GraphPad Instattm, GraphPad Soft-
ware. Differences with P<0.05 were con-
sidered statistically significant.
Results
Graft survival of skin allografts
To study whether IT immune modulation
is also effective in transplant models in
which tissues instead of whole organs are
transplanted, allogeneic skin transplanta-
tion following intrathymic inoculation of
donor-type splenocytes and short-term
immunosuppression was performed. Ta-
ble 1 (groups 1-3) summarizes the graft
survival rates of the different experimen-
tal groups after skin transplantation.
No treatment resulted in rapid rejection
of the skin grafts (group 1, MST 8 days),
whereas treatment with ALS and CsA re-
sulted in significantly prolonged graft
survival after allogeneic skin transplan-
tation (group 2, MST 24 days, P<0.0001)
compared to non-treated animals (group
1). Intrathymic inoculation of donor-sple-
nocytes did not result in prolonged graft
survival after allogeneic skin transplan-
tation (group 3, MST 24 days) compared
to the grafts transplanted in animals treat-
ed with ALS and CsA only (group 2) (Fig-
ure 1A)
Figure 1.Graft survival of cardiac
(vascularized and neonatal) and skin al-
lografts after intrathymic (IT) immune
modulation. (A) Graft survival after
transplantation of skin allografts or
neonatal grafts in ear-pinnae of recipi-
ent rats. (B) Graft survival after trans-
plantation of vascularized cardiac
grafts.72
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Graft survival of  neonatal cardiac tissue
As an alternative tissue transplant model,
we transplanted neonatal cardiac al-
lografts in the ear-pinnae of rats, and used
the contractile activity of the cardiac tis-
sue as read-out system for the efficacy of
the intrathymically induced hyporespon-
siveness. Table 1 (groups 4-7) summa-
rizes the graft survival rates of the differ-
ent experimental groups after vascular
heart transplantation. Transplantation of
neonatal cardiac AO isografts resulted in
indefinite survival in all animals (group
7, MST >125 days). No treatment resul-
ted in rapid rejection of allogeneic skin
grafts (group 1, MST 8 days), whereas
treatment with ALS and CsA resulted in a
slightly prolonged graft survival (group
5, MST 20 days) which did not reach sta-
tistical significance compared to the non-
treated animals. Intrathymic inoculation
of donor splenocytes resulted in a signif-
icant prolongation of the graft survival
rates of neonatal cardiac allografts trans-
planted in the ear-pinnae of recipient rats
(group 10, MST >125 days, P=0.007). In
this group, 2 out of 5 animals rejected their
grafts 22 and 81 days after intrathymic in-
oculation/transplantation, while the other
three animals accepted their grafts perma-
nently (Figure 1A).
Graft survival of vascularized cardiac
allografts
Table 1 (groups 8-11) summarizes the
graft survival rates of the different experi-
mental groups after vascular heart trans-
plantation. IT immune modulation (group
10) resulted in significant prolonged graft
survival (P<0.0001) compared to un-
treated animals (group 8, MST 8 days) and
animals treated with ALS and CsA only
(group 9, MST 20 days). Figure 1B shows
that IT immune modulation is highly suc-
cessful as the survival rate at 125 days
(indefinite survival) is over 90%. AO
isografts (group 11) showed indefinite
survival (MST >125 days) in all animals,
which also differed significantly from the
ALS and CsA treated animals (group 9,
P<0.0001).
Development of vascular lesions in neo-
natal cardiac tissue
We  previously showed that IT immune
modulation does not prevent development
of TA after vascular transplantation of
cardiac allografts in the PVG to AO rat
strain combination13. In this study, we
analyzed whether also after subcutaneous
transplantation of neonatal cardiac tissue
vascular lesions develops in the CA’s of
long-term surviving neonatal cardiac tis-
sue. General histology of the various ex-
perimental groups (groups 4-7) is shown
in Figure 2.
Neonatal AO isografts (group 7) did not
show any sign of an inflammatory re-
sponse to the cardiac tissue.  Large blood
vessels were abundantly present and ap-
parently newly formed (Figure 2A) since
normal, non-transplanted neonatal car-
diac tissue does not contain such vascu-
lar structures. In contrast to isografts, non-
treated allografts (group 4) were charac-
terized by severe parenchymatous infil-
tration with mononuclear cells. In acute-
ly rejecting grafts, no newly formed blood
vessels were observed  (Figure 2B). Treat-
ment with only CsA and ALS (group 5)
resulted in rejection within 3 weeks, and
showed similar histology as the grafts
from the non-treated animals (i.e., severe
parenchymatous infiltration without new-
ly formed blood vessels) (Figure 2C).
Long-term surviving neonatal allografts73
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after IT immune modulation showed
neovascularization which was similar to
the isografts (Figure 2D). In contrast to
the isografts, however, after IT immune
modulation also parenchymatous infiltra-
tion was  present.
We also analyzed whether obliterated
CA’s were present in the neonatal cardiac
allografts in the IT immune modulated
group. Staining for VSM cell α-actin in-
dicated, however, that virtually no CA’s
were present anymore (Figure 3G), which
was similar to the neonatal AO isografts.
Whereas in normal, non-transplanted neo-
natal cardiac tissue CA’s surrounded by
α-actin positive medial VSM cells are
clearly present (Figure 3B), CA’s in sub-
cutaneously transplanted cardiac tissue
are no longer functional and disappear
with time. Since obliteration of the vas-
cular lumen of CA’s with α-actin posi-
tive VSM cells is the hallmark of CTD-
related histopathology, these results sug-
gest that the neonatal heart-in-ear trans-
plant model is not suitable to study the
development of TA.
Although CA’s had completely disap-
peared, high numbers of apparently new-
ly formed blood vessels were observed.
RECA-1 staining confirmed the presence
of endothelial cells on the luminal surface
of these vessels (Figure 3F). To determine
the origin of the blood vessel structures,
MHC class I haplotype specific immuno-
histochemistry was performed. Staining
using mAb OX18 (pan MHC class I) con-
Figure 2.General histology (hematoxylin & eosin staining) of neonatal cardiac allografts transplanted
in the ear-pinnae of recipient rats in the different treatment groups. (A) AO isograft (group 7), 57 days
post transplantation, (B) acutely rejected allograft (group 4), 8 days post transplantation, (C) CsA + ALS
only treatment (group 5), 25 days post transplantation, and (D) IT immune modulation (group 6), 57
days post transplantation. Magnification x400.74
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firmed the presence of MHC class I anti-
gen expression on the EC’s covering the
newly formed blood vessels (Figure 3F).
Moreover, the cardiac tissue was heavily
infiltrated by MHC class I expressing in-
flammatory cells. Staining with mAb
OX27 (donor specific) indicated that the
transplanted myocardial tissue itself ex-
pressed MHC class I, whereas normal,
non-transplanted neonatal cardiac tissue,
hardly expressed MHC class I antigens
(Figure 3E and J). Moreover, the EC’s
covering the newly formed blood vessels
express the donor-type MHC class I ha-
plotype (inset Figure 3J). This observa-
tion suggests that those newly formed
blood vessels are derived from the graft
itself, and are not the result of ingrowth
from the periphery of recipient-derived
blood vessels. This was confirmed by
staining with the recipient haplotype
MHC class I specific mAb U9F4, which
was negative on EC’s of the intragraft
blood vessels, whereas positive staining
was observed on EC’s of veins and arte-
rioles present in (recipient) ear tissue (not
shown). The myocardial tissue was heavi-
ly infiltrated with recipient-derived in-
flammatory cells which were U9F4 posi-
tive (Figure 3I). The newly formed blood
vessel structures contained recipient-de-
rived inflammatory cells, indicating that
the graft and host vasculature were con-
nected (inset Figure 3I). Because of an
ongoing inflammatory response in the
myocardial tissue, the vascular EC’s have
become activated and recipient-derived
inflammatory cells adhere to the sticky
EC’s (Figure 3F).
Discussion
The results obtained after vascularized
cardiac transplantation clearly indicate
that IT immune modulation induces per-
manent (>125 days) graft survival in over
90% of the recipient rats in the MHC-in-
compatible PVG to AO rat strain combi-
nation. Most cardiac allografts transplan-
ted after IT immune modulation remained
beating for over 450 days, however, the
development of transplant arteriosclero-
sis (TA) was not prevented13. In this study
we analyzed the efficacy of IT immune
modulation after allogeneic non-vascular-
ized tissue transplantation (skin and neo-
natal heart) which was compared to vas-
cularized cardiac transplantation.
In contrast to the data obtained after vas-
Figure 3.(facing page) Immunohistochemical analysis of normal, non-transplanted, neonatal PVG car-
diac tissue (A-E) and a PVG allograft (50 days post transplantation) after IT immune modulation (F-J).
(A) EC’s in neonatal cardiac tissue. (B) α-actin positive medial VSM cells in neonatal cardiac tissue. (C)
hardly any MHC class I expression is observed on non-transplanted neonatal cardiac tissue. (D) and (E)
confirmed the absence of MHC class I expression on non-transplanted neonatal cardiac tissue using the
MHC class I haplotype specific mAb’s U9F4 (AO specific, negative control) and OX-27 (PVG spe-
cific), respectively. Arrowheads in figures A-E indicate a CA present in normal, non-transplanted, car-
diac tissue. (F) Newly formed blood vessels contain EC’s as indicated by positive RECA-1 staining.
Arrows indicate inflammatory cells adhering to the endothelium. (G) Virtually no α-actin positive VSM
cells are surrounding the newly formed blood vessels. (H) Intense MHC class I expression on infiltrat-
ing inflammatory cells as well as endothelium. (I) Infiltrating inflammatory cells are of recipient (AO)
origin as indicated by positive U9F4 staining. The inset shows recipient-origin (U9F4 positive) of lumi-
nal inflammatory cells (arrows), whereas the EC’s are U9F4 negative suggesting graft-origin (arrow-
head). (J) Graft-origin of EC’s was confirmed by positive staining using mAb OX-27 (arrowhead),
whereas the luminal inflammatory cells are OX-27 negative (arrows).76
Chapter 3
cularized cardiac allografting, IT immune
modulation did not prolong survival of
skin allografts in the PVG to AO strain
combination compared to control animals
treated with ALS and CsA only. These
results are essentially the same as those
obtained by Nakafusa et al.21,22, who per-
formed skin grafting experiments in the
fully MHC disparate Lew (RT-1l) to Buf
(RT-1b) strain combination after donor-
specific IT immune modulation. Similar
results were obtained after kidney trans-
plantation using this protocol. In their
study, cardiac allografts showed signifi-
cantly prolonged graft survival; 88% of
the animals accepted their grafts perma-
nently (MST >153 vs. 7 days). Our data
and data reported by Nakafusa et al. indi-
cate the presence of tissue-specific non-
MHC antigens on kidney and skin al-
lografts, which are presumably lacking on
splenocytes and, therefore, may account
for organ-specific immunogenicity and
graft rejection. We also performed skin
grafting experiments with intrathymic
inoculation of donor-derived keratino-
cytes instead of splenocytes. This modi-
fication resulted in significant prolonga-
tion of skin graft survival; 40% of the
animals accepted their skin grafts over 50
days, suggesting that tissue specific anti-
gens indeed might play a role in IT im-
mune modulation23.
We also investigated whether IT immune
modulation prevented rejection and in-
duced prolonged graft survival of neona-
tal cardiac allografts transplanted subcu-
taneously in the ear-pinnae of recipient
rats. After Fulmer et al.14 for the first time
described the neonatal heart-in-ear trans-
plantation model in mice, several other
groups have applied this technique in mice
and rats to study the effect of immuno-
suppressive agents on cardiac allograft
survival24,25, the level of cytokine gene
expression in rejecting grafts26, and the
influence of MHC and non-MHC genes
on allograft rejection27.
Our data show that the neonatal heart-in-
ear transplantation model is a useful al-
ternative model to study IT immune mod-
ulation. The results clearly demonstrate
that IT immune modulation significantly
prolongs survival of subcutaneously
transplanted neonatal cardiac tissue in the
PVG to AO strain combination (MST 218
vs. 20 days).
We recently reported that following IT
immune modulation vascularized cardi-
ac allografts still develop TA increasing
with time13. Development of TA is the
hallmark of chronic transplant dysfunc-
tion (CTD), which is being recognized as
the most important problem in clinical
organ transplantation today5.
Development of TA after subcutaneous
transplantation of neonatal cardiac tissue
is unlikely, since the primary targets for
TA, i.e. the CA’s, are nonfunctional after
subcutaneous, non-vascularized trans-
plantation. Routine histology as well as
immunohistochemical analysis revealed
that CA’s were no longer detectable in
long-term surviving allografts after IT
immune modulation as well as in AO
isografts. In contrast to vascularized car-
diac allografts, however, neonatal car diac
allografts and isografts showed presence
of high numbers of large blood vessels
which appeared to be newly formed and
had developed from the graft’s own cells.
The precise trigger for this formation of
cavernous-like vessels is unknown, but
ischemia/hypoxia of myocardial tissue
might be involved.
So, although new, graft-derived, blood77
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vessel structures develop in long-term
surviving allografts, these vessels are not
obliterated by proliferating α-actin posi-
tive VSM cells. In fact, virtually no VSM
cells are present in these vessels at all.
Although not clear from the histological
analyses, these newly formed blood ves-
sels should have connections with the re-
cipient’s vasculature since recipient-de-
rived inflammatory cells, sticking to the
graft-derived EC’s, are clearly present in
the lumen of the newly formed vessels.
These results suggest that vascular rejec-
tion is persisting and, coinciding with the
ongoing parenchymatous inflammatory
response, may lead to further graft dam-
age and loss of contractile activity even-
tually.
In conclusion, also after transplantation
of allogeneic non-vascularized cardiac tis-
sue, IT immune modulation significantly
prolonged graft survival. We propose that
since the appropriate CA’s are lacking in
long-term surviving cardiac tissue, TA
does not develop. Instead, neo-angio-
genesis in graft tissue with graft derived
blood vessels occurs in which TA is does
not develop. Why the newly formed blood
vessels do not develop TA in spite of an
ongoing local alloresponse remains puz-
zling, and as such this model may pro-
vide information how to prevent the de-
velopment of TA.
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Abstract
Background. CMV infection appears to be an important risk factor in the develop-
ment of transplant-related vasculopathy (i.e., transplant arteriosclerosis, TA). In this
paper, we studied the severity of TA development, with or without additional RCMV
infection, in different donor/recipient combinations. Moreover, the relation between
timing of infection and enhanced development of TA was studied.
Methods.  Allogeneic aorta transplantation was performed in the BN to Lew, Lew to
BN, PVG to AO, and DA to WF rat strain combinations, and the severity of TA was
analyzed. To study the effect of timing of RCMV infection on TA, Lew recipients
were infected at several time points before and after BN aortic allografting. More-
over, transmission of infectious virus from BN donors to Lew recipients by the graft
was studied.
Results.  Lew recipients only developed weak TA 4 weeks after transplantation. AO
and WF recipients developed also weak TA which was similar to Lew recipients. In
contrast, BN recipients showed a four-fold increase in the amount of TA compared to
Lew recipients. RCMV infection resulted in enhanced TA only when Lew recipients
were infected 1 day after transplantation (i.e., coinciding with the beginning of the
rejection response). This effect was not present in the other weak TA strain combina-
tions (PVG to AO and DA to WF). Although transmission of virus from the graft to
the recipient occurred after transplantation of a graft from an infected donor 5 and 10
days p.i., CMV-enhanced development of TA was not observed.
Conclusions. RCMV enhances the development of TA in Lew recipients only when
acute rejection and acute infection are present simultaneously. However, this effect
cannot be generalized, and obviously there are more factors than timing of infection
and weakness of TA that determine the CMV-enhanced development of TA.83
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Introduction
Solid organ transplantation has become
an established therapy for patients with
end-stage organ failure. However, despite
the introduction of new immunosuppres-
sive agents in the last two decades, de-
velopment of chronic transplant dysfunc-
tion (CTD) is still a complicating factor
for long-term graft survival. To date, CTD
has become the most important problem
in clinical organ transplantation after the
first perioperative year which cannot be
prevented by current immunosuppressive
protocols1-3. Depending on the type of
organ grafted, 4% to >50% of solid organ
transplants show functional deterioration
and histological changes characteristic of
CTD three years after transplantation4-6.
Irrespective of the organ grafted, graft
vessels eventually develop so called trans-
plant arteriosclerosis (TA), which is, how-
ever, most prominent in cardiac al-
lografts7,8. This vascular remodeling pro-
cess consists of progressive concentric in-
timal thickening (intimal hyperplasia or
neointima formation) coinciding with
ongoing perivascular inflammation (peri-
vasculitis). TA has generally been ac-
cepted as the main cause for progressive
deterioration in graft function. Pathogen-
esis of TA seems to be multifactorial but
precise mechanisms involved in the de-
velopment of this remodeling process still
remain obscure. Risk factors appear to in-
clude cold ischemia time and reperfusion
injury, MHC disparity between donor and
recipient and number of rejection epi-
sodes2,7. In addition, cytomegalovirus
(CMV) infection has been associated with
the development of TA. Studying human
cardiac allografts, Grattan et al. showed
a positive correlation between the pres-
ence of cytomegalovirus and graft athero-
sclerosis9. In addition, Almond et al.
showed CMV to be a risk factor for the
development of CTD in human kidney
allografts10. However, also data have been
described suggesting that CMV does not
contribute to TA after solid organ trans-
plantation11-13. A possible explanation for
these conflicting results is that in some
studies patients received prophylactic
treatment with antiviral drugs preventing
viral replication immediately after trans-
plantation, whereas in other studies anti-
viral therapy was started when active
CMV infection was already manifest.
Also in several experimental transplant
models in rats (heart, kidney, liver and
trachea) the role of CMV infection on the
development of CTD related pathology
has been studied. Using Rat Cytomegalo-
virus (RCMV), it was shown that viral
infection accelerates the development of
CTD related pathology14-17. In the aortic
transplant model in rats, which is a well
established and reproducible model to
study development of TA18, we and oth-
ers have shown that RCMV infection (in-
jected 1 day after transplantation) results
in enhancement of both the perivascular
inflammatory response19-21 and neointima
formation21-25. The increase in perivascu-
lar inflammation observed after RCMV
infection peaks around 1 month after
transplantation, whereas the effects on
neointima formation can be detected 2-3
months after transplantation. Therefore,
it has been hypothesized that the increased
perivascular inflammatory response after
viral infection is the cause of enhanced
neointima formation. This is strengthened
by the observation that an increase in the
viral load results in increased perivascu-
litis20. Inhibition of viral replication and84
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inflammation using antiviral22,25 and
immunosuppressive drugs26, respectively,
prevent RCMV enhanced development of
TA. These observations further indicate
that CMV may play a role in the process
of TA development.
Clinical data suggest that CMV infection
enhances development of CTD related
pathology only when active CMV infec-
tion and acute rejection are present simul-
taneously27,28. We previously showed that
RCMV infection of aortic allograft re-
cipients resulted in enhanced TA only in
a donor/recipient combination in which
only weak TA develops in the absence of
RCMV24. In combinations that develop
strong TA, additional RCMV infection
seems not be able to further accelerate or
enhance the development of TA.
In this paper we investigated the role of
the donor/recipient combination and the
timing of CMV infection on the CMV-
enhanced development of TA after allo-
geneic aorta transplantation in rats. We
first analyzed the development and sever-
ity of TA in various MHC-incompatible
donor/recipient combinations without ad-
ditional RCMV-infection. Based on these
results we selected a donor/recipient com-
bination with weak TA development to
study the effect of timing of CMV infec-
tion on the development of TA. Finally,
to test whether our results can be general-
ized, we tested whether CMV infection
at the time of acute rejection resulted in
enhanced TA in other ‘weak combina-
tions’. However, to our surprise, both oth-
er combinations tested failed to show the
CMV effect on the development of TA,
even after sublethal irradiation of the re-
cipients prior to transplantation and infec-
tion. Obviously, there are more factors
involved in determining whether CMV
enhances development of TA, than the
timing of infection and the ‘weakness’ of
TA.
Materials and Methods
Animals
Specified pathogen free male PVG (RT-
1c), AO (RT-1u), DA (RT-1a), WF (RT-1u),
Lew (RT-1l), and BN (RT-1n) rats were ob-
tained from Harlan (Zeist, the Nether-
lands). Lew and BN rats used for RCMV
infection experiments were bred at the
central animal facilities of the Maastricht
University. The rats were 8-10 wk of age,
maintained under clean conventional con-
ditions, and were fed standard rat chow
and acidified water ad libitum. All ani-
mals received humane care in compliance
with the Principles of Laboratory Animal
Care (NIH Publication No.86-23, revised
1985) and the Dutch Law on Experimen-
tal Animal Care.
Aorta transplantation
Aortic allografts (10-12 mm) were trans-
planted as described previously18. Brief-
ly, the abdominal aorta between the left
renal artery and the bifurcation was re-
moved from the donor rat and perfused
with saline to remove blood cells. Subse-
quently, the aortic graft was orthotopically
transplanted into the recipient rat via end-
to-end anastomosis using 9-0 nylon su-
ture. Total ischemic time was consistent-
ly less than 30 minutes during which the
grafts were kept in ice-cold saline. Trans-
plantations were performed in the follow-
ing MHC incompatible strain combina-
tions: PVG to AO, DA to WF, BN to Lew,
and Lew to BN. Isograft controls consist-
ed of aortic grafts transplanted from BN
to BN rats.85
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Experimental groups
To study whether the development of TA
differs among different donor/recipient
combinations (in the absence of RCMV),
aortic transplantations were performed in
the strain combinations as listed in Table
1A. BN allografts transplanted in Lew
recipient rats were explanted 4, 8, 12 and
24 weeks after transplantation (groups 1-
4) and processed for histological analy-
sis. In addition, aortic allografts were
transplanted in the Lew to BN (group 5),
PVG to AO (group 6) and DA to WF
(group 7) strain combinations, and ex-
planted 4 weeks after transplantation. BN
isografts (group 8) served as controls and
were sacrificed 12 weeks after transplan-
tation.
To study the effect of timing of RCMV
infection on the development of  TA, re-
cipient rats received 5 Gy total body irra-
diation (TBI) 6 hours before administra-
tion of virus to promote viral replication.
Recipient rats were divided into 6 differ-
ent treatment groups (groups 9-14) as list-
ed in Table 1B. Allograft recipients were
mock-infected (group 9) or RCMV-infect-
ed shortly after transplantation (day 1 or
day 1+5; groups 10 & 11) or late after
transplantation (day 21 or day 21+25;
groups 12 & 13). In addition, one group
of recipient rats was infected 21 days pri-
or to transplantation (group 14) to study
the effect of chronic RCMV infection of
the host on the development of TA.
To study whether RCMV is transferred
after aortic transplantation resulting in
systemic infection of the recipient and
possibly affecting TA, allografts were
transplanted into irradiated hosts 5, 10,
and 21 days after infection of the donor
(groups 15, 16, and 17, respectively).
Recipient rats were sacrificed 7 weeks
after transplantation and grafts were re-
moved and processed for histological
analysis and virus detection.
Finally, we studied whether RCMV in-
fection influences TA development in oth-
er combinations than the BN to Lew strain
combination (Table 1C). Therefore, aor-
tic transplantation and subsequent RCMV
infection (with or without TBI) was per-
formed in the PVG to AO (groups 18-21)
as well as the DA to WF (groups 22 &
23) strain combination. Grafts were re-
moved at 12 weeks after transplantation
and processed for histological analysis.
Infection with RCMV
RCMV infection was performed by intra-
peritoneal (i.p.) injection of 3x105 plaque
forming units (pfu) RCMV (Maastricht
strain)29. The virus-pool used consisted of
a salivary gland homogenate which was
prepared as described elsewhere30. Most
recipients that were RCMV-infected were
sublethally irradiated (5 Gy) 1 day after
aortic transplantation. This method of
immune suppression is standard for the
animals used in our infection experiments
and is routinely used to enhance the re-
plication and dissemination of RCMV in
adult rats31,32. To analyze whether irradi-
ation is a prerequisite for RCMV-en-
hanced TA development, recipients from
groups 18, 20, 22, and 23 were not irradi-
ated before infection (Table 1C).
Transfer of infectious virus by aortic
allografts
To study whether aortic allografts carries
the risk to transfer RCMV to recipient rats
resulting in systemic RCMV infection of
the host, a sensitive infection transfer as-
say was used as described elsewhere33.
Donor BN rats were sublethally irradi ated86
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Table 1. Groups used for aorta transplantation to study the effect of recipient genotype,
RCMV infection of the recipient, and transfer of RCMV from the donor on the
development of transplant arteriosclerosis.
Group N a Graft Graft 5 Gy TBI RCMV RCMV Day of Sacrifice d
donor recipient  recipient recipient b donor b infection c
A
19 B N Lew --- - 4
24 B N Lew --- - 8
34 B N Lew --- - 12
44 B N Lew --- - 24
54 Lew BN --- - 4
66 PVG AO --- - 4
74 D A W F --- - 4
85 B N BN --- - 12
B
95 B N Lew +-- 1 (mock) 7
10 5 BN Lew ++- 17
11 5 BN Lew ++- 1 & 5 7
12 5 BN Lew ++- 21 7
13 5 BN Lew ++- 21 & 25 7
14 5 BN Lew ++--21 7
15 5 BN Lew +-+-5 7
16 6 BN Lew +-+-10 7
17 4 BN Lew +-+-21 7
C
18 6 PVG AO --- - 12
19 4 PVG AO +-- - 12
20 6 PVG AO -+- 11 2
21 5 PVG AO ++- 11 2
22 4 DA WF --- - 12
23 5 DA WF -+- 11 2
a number of animals analyzed
b animals were infected with 3x105 plaque forming units (pfu) RCMV salivary gland
  homogenate
c animals were non-infected (-) or infected before or after transplantation (day 0)
d weeks after transplantation
(5 Gy) followed by i.p. injection of 3x105
pfu RCMV. After 5, 10, and 21 days post
infection, aorta allografts were transplan-
ted into sublethally irradiated Lew re-
cipient rats. At the time of transplantation,
parts of the donor aorta and salivary
glands were removed and processed for
RCMV detection (plaque assay, immuno-
histochemistry and PCR analysis). Re-
cipient rats were sacrificed 7 weeks after
transplantation. Salivary glands and aor-
tic tissue (both the graft and autologous87
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part) were removed and processed for
RCMV detection.
Detection of infectious virus by plaque-
assay
Presence of infectious virus was quanti-
tated using a plaque-assay as described
previously29. Salivary glands and aortic
tissue (graft as well as autologous part)
were suspended in EMEM (supplemen-
ted with 2% fetal calf serum (FCS), 2 mM
L-glutamine, 1% non-essential amino ac-
ids (all obtained from Gibco BRL, Life
Technologies B.V., Breda,  The Nether-
lands) and 0.1 mg/ml gentamycin (Cen-
trafarm B.V., Etten-Leur, The Nether-
lands) in a 10% weight/volume ratio. Tis-
sues were homogenized and sonicated,
and subsequently 10- and 100 fold dilu-
tions of the supernatants were inoculated
on a confluent rat embryonic fibroblast
monolayer in 24-well tissue culture plates
(Greiner B.V., Alphen a/d Rijn, The Ne-
therlands).  After 7 days of incubation in
culture medium containing 0.25% aga-
rose (Seakem ME, FMC Bioproducts,
Rockland, Maine, USA), cells were fixed
in 10% PBS buffered formalin and stained
with methylene-blue. The number of
plaques was quantitated microscopically,
and the virus titer was calculated and ex-
pressed as plaque forming units (pfu).
Detection of RCMV antigens
For detection of RCMV antigens, 4 ￿m
formalin-fixed paraffin embedded tissue-
sections were stained with RCMV mon-
oclonal antibody (mAb 8)34. Briefly, af-
ter deparaffination tissue sections were
incubated with mAb8 for 60 minutes.
Subsequently, sections were incubated
with a second step alkaline-phosphatase-
conjugated rabbit anti-mouse antibody
(DAKO A/S, Glostrup, Denmark) for 30
minutes. The chromogen Fast Red was ap-
plied for 30 minutes, and subsequently
sections were counterstained with May-
er’s hematoxylin, dehydrated and cover-
slipped.
Detection of RCMV DNA
To determine the presence of viral DNA,
salivary glands and aortic tissue were cut
in small pieces and stored at -80￿C until
analysis. After DNA extraction, a semi-
quantitative nested PCR was performed
on the RCMV DNA polymerase gene
(GenBank accession no. U50550)35.Total
cellular DNA was extracted from the sali-
vary glands and aorta with a DNA extrac-
tion kit (Gull Laboratories, Salt Lake City,
Utah, USA). The DNA samples were se-
rially diluted from 100 to 10-8 ￿g. Each
of the diluted DNA samples was incuba-
ted for 10 min. at 95￿C, immediately
cooled on ice, and subjected to a two
round (nested) PCR. The sequences of the
primers as well as the PCR conditions are
described elsewhere35. The first and sec-
ond round PCR resulted in DNA frag-
ments of 536 bp and 431 bp, respective-
ly. The PCR products were analyzed by
agarose gel electrophoresis and visualized
by ethidium bromide staining.
Quantitation of transplant arteriosclero-
sis
Grafts removed at autopsy were fixed in
10% PBS buffered formalin and embed-
ded in paraffin. Tissue sections (4 ￿m)
were taken from the center of each graft
and were stained with Lawson solution
(Klinipath, Duiven, The Netherlands) to
visualize elastin fibers. TA was quanti-
tated using a computerized morphomet-
ric analysis system (QWin Software,88
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Leica Microsystems B.V., Rijswijk, The
Netherlands). Presence of  TA was ex-
pressed as the surface neointima/surface
media ratio.
Statistical analysis
To analyze differences in the ratio surface
neointima/surface media for statistical
significance, the Kruskal-Wallis One-Way
ANOVA was performed. If this test re-
vealed a significant difference, a Mann-
Whitney U test was performed to analyze
differences between subgroups. Differen-
ces were considered to be statistically sig-
nificant when P-values were <0.05.
Results
TA development in different strain com-
binations
Development of TA after aortic transplan-
tation was analyzed in different donor/
recipient combinations (Table 1A). The
development of TA was quantitated 4
weeks after transplantation and the results
are shown in Figure 1A. Of the four strain
combinations analyzed, three developed
weak TA, whereas one developed strong
TA. BN allografts transplanted into Lew
recipients (group 1) resulted in develop-
ment of only weak TA. In contrast, Lew
allografts transplanted into BN recipient
rats (group 5) showed a four-fold increase
in the amount of TA compared to Lew
recipients (P<0.05). Although slightly
higher compared to Lew recipients, also
AO recipients of PVG allografts (group
6) and WF recipients of DA allografts
(group 7) showed weak TA 4 weeks after
transplantation (P<0.05 vs. Lew to BN).
Representative photomicrographs of aor-
tic allografts transplanted in the BN to
Lew and Lew to BN strain combinations
(4 weeks after transplantation) are shown
in Figures 1B and C.
Since Lew recipients developed only
weak TA 4 weeks after transplantation,
we analyzed whether there is a further
increase in TA at later time points. Aortic
allografts were transplanted in the BN to
Lew combination, and grafts were re-
moved 4, 8, 12 and 24 weeks after trans-
plantation (n=4/time point, groups 1-4)
and the amount of neointima formation
was quantitated. BN isografts served as
syngeneic controls (group 8) and were
removed 12 weeks after transplantation
(n=5). Figure 2 shows the development
of TA (expressed as the ratio NI/media)
at different time points after transplanta-
tion. One month after transplantation, BN
allografts showed mild TA. An increase
in the amount of  TA is observed at 8 and
12 weeks after transplantation, reaching
maximal TA 24 weeks after engraftment.
In contrast to Lew recipients, BN recipi-
ents developed the similar amount of TA
within 4 weeks after transplantation and
no further increase in time was observed
(data not shown). BN isografts hardly
show any signs of TA 12 weeks after
transplantation.
Effect of timing of RCMV infection on the
development of TA
We recently showed that RCMV infec-
tion enhances development of TA only in
strain combinations that develop weak TA
after allogeneic aorta transplantation24.
Figure 1A shows that Lew recipients de-
velop weak TA after transplantation of BN
allografts developing with time (Figure
2), whereas BN recipients are ‘high-re-
sponders’ and develop maximal TA al-89
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Figure 1. Development of TA (1 month after transplantation) after allogeneic aorta transplantation in
different rat strain combinations. (A) Neointima formation is expressed as the ratio surface neointima/
surface media. (* P<0.05 vs. BN to Lew, PVG to AO, and DA to WF combinations, Mann-Whitney U
test). Representative photomicrographs after Lawson-staining (elastin) of aortic allografts transplanted
in the (B) BN to Lew and (C) Lew to BN strain combinations. Grafts were explanted 4 weeks after
transplantation. Abbreviations: a, adventitia; iel, internal elastic lamina; l, lumen; m, media; ni, neointima.
Magnification x50
ready 1 month after transplantation.
Therefore, the BN to Lew combination
was used to study the effect of timing of
RCMV infection on the development of
TA. Recipient rats were mock-infected
(group 9) or infected with RCMV 1 day
(group 10) or 21 days (group 12) after
transplantation. In addition, one group of
rats was infected 21 days prior to trans-
plantation (group 14). Grafts were re-
moved 7 weeks after transplantation and
the amount of neointima formation was
quantitated (Figure 3A). Only infection
shortly after transplantation (day 1,
group 10) showed a significant increase
(P<0.05) in neointima formation com-90
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pared to mock-infection. Infection 21
days before (group14) and 21 days after
(group 12) transplantation did not result
in increased neointima formation. To ana-
lyze whether the absence of increased
neointima formation in animals infected
21 days after transplantation was due to a
low viral load, Lew recipients were in-
fected twice shortly (days 1 & 5, group
11) or late (days 21 & 25, group 13) after
transplantation. Again, only infection
shortly after transplantation resulted in
increased neointima formation 7 weeks
after transplantation (ratio neointima/me-
dia: 1.68–0.14 (group 11) vs. 1.17–0.26
(group 13) and 1.11–0.25 (group 9),
P<0.05). These results indicate that the
viral load is not responsible for the dif-
ferences observed, and that RCMV infec-
tion enhances TA only when infection is
given around the time of transplantation.
Effect of RCMV infection of the donor on
the development of TA
Since primary CMV infection after trans-
plantation of an organ from a seroposi-
tive donor into a seronegative recipient
has been associated with an increased risk
for the development of TA, we analyzed
Figure 2. Kinetics of the development of TA after
allogeneic aorta transplantation in the BN to Lew
strain combination. Neointima formation is ex-
pressed as the ratio surface neointima/surface me-
dia.
Table 2. Risk of transfer of RCMV from the donor to the recipient after allogeneic
aorta transplantation at different time points after infection of the donor
(represented as the number of positive animals/total number of animals).
         donor (BN)                          recipient (Lew) 7 weeks post transplantation
transplantation             IHC          plaque-assay IHC                    plaque-assay
(days p.i.)
           aorta             aorta
aorta SG aorta SG SG SG
auto graft auto graft
5 0/4 0/4 1/4 0/4 0/6 0/6 4/6 0/6 0/6 6/6
10 0/4 0/4 1/4 4/4 0/4 0/4 2/4 0/4 0/4 3/4
21 0/2 0/2 0/2 2/2 0/4 0/4 0/4 0/4 0/4 0/4
(Abbreviations: IHC, RCMV specific immunohistochemistry; p.i., post infection; SG,
salivary gland)91
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whether reactivation of RCMV trans-
ferred by the graft enhances neointima
formation after transplantation. We first
analyzed the presence of virus in aortic
tissue at several time points  (5, 10, and
21 days) after infection. Moreover, trans-
fer of infectious virus after transplanta-
tion, resulting in systemic infection of the
recipient, and its possible effect on the
development of TA was analyzed. BN
donors were infected with RCMV and 5,
10, and 21 days p.i. aortic allografting was
performed into irradiated Lew recipient
rats (groups 15, 16, and 17, respectively).
At the time of transplantation, also parts
of (non-transplanted) donor aorta and sali-
vary glands were removed and processed
for virus detection. Aortic grafts (BN) as
well as autologous recipient aorta (Lew)
and salivary glands were removed 7
weeks after transplantation and processed
for virus detection and neointima forma-
tion. Results of RCMV-specific immuno-
histochemistry (mAb8) and plaque-assay
are summarized in Table 2. Using specific
immunohistochemistry RCMV infected
cells could not be detected in donor aor-
tic tissue and salivary glands 5, 10 and 21
days post infection. However, results from
the plaque-assay indicated presence of in-
fectious virus in aortic tissue 5 and 10
days after infection (1/4 animals at both
time points). In the salivary glands of the
donor-rats infectious virus was present in
all animals analyzed 10 and 21 days post
infection. These data indicate that aortic
tissue of some of the animals did contain
infectious virus relatively shortly after
infection (5 and 10 days p.i.). Three weeks
after infection, RCMV could not be de-
tected in aortic tissue by immunohis-
tochemistry and plaque-assay, whereas
the salivary glands were RCMV positive.
Although RCMV could not be detected
by plaque-assay in aortic tissue transplan-
ted 5 or 10 days post infection in most
animals, transplantation of these grafts
resulted in transmission of virus to the
recipient. Seven weeks after transplanta-
Figure 3.(A) Effect of timing of RCMV infection
on the development of TA after allogeneic aorta
transplantation in the BN to Lew rat strain combi-
nation 7 weeks after transplantation. Neointima for-
mation is expressed as the ratio surface neointima/
surface media. (* P<0.05, Mann-Whitney U test).
(B) Effect of  RCMV infection on the development
of TA after allogeneic aorta transplantation in the
PVG to AO and DA to WF rat strain combinations
12 weeks after transplantation. Neointima forma-
tion is expressed as the ratio surface neointima/
surface media.92
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Figure 4. Transfer of RCMV after transplantation of an aortic allograft 5 days after infection of the
donor. (A) HE staining of recipient salivary gland 7 weeks after transplantation, and (B) mAb8 (RCMV)
staining of recipient salivary gland 7 weeks after transplantation. Arrowheads indicate RCMV infected
ductal epithelial cells. Magnification x400. (C) Nested RCMV PCR performed on aortic and salivary
gland tissue of the donor at the time of transplantation, and performed on the aortic graft and salivary
gland tissue of the recipient 7 weeks after transplantation. Grafts were transplanted 5, 10, and 21 days
after infection of the donor with RCMV.93
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tion 6/6 and 3/4 recipient rats (transplan-
ted 5 and 10 days p.i., respectively)
showed signs of systemic infection as in-
dicated by the presence of infectious vi-
rus in their salivary glands. Figures 4A
and B show representative photomicro-
graphs of RCMV infected cells in sali-
vary glands of recipient rats transplanted
with aortic allografts 5 days after infec-
tion of the donor.
Twenty-one days p.i. donor aortic tissue
did not contain detectable levels of
RCMV, whereas donor salivary glands
contained infectious virus as determined
by the plaque-assay. After transplantation,
no virus could be detected in the recipi-
ent salivary glands and aortic tissue (graft
and autologous part) suggesting that no
virus transmission had occurred. How-
ever, since RCMV specific immunohisto-
chemistry as well as plaque-assay are rel-
atively insensitive techniques to detect
virus infected cells, a PCR-based ap-
proach was followed to detect viral DNA
in aortic tissue and salivary glands after
transplantation.
RCMV specific nested PCR was per-
formed on donor (aorta and SG) and re-
cipient (autologous aorta, aorta graft, and
SG) tissues. The results obtained by the
nested PCR confirmed the results ob-
tained by IHC and plaque-assay and are
shown in Figure 4C. Five and ten days
p.i., viral DNA could be detected in do-
nor aortic tissue, whereas the donor sali-
vary glands did not contain detectable lev-
els of viral DNA. Twenty-one days p.i.,
however, no viral DNA could be detec-
ted in donor aortic tissue, whereas at this
time point viral DNA was present in the
donor salivary glands. After transplanta-
tion, viral DNA could be detected in the
recipient salivary glands only when trans-
plantation was performed at 5 and 10 days
p.i.. When transplanted 21 days p.i., no
viral DNA could be detected in the re-
cipient salivary glands 7 weeks after trans-
plantation. This indicates that indeed no
viral transmission had occurred, confirm-
ing the results obtained by plaque-assay.
BN donors were infected 21 days prior to
transplantation (group 17) and after 7
weeks, grafts were removed and the
amount of neointima formation was quan-
titated. As expected, infection of the do-
nor 21 days prior to transplantation did
not enhance neointima formation com-
pared to mock-infection (ratio neointima/
media: 1.10–0.18 (group 17) vs. 1.11
–0.25 (group 9)), since we showed that
21 days p.i. no detectable amounts of vi-
rus were present in aortic tissue, and no
viral transmission was observed after
transplantation. Although we clearly
showed effective viral transmission after
transplantation of aortic allografts 5 or 10
days p.i., no enhancing effect on the de-
velopment of TA was observed after trans-
plantation (data not shown). One expla-
nation is that the amount of virus which
is being transferred from the aortic al-
lograft to the recipient at the beginning of
the rejection response is not sufficient to
induce this enhancing effect.
Effect of RCMV infection on the develop-
ment of TA in other strain combinations
RCMV infection enhances neointima for-
mation after aortic allografting in the BN
to Lew rat strain combination only when
RCMV is administered shortly after trans-
plantation (day 1 and/or 5 post transplan-
tation), indicating that active RCMV in-
fection and acute rejection should be pre-
sent simultaneously. To study whether this
effect can be generalized and is also94
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present in other strain combinations that
show weak TA in the absence of RCMV,
we performed similar experiments in the
MHC incompatible PVG to AO (groups
19-21) and DA to WF (groups 22 & 23)
strain combinations. In the PVG to AO
combination, we also tested whether ir-
radiation of the recipient 6 hr before in-
fection would facilitate the possible
RCMV mediated increase in TA develop-
ment. Therefore, recipient rats were left
untreated (group 18) or received 5 Gy TBI
(group 19). Two other groups included
RCMV infected recipient rats without
(group 20) or with (group 21) 5 Gy TBI.
Grafts were removed at 12 weeks after
transplantation and the surface neointima
was quantitated. Results are shown in Fi-
gure 3B. In contrast to RCMV infection
after transplantation in the BN to Lew
strain combination, RCMV does not en-
hance neointima formation in the PVG to
AO combination.
In the DA to WF combination, we also
observed development of weak TA 4
weeks after transplantation. To investigate
the effect of RCMV infection on the de-
velopment of TA in this particular strain
combination, DA aortic allografts were
transplanted into WF recipient rats which
were left untreated (group 22) or RCMV
infected (group 23) 1 day after transplan-
tation. Grafts were removed 12 weeks
after transplantation and neointima forma-
tion was quantitated. Results are shown
in Figure 3B. Also in this strain combina-
tion, RCMV infection did not result in
enhanced neointima formation.
Discussion
Chronic transplant dysfunction (CTD),
histologically characterized by oblitera-
tion of the graft vasculature (i.e., trans-
plant arteriosclerosis, TA), is the primary
cause of allograft loss after the first peri-
operative year and is today’s most impor-
tant problem in clinical organ transplan-
tation. The etiology of TA is multifacto-
rial and alloantigen-dependent as well as
independent risk factors have been iden-
tified2,7. Cytomegalovirus (CMV) infec-
tion is one of the alloantigen-independent
factors associated with increased risk for
the development of TA. The role of CMV
infection in the process of TA develop-
ment has been studied after human solid
organ transplantation, but results are con-
flicting9-13. Using the aorta transplant
model in rats, we and others showed that
Rat Cytomegalovirus (RCMV) infection
results in enhanced perivascular inflam-
mation19-21 as well as in enhanced neoin-
tima formation21-25, indicating that also in
this animal model CMV enhances the
development of TA. Several studies sug-
gest that CMV enhances development of
TA only when active CMV infection and
acute rejection are present simultaneous-
ly27,28. In the experimental transplant mod-
els, recipient rats generally are infected 1
day after transplantation, indeed suggest-
ing that active infection and the beginning
rejection response should be present si-
multaneously for CMV-enhanced devel-
opment of TA.
In this study we analyzed whether active
infection at the time of acute rejection is
indeed a prerequisite for the enhancing
effect on TA after allogeneic aorta trans-
plantation in rats, and therefore the tim-
ing of RCMV infection on the develop-95
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ment of TA was studied. However, since
our previous results suggest that CMV
only enhance TA in rat strain combina-
tions with weak TA development after
allogeneic aorta transplantation24, we first
analyzed the development of TA in sev-
eral donor/recipient combinations in the
absence of RCMV infection. Lew recipi-
ents of BN grafts developed weak TA 4
weeks after transplantation, and reached
maximal neointima formation 24 weeks
after transplantation. In contrast, in the
reciprocal Lew to BN combination maxi-
mal neointima formation was already ob-
served 4 weeks after transplantation, in-
dicating that Lew rats are ‘low-respond-
ers’ whereas BN rats are ‘high-respond-
ers’. Similar observations were reported
by Geerling et al.36. Also AO and WF re-
cipient rats showed development of
weak TA compared to BN recipients. Re-
cently we reported that the rate of devel-
opment of TA is for a major part deter-
mined by the recipient genotype37. Such
differences might also explain the differ-
ences in TA development found in this
study. Similar genetic differences might
actually also contribute to the variety in
the incidence and severity of CTD and TA
observed among human transplant recipi-
ents.
Of the four strains tested, Lew recipient
rats showed the weakest development of
TA 4 weeks after transplantation, followed
by AO and WF recipients. Therefore, we
used the BN to Lew strain combination
to study the effect of timing of RCMV
infection on the development of TA. Lew
recipient rats were infected with RCMV
21 days before or 1 day or 21 days after
transplantation. Only infection shortly
after transplantation (1 day) resulted in
enhanced neointima formation. These re-
sults suggest that indeed active infection
and acute rejection should be present si-
multaneously to get enhanced neointima
formation, resembling clinical data on the
effect of CMV on CTD27,28. Moreover,
these results suggest synergistic effects of
CMV infection on the developing
alloresponse shortly after transplantation
as the underlying mechanism for CMV
enhanced development of  TA.
In clinical organ transplantation, primary
CMV infection after transplantation of a
seropositive donor in a seronegative re-
cipient increases the risk for CTD and TA.
To mimick this situation, transplantation
of a graft from an infected donor into an
uninfected recipient was performed. We
analyzed whether also in this situation
CMV enhanced neointima formation
could be observed. Infection of the donor
3 weeks before transplantation did not
result in increased neointima formation.
Since analysis of donor aortic tissue by
RCMV specific immunohistochemistry,
plaque-assay and RCMV-specific PCR
revealed that 3 weeks after infection no
virus is present anymore in aortic tissue,
it is not surprising that transplantation of
an aortic allograft from a RCMV infec-
ted donor 3 weeks after transplantation
did not show enhanced neointima forma-
tion. The course of RCMV infection can
be divided in 3 distinct phases: acute
phase (1-2 weeks p.i.), chronic phase (3-
12 weeks p.i.) and latent phase (>12
weeks p.i.)29,31. In the acute phase several
internal organs can be infected (e.g., kid-
ney, liver, heart), whereas in the chronic
phase infectious virus can only be detec-
ted in the salivary glands. Indeed, the do-
nor salivary glands contained infectious
virus 3 weeks after infection. In contrast
to aortic (and cardiac) allografts, how-96
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ever, kidney and lung allografts can ef-
fectively transfer virus to the recipient
rats, also in the chronic phase of infec-
tion33,38. Even in the latent phase, kidney
allografts have been shown to effectively
transfer RCMV to the host33.
We also transplanted allografts 5 and 10
days after infection (i.e., in the acute phase
of infection). Plaque-assay as well as nes-
ted PCR analysis showed presence of vi-
rus in aortic tissue, and allografting re-
sulted in systemic infection of virtually
all recipient rats. Although RCMV can be
effectively transferred by aortic allografts
if transplanted within 10 days after infec-
tion of the donor, the development of TA
was not enhanced 7 weeks after transplan-
tation. A possible explanation is that the
viral load is not sufficient during the acute
rejection episode to enhance the develop-
ment of TA. Alternatively, the acute in-
fection phase is somewhat delayed after
transplantation of an infected aortic al-
lograft compared to intraperitoneal ad-
ministration of high dosages of RCMV.
In this situation, acute rejection and acute
infection are not present simultaneously
and consequently, RCMV does not en-
hance the development of TA.
Finally, we tested whether our results in
the BN to Lew strain combination could
be generalized. Therefore, aortic trans-
plantation in two other strain combina-
tions, both showing weak TA in the ab-
sence of RCMV, was performed. Recipi-
ent rats were mock- or RCMV infected 1
day after transplantation. However, to our
surprise, in both the PVG to AO and DA
to WF rat strain combinations, RCMV
infection did not result in enhanced neoin-
tima formation.
The effect of RCMV on the development
of TA after allogeneic aorta transplanta-
tion was for the first time described in the
DA to WF rat strain combination by Lem-
ström et al.23. We attempted to reproduce
these data, however RCMV infection did
not result in enhanced neointima forma-
tion 12 weeks after transplantation. Al-
though we used the same strain combina-
tion and the same RCMV strain (Maas-
tricht strain), we were not able to repro-
duce the data as described previously.
Possibly, minor genetic differences be-
tween the rats used in our study and the
rats used in studies described by Lem-
ström et al. may account for this. In addi-
tion, differences in the microbiological
status of the rats used in the different stud-
ies may also have influenced the experi-
mental outcome.
In conclusion, this study shows that the
development of TA after allogeneic aorta
transplantation differs between different
rats strains. The kinetics and severity of
TA are primarily determined by the re-
cipient genotype. RCMV infection en-
hances the development of TA only when
active RCMV infection and acute rejec-
tion are present simultaneously, favoring
synergy between the alloreponse and
CMV infection as the underlying mecha-
nism. This RCMV effect, however, can-
not be generalized, indicating that obvi-
ously there are more factors than time of
infection and recipient-genotype, deter-
mining RCMV enhanced development of
TA.
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Abstract
Background.  Chronic transplant dysfunction (CTD) is the major complication in
long-term survival of solid organ transplants. Histologically, CTD is characterized
by transplant arteriosclerosis (TA), consisting of concentric myointimal proliferation
(vascular smooth muscle cells) resulting in the development of an occlusive neointima
in the arterial structures of the graft. Development of TA apparently is multifactorial
and alloantigen-dependent as well as -independent factors have been identified. How-
ever, also genetic variation between transplant recipients appears to be involved in
the process of TA development.
Methods.  In this study we analyzed the contribution of host MHC and non-MHC
encoded genes on the development of TA in aortic allografts using different rat strains.
Aortic allografts were transplanted in Lew, BN and F344 rats as well as in the MHC-
congenic Lew.1N and BN.1L rat strains. Moreover, allografts were transplanted in
(LewBM ->BN) and (BNBM ->Lew) bone marrow chimeric rats. Grafts were explanted
at different time points after transplantation and the severity of TA was determined by
morphometry.
Results.  Rats bearing the BN non-MHC haplotype (BN and BN.1L) appeared to be
high TA responders compared to rats bearing the Lew non-MHC haplotype (Lew and
Lew.1N). Differences were primarily observed in the kinetics of TA development
rather than in the degree of TA developing eventually. Allografts transplanted in F344
and bone marrow chimeric rats suggested that the high TA responsiveness observed
in BN and BN.1L rats is most likely determined by factors other than the immuno-
logic responder-status.
Conclusion.  The kinetics of TA development is predominantly determined by host
non-MHC encoded determinants, indicating that the rate of development of TA is
genetically controlled. Which factors are responsible for this effect remains unclear.
Since genetic differences between organ transplant recipients appear to determine the
rate of TA development, identification of the gene products responsible for this phe-
nomenon will be essential both in tracing patients who are at risk to develop TA fast,
as well as in developing new strategies to prevent or treat TA.103
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Introduction
To date, the development of chronic trans-
plant dysfunction (CTD) is the primary
cause of loss of solid organ transplants
after the first postoperative year. Unfor-
tunately, an adequate strategy to prevent
or treat CTD is still lacking1,2. The most
characteristic histologic feature of CTD
is transplant arteriosclerosis (TA) which
is characterized by a generalized, concen-
tric intimal thickening predominantly
consisting of vascular smooth muscle
cells intermingled with some inflamma-
tory cells (T cells and macrophages)3,4. TA
has generally been accepted as the main
cause of progressive deterioration in graft
function leading to death or the need for
retransplantation eventually. The patho-
genesis of TA appears to be multifacto-
rial, though alloreactivity of the host
against the graft seems to be the most
important factor contributing to the de-
velopment of TA, and several alloantigen
associated risk factors (e.g., histoincom-
patibility and acute rejection) have been
identified. However, also alloantigen in-
dependent factors like ischemia/reperfu-
sion injury, donor brain death and viral
infections seem to contribute to the de-
velopment of TA1,5.
Among transplant recipients, transplan-
ted with similar HLA-incompatible grafts
and receiving similar immunosuppres-
sion, variation exists in both the rejection
rate and long-term outcome. This varia-
tion has not been fully explained, but data
indicate that different individuals might
display different immune responses
against an allograft (different immunolog-
ic responder status)6. One possible candi-
date responsible for such individual varia-
tion is genetic variance in the regulation
of cytokine gene expression. Thus accel-
erated onset of TA in human cardiac al-
lografts as well as CTD in lung allografts
has been found to correlate with geneti-
cally predisposed high TGF-β produc-
tion7-9. In addition, individual variation in
other, non-immune related, yet unidenti-
fied factors, might also contribute in de-
termining the rate and severity of TA af-
ter solid organ transplantation.
To gain further insight in the contribution
of recipient MHC and non-MHC (among
others the immunologic responder status)
encoded determinants, we here analyzed
the development of TA in aortic allografts
using different rat strains as donors and
recipients. Using morphometry we
showed that Lew and BN rats used as
hosts displayed significant differences in
primarily the kinetics of TA development
(low vs. high TA responders, respective-
ly). Aortic transplantation performed in
congenic BN and Lew rat strains revealed
that these differences were independent
of the MHC-haplotype of the host. Since
Lew and BN rats represent strains with a
different immunologic responder status
(Th1-prone vs. Th2-prone)10, we won-
dered whether the Th2-skewed respond-
er status of BN rats contributed to the high
TA responsiveness. However, F344 hosts
(Th2-prone responder) developed only
mild TA, suggesting that factors other than
recipient’s immunologic responder status
are involved in determining the onset and
severity of TA after allogeneic aorta trans-
plantation in rats. This was further streng-
thened by results obtained from allografts
transplanted in bone marrow chimeric
rats.104
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Materials and Methods
Animals
Specified pathogen free male Lew (RT-
1l), BN (RT-1n), F344 (RT-1lvl) and DA
(RT-1a) rats were obtained from Harlan
(Zeist, The Netherlands). MHC congenic
Lew.1N (RT-1n) and BN.1L (RT-1l) rats
were obtained from the central animal
facilities of Maastricht University. Rats,
8-10 weeks of age, were kept under clean
conventional conditions and were fed
standard rat chow and acidified water ad
libitum. All animals received humane care
in compliance with the Principles of La-
boratory Animal Care (NIH Publication
No.86-23, revised 1985) and the Dutch
Law on Experimental Animal Care.
Aorta transplantation
Aortic allografts (10-12 mm) were trans-
planted as described previously11. Brief-
ly, the abdominal aorta between the left
renal artery and the bifurcation was re-
moved from the donor rat and perfused
with saline to remove blood cells. Subse-
quently, the aortic graft was orthotopically
transplanted into the recipient rat via end-
to-end anastomosis using 9-0 nylon su-
ture. Total ischemic time was consistent-
ly less than 30 minutes during which the
grafts were kept in ice-cold saline.
Experimental groups
To study whether the kinetics and the sev-
erity of TA differ among different donor/
recipient rat strain combinations, aortic
transplantations were performed in the
combinations as listed in Table 1.
First we analyzed the development of TA
in the fully MHC incompatible BN to Lew
(groups 1-4) and the reciprocal Lew to BN
(groups 5-8) strain combinations (Table
1A). Aortic allografts were explanted 4,
8, 12 and 24 weeks after transplantation
and subsequently processed for histo-
logic and morphometric analysis. BN iso-
grafts (group 9) served as controls and
were explanted 3 months after transplan-
tation.
To study whether the differences observed
in the above mentioned strain combina-
tions were determined by recipient’s
MHC or non-MHC encoded determi-
nants, additional aortic allografting was
performed using MHC-congenic Lew.1N
and BN.1L rats (Table 1B). Lew.1N con-
genic rats bear the BN-derived MHC ha-
plotype on the Lew (non-MHC) genetic
background, whereas BN.1L congenic
rats bear the Lew derived MHC haplo-
type on the BN (non-MHC) genetic back-
ground. Transplantations were performed
in the MHC-incompatible, but non-MHC
identical, BN to BN.1L (groups 10 & 11)
and Lew to Lew.1N (groups 12 & 13)
combinations. Grafts were explanted 4
and 8 weeks after transplantation.
Since the immunological responder-sta-
tus of the host might be involved in de-
termining the kinetics and severity of TA,
BN allografts were also transplanted into
F344 hosts (group 14). The F344 rat strain
displays a similar immunologic respon-
der-status as BN rats, but possesses the
Lew MHC-haplotype.
To analyze the contribution of the bone
marrow (BM) compartment in determin-
ing the severity of TA, MHC-incompati-
ble bone marrow (BM) chimeras were
generated (as described below). Six weeks
after BM transplantation, DA aortic al-
lografts were transplanted in Lew BM
chimeric BN rats (group 15) as well as
BN BM chimeric Lew rats (group 16)
(Table 1C). Grafts were explanted 12105
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weeks after aortic allografting and pro-
cessed for histologic and morphometric
analysis.
In a final series of experiments we ana-
lyzed whether only the recipient or the
combined contribution of donor and re-
cipient determines the severity of TA.
Transplantations were performed using a
fully MHC incompatible third party do-
nor (DA) (Table 1D). DA aortic allografts
were transplanted in BN, Lew, BN.1L and
Lew.1N recipients (groups 17, 18, 19, &
20, respectively) and were explanted 4
weeks after transplantation.
Table 1. Groups used for aorta transplantation to study the effect of recipient genotype
on the development of transplant arteriosclerosis.
Group N a Graft donor Graft MHC non-MHC Sacrifice b
recipient disaparity disparity
A
18 B N Lew ++ 4
24 B N Lew ++ 8
34 B N Lew ++ 12
44 B N Lew ++ 24
58 Lew BN ++ 4
64 Lew BN ++ 8
74 Lew BN ++ 12
84 Lew BN ++ 24
94 B N BN -- 12
B
10 4 BN BN.1L +- 4
11 4B NBN.1L +- 8
12 4 Lew Lew.1N +- 4
13 4 Lew Lew.1N +- 8
C
14 5 BN F344 ++ 4
15 4 DA d LewBM->BN ++ 10
16 1 c DA d BNBM->Lew ++ 10
D
17 7 DA BN ++ 4
18 7 DA Lew ++ 4
19 6 DA BN.1L ++ 4
20 6 DA Lew.1N ++ 4
a number of animals analyzed
b   weeks after aorta transplantation
c 1 out of 4 animals displayed complete bone marrow chimerism which was used for
   subsequent DA aortic allografting
d aortic allografting was performed 6 weeks after bone marrow transplantation106
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Quantitation of transplant arterioscle-
rosis
Grafts removed at autopsy were fixed in
Bouin’s fixative and embedded in paraf-
fin. Tissue sections (7 ￿m) were taken
from the center of each graft and were
stained with Lawson’s solution (Klini-
path, Duiven, The Netherlands) to visu-
alize elastin fibers. TA was quantitated
using a computerized morphometric ana-
lysis system (QWin Software, Leica Mi-
crosystems B.V., Rijswijk, The Nether-
lands). Degree of TA was expressed as the
total neointimal cross-sectional area (ex-
pressed in ￿m2).
Generation of bone marrow chimeric rats
Both femora and tibiae of  the donor rats
were excised and surrounding muscle and
connective tissue were removed. Both
ends were removed with small pincers,
and the marrow cavity was flushed with
RPMI 1640 (Life Technologies) using a
syringe with a needle. Clusters were dis-
aggregated by vigorous pipetting and the
cell suspension was filtered using nylon
gauze. BM cells were washed, counted
and set to a concentration of 2x108 nucle-
ated cells/ml. Male recipient rats, aged 7-
10 weeks, were lethally γ-irradiated (BN
8.5 Gy and Lew 9.5 Gy) using a 137Cesi-
um source (IBL 673, CIS Bio Internation-
al). Irradiated BN and Lew hosts received
1x108 Lew and BN BM cells respective-
ly by tail vein injection. Four to six weeks
after bone marrow transplantation, chi-
merism was determined in the peripheral
blood by flowcytometry. If complete chi-
merism (>98% donor cell derived) was
observed aortic transplantation of DA al-
lografts into the chimeric hosts was per-
formed.
Statistical analysis
All data are expressed as mean – SEM.
To analyze differences in the degree of
neointima formation for statistical signifi-
cance, the One-Way ANOVA was per-
formed. If this test revealed a significant
difference, a Bonferroni’s Multiple Com-
parison test was performed to analyze dif-
ferences between subgroups. Differences
were considered to be statistically signif-
icant when P-values were <0.05.
Results
Kinetics and severity of TA in Lew and
BN recipients
First, we analyzed the kinetics and sever-
ity of TA in MHC- and non-MHC incom-
patible aortic allografts transplanted be-
tween BN and Lew recipient rats. As
shown in Figure 1, 4 weeks after trans-
plantation BN allografts transplanted in
Lew hosts showed only weak TA and a
subsequent increase with time of the de-
gree of TA was observed reaching a maxi-
mum by 24 weeks after transplantation.
In contrast, Lew allografts transplanted in
BN hosts displayed maximal TA already
4 weeks after transplantation and the mag-
nitude of the TA lesions remained virtu-
ally the same over time. Compared to Lew
hosts, BN hosts showed significantly
more TA 4 and 8 weeks after transplanta-
tion (P<0.001 and P<0.05, respectively),
whereas at later time points significant
differences between the degree of TA in
BN and Lew hosts were no longer ob-
served. BN isografts showed only very
little TA 12 weeks after transplantation,
indicating that the development of TA
under these experimental conditions is
primarily an allo-immune mediated pro-
cess.107
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Severity of TA in MHC congenic Lew.1N
and BN.1L recipients
From the data depicted in Figure 1 we
defined BN hosts as high TA responders
and Lew hosts as low TA responders. Sub-
sequently, we analyzed whether this dif-
ference between BN and Lew rats is pri-
marily determined by recipient MHC or
non-MHC encoded determinants. There-
fore, BN and Lew allografts were trans-
planted in MHC-congenic Lew.1N and
BN.1L hosts, respectively, and the degree
of TA present at 4 and 8 weeks after trans-
plantation was compared to the degree of
TA present in the (non-congenic) Lew and
BN counterparts. Figure 2A shows that
allografts transplanted in the Lew to
Lew.1N combination show significantly
less TA compared to Lew allografts trans-
planted in BN hosts at both 4 and 8 weeks
after transplantation (P<0.001).
On the other hand, as shown in Figure 2B,
allografts transplanted in the BN to BN.1L
combination showed a tendency of in-
Figure 1.Kinetics and severity of the development
of TA after allogeneic aorta transplantation in the
BN to Lew and Lew to BN rat strain combinations.
Allografts were explanted 4, 8, 12 and 24 weeks
after transplantion. BN isografts served as controls
and were explanted 12 weeks after transplantation.
Neointima formation is expressed as the surface
neointima (in ￿m2). (* P<0.05, ** P<0.001, One-
Way ANOVA and Bonferroni’s Multiple Compari-
son test).
Figure 2.Development of TA after allogeneic aorta transplantation in MHC-congenic Lew.1N (A) and
BN.1L (B) recipient rats. Allografts were explanted 4 and 8 weeks after transplantion. Neointima forma-
tion is expressed as the surface neointima (in ￿m2). (NS, not significant, ** P<0.001, One-Way ANOVA
and Bonferroni’s Multiple Comparison test).108
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creased TA development compared to the
BN to Lew combination at 4 and 8 weeks
post transplantation. So, BN.1L hosts tend
to develop more TA when compared to
the Lew hosts transplanted with a fully
MHC disparate BN allograft.
These data indicate that the severity of TA
is primarily determined by the recipient’s
non-MHC haplotype, and that recipients
bearing the BN-encoded non-MHC (BN
and BN.1L) are high TA responders,
whereas recipients bearing the Lew-en-
coded non-MHC (Lew and Lew.1N) are
low TA responders.
Severity of TA in F344 hosts
BN-encoded non-MHC determinants thus
seem to predispose for the development
of more severe TA, but the precise deter-
minants responsible for this observation
are unknown. One possible explanation
might be the difference in capacity to pro-
duce Th1- and Th2-type cytokines upon
stimulation. Lew rats are Th1-prone rats,
whereas BN rats rather respond with a
Th2-type cytokine response pattern upon
stimulation. To analyze whether severity
of TA is correlated with a Th2-skewed
immune response, aortic transplantation
was performed in the fully MHC dispa-
rate BN to F344 combination. Like BN
rats, F344 rats also show a Th2-skewed
immune response, whereas they bear the
Lew-derived MHC haplotype. The degree
of TA in the BN to F344 strain combina-
tion was compared to the degree of TA in
the BN to Lew and Lew to BN strain com-
binations. As shown in Figure 3, the F344
hosts developed moderate TA, similar to
allografts transplanted in the BN to Lew
combination, indicating that F344 rats are
also low TA responders. These results
suggest that apparently non-MHC encod-
ed factors other than recipient’s Th2-
skewed immune response are involved in
determining the rate of development of
TA.
Development of TA in Lew bone marrow
chimeric BN hosts
The finding, that the T cell responding
profile of the recipient is not a major fac-
tor in determining the kinetics of TA de-
velopment was further strengthened by
the data of TA development in BM chi-
meric rats. Lew BM chimeric BN (LewBM
->BN) and BN BM chimeric Lew (BNBM
->Lew) rats were generated (as described
in the Materials & Methods section) and
the level of chimerism was determined by
MHC class I haplotype specific flowcy-
tometry. All four LewBM->BN rats showed
complete chimerism, whereas only 1 out
of 4 BNBM->Lew rats showed complete
chimerism (not shown). Only the com-
plete BM-chimeric rats were transplant-
ed with a DA aortic allograft 6 weeks af-
Figure 3.Development of TA after allogeneic aorta
transplantation in the BN to Lew, Lew to BN and
BN to F344 strain combinations. Allografts were
explanted 4 weeks after transplantion. Neointima
formation is expressed as the surface neointima (in
￿m2). (* P<0.05, One-Way ANOVA and Bonfer-
roni’s Multiple Comparison test).109
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ter BM transplantation. Ten weeks after
aortic transplantation, the LewBM->BN
rats showed definite TA (0.99x105 –
2.34x104 ￿m2), whereas in the BNBM
->Lew rat no TA could be observed. Al-
though severe perivasculitis and endothe-
lial cell damage indicative of alloreactiv-
ity was present (not shown), the eventual
development of TA 10 weeks after trans-
plantation seemed to be less pronounced
compared to the non-BM chimeric coun-
terparts. However, in the LewBM->BN rats
TA was observed, whereas in the BNBM
->Lew rat no TA was detectable, indicat-
ing that the BN hosts still possessed the
‘high’ TA responder phenotype, despite
complete reconstitution with the Lew-
derived lymphoid system.
Severity of TA in third party (DA) al-
lografts
Although recipients carrying the non-
MHC genotype of the BN strain always
displayed high TA responsiveness, even
after transplantation of only non-MHC
mismatched grafts, transplantation of ful-
ly (MHC- and non-MHC) incompatible
DA allografts to Lew and BN hosts did
not result in the expected TA response
patterns. At 4 weeks after transplantation
both BN and Lew rats displayed a virtu-
ally identical, minimal degree of TA (Fig-
ure 4). This was not due to a lack of anti-
genicity of the DA-grafts, since in the DA
to BN.1L combination again, as expect-
ed, a strong TA response upon transplan-
tation was observed (Figure 4). These data
indicate, that although BN-encoded non-
MHC determinants predispose for the rate
of development of severe TA, also the
specific combination of donor and recip-
ient can significantly influence the over-
all outcome of this process.
Discussion
The development of chronic transplant
dysfunction (CTD) and its sequelae re-
main a major complication in the long-
term survival of solid organ transplants.
The common histomorphological feature
of CTD is development of transplant ar-
teriosclerosis (TA), which is characterized
by concentric myointimal proliferation of
predominantly vascular smooth muscle
cells resulting in the development of an
occlusive neointima in the arterial struc-
tures of the graft1,2,12. Pathogenesis of TA
seems to be multifactorial and risk fac-
tors appear to include ischemia/ reperfu-
sion injury, donor brain death, histoin-
compatibility, acute rejection and viral
infections1,5.
Among transplant recipients, however,
transplanted with similar HLA-incompa-
tible grafts, receiving similar immunosup-
pression and exposed to the same known
risk factors, variation exists in both the
Figure 4.Development of TA after allogeneic aorta
transplantation using third party (DA) donors. Al-
lografts were explanted 4 weeks after transplantion.
Neointima formation is expressed as the surface
neointima (in ￿m2). (NS, not significant, * P<0.05,
One-Way ANOVA and Bonferroni’s Multiple Com-
parison test).110
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rejection rate and long-term outcome.
This variation has not been fully explained
yet, but data indicate that different indi-
viduals might display differences in their
immune responses against an allograft6.
These differences in immunologic re-
sponder status might at least be in part
due to genetic variance in the regulation
of cytokine gene expression, which have
been shown to correlate with the devel-
opment of CTD and TA7-9.
In this study we dissected the influence
of host MHC- and non-MHC encoded
determinants on the development of TA
using an aortic transplant model in rats.
First, we analyzed the onset and severity
of TA in aortic allografts transplanted be-
tween Lew and BN hosts. In contrast to
Lew hosts, which gradually developed TA
with time, BN hosts developed maximal
TA already 4 weeks after transplantation
(vs. 24 weeks in Lew hosts). The severity
of TA in both strains was eventually sim-
ilar, indicating that rather the rate of TA
development than the severity per se was
different. Similar observations were re-
ported by Geerling et al. who further
showed increased intragraft cytokine
mRNA expression levels in BN hosts
compared to Lew hosts 1 month after
transplantation13. Aortic transplantation in
MHC-congenic Lew.1N and BN.1L rats
revealed that high TA responsiveness is
at least in part determined by non-MHC
encoded determinants. However, it should
be noted that also the interaction between
host and graft can influence the severity
and kinetics of TA development in cer-
tain donor-recipient combinations.
From an immunological point of view, a
major difference between Lew and BN
rats is the (non-MHC encoded) immuno-
logical responder status and, as a result,
the susceptibility for inducible autoim-
mune diseases10. Lew rats display a Th1-
skewed immune status and are suscepti-
ble for Th1-mediated autoimmune diseas-
es like EAE. In contrast, BN rats display
a more Th2-skewed immune profile and
are therefore susceptible for Th2-media-
ted autoimmune diseases like mercuric-
chloride induced glomerulonephritis. A
Th2-type immune response has been sug-
gested to be associated with the develop-
ment of TA in rats14. We analyzed there-
fore whether also in our aortic transplant
model the high TA responsiveness ob-
served in BN rats was related to the Th2-
skewed immune status. However, F344
hosts, which like BN rats display a Th2-
skewed responder status10, turned out to
be low TA responders. These results indi-
cate that although recipient’s non-MHC
encoded determinants predispose for low
or high TA responsiveness, it is unlikely
that the Th1 vs. Th2 immune status of the
hosts contributes significantly to this phe-
nomenon. This conclusion is further sup-
ported by the notion that also Lew bone
marrow chimeric BN rats, in which the
original BN lymphoid system has been
completely replaced by immune cells de-
rived from the inoculated Lew bone mar-
row, thereby also changing the immuno-
logic responder profile from a BN to a
Lew type, still develop more TA com-
pared to the reciprocal BN bone marrow
chimeric Lew rat. Thus, the results pre-
sented in this study suggest that the rate
of TA development in different rat strains
is genetically controlled by non-MHC
encoded factors other than the recipient’s
immunologic responder status. In a recent
study by Harmon et al. it was demonstrat-
ed that also in a mouse model of arterial
remodeling the mechanism leading to lu-111
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men narrowing in the vascular remodel-
ing process is genetically controlled, and
substantial differences between the differ-
ent mouse strains were observed15.
Current thinking on the process of TA
holds that donor-derived medial VSM
cells of affected arteries start to prolifer-
ate and migrate from the media to the sub-
endothelial space in response to cytokines
and growth factors3,16,17. However, we re-
cently demonstrated in our aortic trans-
plant model that the neointimal VSM cells
and EC’s are not donor but host-derived.
Moreover, recent data indicate that the
neointimal VSM cells18,19 as well as en-
dothelial cells (EC’s) (J.L. Hillebrands,
submitted) are predominantly non-bone
marrow derived. Since neointimal lesions
predominantly consist of such host-de-
rived VSM cells and EC’s, it is tempting
to speculate that these neointimal VSM
cells and EC’s intrinsically determine the
rate and severity of neointima formation.
Which EC and VSM cell produced fac-
tors are essential in this process is un-
known, but one of the possible candidates
is elastase, a VSM cell and EC produced
factor involved in the development of
TA20. Focal breaks in the internal elastic
lamina are a key feature of TA which may
be attributed to increased elastase activi-
ty1,21. Besides it’s elastolytic effect, elas-
tases are known to regulate cytokine and
growth factor activity (a.o. bFGF and
TGF-β), and may, in this way be involved
in the development of TA20. Of the rats
strains analyzed in this study, BN rats dis-
played the high TA responder phenotype.
Specifically this rat strain shows increased
elastase activity, which might be involved
in the spontaneous development of elas-
tic laminae defects in BN rats22. How-
ever,  also other genetic characteristics of
BN rats may influence the development
of such lesions in elastic laminae23. Inhi-
bition of elastase activity has been shown
to attenuate the development of TA in rab-
bits, indicating that elastase indeed is in-
volved in the process of TA develop-
ment20.
Also differences in the production of va-
soactive peptides between the different rat
strains may have contributed to the ob-
served differences in TA responsiveness.
For example endothelin-1, an EC pro-
duced potent vasoconstrictor, that is mi-
togenic for VSM cells, has been associ-
ated with the development of TA in rats
24,25. To our knowledge, however, no data
are available on the expression levels of
endothelin-1 in different rats strains. Fi-
nally, in rats the proliferative response of
neointimal VSM cells might also be
strain-dependent, as has been demonstra-
ted in a mouse model of arterial remodel-
ing15.
In conclusion, this study shows that the
rate of TA development is genetically de-
termined by host non-MHC encoded de-
terminants. In our rat model the BN non-
MHC predisposes for high TA responsive-
ness. However, which gene product(s)
precisely determine the rate of TA devel-
opment remains speculative. Since it is
likely that also in the human situation
genetic differences between organ trans-
plant recipients will determine the rate of
TA development and the long-term out-
come of transplantation, identification of
the gene products responsible for this
phenomenon will be essential both in trac-
ing patients who are at risk to rapidly de-
velop TA, as well as in developing new
strategies to prevent or treat TA.112
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Abstract
The development of transplant arteriosclerosis (TA) is today’s most important prob-
lem in clinical organ transplantation. Histologically, TA is characterized by perivas-
cular inflammation and progressive intimal thickening. Current thought on this pro-
cess of vascular remodeling assumes that neointimal vascular smooth muscle (VSM)
cells and endothelium in TA are graft-derived, holding that medial VSM cells prolif-
erate and migrate into the subendothelial space in response to signals from inflam-
matory cells and damaged graft endothelium. Using MHC class I haplotype-specific
immunohistochemical staining and single-cell PCR analyses, we show that the neoin-
timal α-actin-positive VSM cells in rat aortic or cardiac allografts are of recipient and
not of donor origin. In aortic but not in cardiac allografts, recipient-derived endothe-
lial cells (EC's) replaced donor endothelium. Cyclosporine treatment prevents neoin-
tima formation and preserves the vascular media in aortic allografts. Recipient-de-
rived EC's do not replace graft endothelium after cyclosporine treatment. We propose
that, although it progresses beyond the needs of functional repair, TA reflects the
activity of a normal healing process that restores vascular wall function following
allograft-induced immunological injury.117
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Introduction
The development of chronic transplant
dysfunction (CTD) has become a limit-
ing factor for long-term graft survival and
is today’s most important problem in cli-
nical organ transplantation after the first
perioperative year. To date, CTD cannot
be prevented by current immunosuppres-
sive protocols1,2. Depending on the type
of organ transplanted (liver, kidney, heart,
lung) the incidence of CTD 3 years after
engraftment varies from 4 to >50%3-5.
Irrespective of the organ grafted, graft
vessels eventually develop so-called
transplant arteriosclerosis (TA), which is,
however, most prominent in cardiac al-
lografts6,7. This vascular remodeling pro-
cess consists of progressive concentric
intimal thickening (intimal hyperplasia or
neointima formation) coinciding with
ongoing perivascular inflammation. TA
has generally been accepted as the main
cause of progressive deterioration in graft
function. Pathogenesis of TA seems to be
multifactorial, but precise mechanisms
involved in the development of this re-
modeling process still remain obscure.
Risk factors appear to include cold is-
chemia time and reperfusion injury, MHC
disparity between donor and recipient,
number of rejection episodes, and infec-
tion (especially by cytomegalovirus)2,6.
Current thought on the process of TA
holds that in response to signals from
inflammatory cells (perivasculitis) and
activated or damaged graft endothelium,
donor-derived medial vascular smooth
muscle (VSM) cells of affected arteries
start to proliferate and migrate from the
media into the subendothelial space just
beneath the endothelial cell (EC) layer8-
10. According to this concept, neointimal
EC's and VSM cells in TA originate from
graft tissue and are therefore donor-de-
rived.
Since the early 1970s, several groups have
studied the origin of EC's (donor vs. re-
cipient) after solid organ transplantation
(kidney, heart, and lung) in humans. How-
ever, data both supporting11-16 and dis-
counting17-20 repopulation of graft vessels
by recipient-derived EC's were reported.
Graft survival rates are significantly im-
proved after solid organ transplantation
since the introduction of new immuno-
suppressive drugs in the last two decades.
From that time, not acute rejection but
CTD and TA have become a major prob-
lem in clinical organ transplantation. To
date, however, only few studies have ad-
dressed the question of whether the neoin-
timal VSM cells are indeed graft-derived
(donor-derived), and again results con-
flict20-24. So far, no conclusive results have
been described on the origin of EC's and
VSM cells after solid organ transplanta-
tion.
From previous studies in our laboratory,
using small-caliber vascular grafts of syn-
thetic biodegradable biomaterial, we
know that such artificial grafts allow de
novo formation of a new vessel wall25,26.
In time, a neointima and neomedia were
found to develop inside the lumen of the
graft. Since the graft itself only consists
of synthetic material, the cellular compo-
nents forming the neomedia and the
neointima, in this model, must be recipi-
ent-derived. Based on these observations
we hypothesized that also after regular
allogeneic organ transplantation a simi-
lar process of de novo vessel wall forma-
tion (vascular remodelling) will occur in
the arteries of the graft, constituting cells
originating from the recipient27.118
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To test this hypothesis, we used two ex-
perimental transplant models. First, we
used the allogeneic aorta transplant mod-
el in rats, which is a well-described and
reproducible model to study TA28. Sec-
ond, we used a cardiac transplant model
in which MHC-incompatible cardiac al-
lografts are transplanted following in-
trathymic immune modulation and short-
term immunosuppression29. Cardiac al-
lograft survival is significantly prolonged,
but development of TA in the coronary
artery (CA) tree cannot be prevented, re-
sembling clinical outcome after cardiac
transplantation30. Using both transplant
models we analyzed the origin of neoin -
timal EC's and VSM cells, using MHC
class I haplotype-specific immunohisto-
chemistry and two independent PCR-
based analyses31,32. Recipient- and donor-
specific PCR analyses were performed on
70-￿m-thick tissue samples, microdissec-
ted neointimal cell clusters, and single-
VSM-cell nuclei (aorta allografts), and on
microdissected whole CA's and single-
VSM-cell nuclei (cardiac allografts).
Si milar analyses were performed on aor-
tic allografts that were γ-irradiated prior
to transplantation, and grafts from recipi-
ents that were treated with Cyclosporine
(CsA).
Our results indicate that after allogeneic
aorta transplantation neointimal EC's and
VSM cells are of recipient and not of do-
nor origin. CsA treatment prevented
neointima formation and preserved the
vascular media. After CsA treatment the
EC's were still of donor origin and had
not been replaced by recipient-derived
cells. Although the neointimal VSM cells
in cardiac allografts are of recipient ori-
gin, recipient-derived cells do not replace
donor EC's.
Thus, in contrast to current thought, VSM
cells constituting the hyperplastic neoin-
tima in aortic as well as cardiac allografts
are of recipient and not of donor origin.
EC replacement is not a general pheno-
menon after allogeneic organ transplan-
tation and might be related to the severity
of the initial damage of graft endothe-
lium. We propose that TA is part of a nor-
mal healing process trying to restore func-
tion of the damaged vessel wall. Recipi-
ent-derived EC's and VSM cells are in-
volved in this repair process, which, how-
ever, does not seem to be controlled ade-
quately and eventually may lead to total
occlusion of the vessels.
Methods
Animals
Specific pathogen-free Lewis (Lew, RT-
1l), Brown Norway (BN, RT-1n), Pibold
Viral Glaxo (PVG, RT-1c) and Albino
Oxford (AO, RT-1u) rats were obtained
from Harlan (Zeist, The Netherlands). The
rats were 7-10 weeks of age and were used
for aorta and cardiac transplantation. All
transplantations were performed from fe-
male donor to male recipient rats. Ani-
mals were maintained under clean con-
ventional conditions and fed standard rat
chow and acidified water ad libitum. All
animals received humane care in compli-
ance with NIH principles of laboratory
animal care and the Dutch Law on Ex-
perimental Animal Care.
Aorta transplantation
Aortic allografts (10-12 mm) were trans-
planted orthotopically as described pre-
viously28. Total ischemic time was con-
sistently less than 30 minutes. Transplan-119
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tations were performed in the following
MHC-incompatible strain combinations:
PVG to AO , BN to Lew and Lew to BN.
Isograft controls consisted of aortic grafts
transplanted from AO to AO and BN to
BN rats. Grafts were removed at autopsy
1 month (BN to Lew and Lew to BN) or
3 months (PVG to AO and isograft con-
trols) after transplantation and processed
for histological evaluation or microdissec-
tion.
Cardiac transplantation
Cardiac allografting was performed from
female PVG to male AO recipient rats.
To prevent acute rejection, recipient rats
were intrathymically immunomodulated
as described elsewhere29. Immediately
after cardiac transplantation (day 0), 1 ml
rabbit anti-rat lymphocyte serum (Accu-
rate Chemical & Scientific Corp., West-
bury, NY, USA) was injected intra-
peritoneally. CsA (Sandoz Pharma AG,
Basel, Switzerland) was injected intra-
muscularly on days 1, 2, and 3 after trans-
plantation (15 mg/kg). Cardiac allografts
thus transplanted show significantly pro-
longed graft survival but eventually de-
velop TA indicative of CTD30.
Treatment groups
Aortic allografting was performed from
female PVG donor to male AO recipient
rats. One group was left untreated (n=4),
whereas in the other group aortic al-
lografts were ex vivo 50 Gy γ-irradiated
(137Cs, IBL 673, CIS Bio International,
Gif-Sur-Yvette, France) prior to transplan-
tation in order to prevent proliferation and
migration of donor-derived medial VSM
cells (n=3). Three AO isograft controls
were performed (n=3). To study the ef-
fect of CsA treatment on the development
of TA, another set of aorta transplanta-
tions was performed in the female Lew
to male BN combination. Recipient rats
received either no treatment (n=5) or CsA
(Sandoz Pharma AG) at 5 mg/kg/d (n=5)
or 10 mg/kg/d (n=4) for 28 days. These
concentrations were shown to reduce in-
timal hyperplasia and preserve medial
nuclear density after allogeneic aorta
transplantation in rats33. CsA was admin-
istered as a liquid in olive oil by intra-
muscular injections. BN to Lew allografts
(n=3) and BN isografts (n=5) served as
control groups.
To analyze TA in cardiac allografts, three
female-derived PVG grafts were trans-
planted into male AO recipient rats fol-
lowed by intrathymic immunomodulation
as described above (n=3). Grafts were
harvested 530 days (19 months) after
transplantation and processed for histo-
logical analysis and microdissection.
CsA blood levels
Twenty-four-hour trough whole blood
CsA levels were determined 2 and 4
weeks after aortic transplantation. Blood
was analyzed using the Emit 2000 cy-
closporine-specific assay (Dade Behring,
Marburg, Germany).
Immunohistochemical  analyses
At the time of sacrifice, the explanted
aortic and cardiac grafts were either fixed
in Bouin’s fixative and embedded in par-
affin or immediately frozen in liquid ni-
trogen and stored at -80￿C for cryostat
sections. For evaluation of vascular
changes, paraffin cross sections (7 ￿m)
from the center of the grafts were pre-
pared, and double staining was performed
for elastin (Lawson solution, Klinipath,
Duiven, The Netherlands) and α-actin to120
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detect neointimal VSM cells in arterio-
sclerotic lesions. Briefly, α-actin- positive
intimal cells were detected by an indirect
immunoperoxidase technique using mAb
asm-1 directed against VSM cell α-actin
isoform34,35 (Roche Molecular Biochemi-
cals, Almere, The Netherlands). Incuba-
tion with the primary asm-1 antibody was
followed by incubation with a second-
step horseradish peroxidase-conjugated
rabbit anti-mouse antibody (DAKO A/S,
Glostrup, Denmark). Subsequently, chro-
mogen 3-amino-9-ethyl carbazole was
applied, followed by counterstaining with
Mayer’s hematoxylin. Sections were cov-
erslipped with Kaiser’s glycerol gelatin
(Merck, Amsterdam, The Netherlands).
To detect MHC class I expression on EC's
and graft-infiltrating inflammatory cells
the following mAb’s were used: OX18
(pan-class I)36, OX27 (PVG [RT-1c] and
BN [RT-1n] class I)37 and U9F4 (AO [RT-
1u] class I38. To detect EC's and infiltrat-
ing macrophages, mAb’s RECA-139 and
ED140 were used, respectively. MHC class
I, EC, and macrophage staining was per-
formed on 7-￿m cryostat sections using
the DAKO EnVision staining kit
(DAKO). Sections were counterstained
with Mayer’s hematoxylin and coverslip-
ped with Depex mounting medium (BDH
Laboratory Supplies, Poole, United King-
dom).
Quantitation of TA
After histological staining of tissue sec-
tions for elastin and α-actin, presence of
TA was quantitated using a computerized
morphometric analysis system (QWin
Software; Leica Microsystems B.V.,
Rijswijk, The Netherlands). Total surface
area of arteriosclerotic lesions (neointi-
ma) was calculated and expressed as ￿m2.
Microdissection of neointimal tissue
Microdissection of neointimal tissue was
performed on α-actin-stained 7-￿m cry-
ostat sections (taken from the center of
the graft) from aortic as well as cardiac
allografts. α-Actin staining ensured posi-
tive identification of neointimal VSM
cells in aortic allografts and affected CA's
in cardiac allografts. After counterstain-
ing with Mayer’s hematoxylin, tissue sec-
tions were placed in PBS and stored over-
night at 4￿C. Subsequently, microdissec-
tion was performed using a micromanipu-
lator (Leica) from neointimal lesions con-
taining large numbers of α-actin-positive
VSM cells. Cell clusters consisting of 20-
30 cells were microdissected from neoin-
timal lesions in aortic allografts as well
as in CA's. To prevent potential contami-
nation of the cell clusters with infiltrat-
ing mononuclear cells, single nuclei from
α-actin-positive neointimal cells in aor-
tic allografts and CA's were microdissect-
ed as well. For single cell picking, nuclei
were randomly selected among α-actin-
positive cells having an easily visible nu-
cleus surrounded by α-actin-positively
stained cytoplasm. Microdissected cell
clusters and isolated single nuclei were
directly transferred into PCR reaction
tubes containing 20 ￿l Milli-Q water (Mil-
lipore B.V., Etten-Leur, The Netherlands)
and stored at –20￿C until PCR analysis.
PCR analyses
The first PCR that was used to analyze
the origin of neointimal cell types after
aortic and cardiac allografting was based
on polymorphic regions present in the
Tap2 gene encoding a subunit of a pep-
tide transporter involved in loading of
MHC class I molecules with peptides31.
Because the Tap2 gene is located within121
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the MHC, all MHC haplotypes are asso-
ciated with a specific Tap2 allele. To de-
termine the Tap2 genotype of isolated
DNA, a PCR procedure developed by Joly
et al. was used based on differences in
restriction sites found in the sequences of
the Tap2 cDNAs31. Oligonucleotides used
were as follows: 360 5’-ccgggctctaga
TGCAGACCGTGAGAAGCTTTG-3’
and 361 5’-ccgggcgaattcCTGCACACC-
GACGTTCAGAAT-3’ (sequences in
lower case do not correspond to Tap2 se-
quen ces  but were introduced for cloning
of the various alleles by PCR). Since mi-
crodissected cell clusters and single nu-
clei did not contain sufficient DNA to give
a positive signal (not shown), the Tap2
PCR was performed on 70-￿m-thick tis-
sue samples obtained from aortic al-
lografts. In addition, microdissected CA's
showing severe TA from one graft were
pooled (~10-20 CA's) to get sufficient
template DNA to perform the Tap2 PCR.
After amplification, 10 ￿l of the PCR re-
action mixture was analyzed on a GelStar
(BMA, Rockland, ME, USA) 2% agar-
ose gel. Sizes of the PCR products of the
different rat strains were: Lewis, 380 bp;
BN, 360 bp; PVG, 340 bp; and AO, 360
bp.
Since all transplantations were performed
in female (donor) to male (recipient)
combinations, we could also use sex
markers as indicators for cellular origin.
Therefore, a nested PCR procedure was
developed that specifically enabled iden-
tification of an Y chromosome-associ-
ated DNA sequence (European Molecu-
lar Biology Laboratory [EMBL]/Genbank
data libraries accession no. X80155)41 at
the single-cell level and thereby the (male)
origin of cells (described in detail else-
where32). The following Y chromosome-
specific oligonucleotides were used: first
round 5’-CAGGCTGGAAAGGCTTG-
TAG-3’ (forward) and 5’-CCCATGTTT-
GGTCCACATAG-3’ (reverse), and sec-
ond round 5’-GCTGGTGATTTGCAGA-
GTGA-3’ (forward) and 5’-GAATGT-
TCG ATTCCGACTGG-3’ (reverse). The
first and second round of PCR amplifica-
tion resulted in 549-bp and 128-bp DNA
fragments, respectively. After amplifica-
tion, 10 ￿l of the 2nd round reaction mix-
ture was analyzed on a GelStar (BMA,
Rockland, ME, USA) 2% agarose gel. All
amplifications were carried out using an
Amplitron II Thermolyne thermocycler
(Barnstead/Thermolyne, Dubuque, Iowa,
USA).
Restriction enzyme analysis
Since Tap2 PCR fragments derived from
Lew DNA bear a HindIII restriction site
and BN-derived DNA fragments do not,
further discrimination between Lew- and
BN-derived DNA could be made by Hind
III restriction analysis. After Tap2 PCR
analysis, 5 ￿l PCR product was added to
5 ￿l restriction mix containing 5 U Hind
III (Life Technologies B.V., Breda, The
Netherlands). After incubation for 1 hour
at 37￿C, DNA samples were analyzed by
2% agarose gel electrophoresis. Lew-de-
rived DNA was cut into two fragments
(276 and 104 bp), whereas BN-derived
DNA remained uncut.
Since PVG- and AO-derived DNA both
lack the HindIII restriction site in their
Tap2 sequence, discrimination could only
be made by difference in size of the PCR
products (340 and 360 bp respectively).
Therefore, those PCR products were elec-
trophoresed on a 12% polyacrylamide gel
using a Mini-PROTEAN II BIO-RAD
system (Bio-Rad Laboratories B.V.,122
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Veenendaal, The Netherlands). After elec-
trophoresis the gel was soaked in ethidi-
um bromide-containing TBE buffer to
visualize PCR products.
Statistical analysis
To analyze differences in surface area of
arteriosclerotic lesions for statistical
significance, a Mann-Whitney U Test was
performed using SPSS 7.5.2 for Windows
(SPSS, Chicago, IL, USA). Differences
were considered to be statistically signif-
icant when P values were less than 0.05.
Results
Effect of irradiation and CsA treatment
on TA
Transplantation of fully MHC mis-
matched aortic allografts in the PVG to
AO rat strain combination resulted in the
development of severe TA. Whereas AO
isografts were unaffected or only slightly
affected, allografts showed significant
(P < 0.05) neointima formation 3 months
after transplantation, indicating that TA
in this model is mainly caused by an al-
loantigen-driven process (Figure 1A). We
then asked whether aortic allografts,
which contain medial VSM cells that have
lost migratory and proliferative capacities,
still lead to development of neointimal
lesions after transplantation. To answer
this question, PVG aortic allografts were
ex vivo 50 Gy γ-irradiated prior to engraft-
ment into AO recipients. As shown in Fig-
ure 1A, γ-irradiated allografts developed
neointimal lesions to the same extent as
nonirradiated allografts, indicating that
graft medial VSM cells probably do not
contribute to the process of TA.
Subsequently, the influence of immuno-
suppressive therapy on the development
of TA after allogeneic aorta transplanta-
tion was analyzed. Aortic grafts were
transplanted in the Lew to BN combina-
tion. From previous studies it became
obvious that severe TA develops within 4
weeks after transplantation in this strain
combination (Figure 1B)42. Recipient rats
received either no treatment or CsA at 5
mg/kg/d or 10 mg/kg/d for 28 days. After
14 and 28 days, 24-hour trough whole
blood CsA levels were determined in three
animals from either group. No differ-
ences were observed between the 14- and
28-day time points, and therefore data
from both time points were pooled. Ani-
mals treated with 5 mg/kg/d and 10 mg/
kg/d CsA had mean trough levels of 1016
– 268 ng/ml and 2383 – 327 ng/ml, re-
spectively. The non-treated group had
trough levels below detection level (<25
ng/ml). Treatment with 5 mg/kg/d and 10
mg/kg/d both resulted in complete inhi-
bition of neointima formation 28 days
after transplantation ( P < 0.01 and P <
0.05, respectively) (Figure 1B). After CsA
treatment, no differences were observed
compared with the isograft (BN to BN)
controls.
Representative micrographs of vascular
wall morphology are shown in Figure 1,
C-F. The nontreated group displayed se-
vere neointima formation with presence
of large numbers of α-actin-positive VSM
cells (Figure 1C). The media had become
acellular, and medial α-actin-positive
VSM cells had disappeared. In addition,
graft infiltrating ED1+ macrophages were
present in both the adventitia and neoint-
ima (Figure 1D).
After CsA treatment, however, morphol-
ogy appeared to be normal (no neointima
formation) in both treatment groups and123
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Figure 1. Development of  TA (expressed as ￿m2) after allogeneic aorta transplantation (A and B). (A)
Non-irradiated as well as 50 Gy γ-irradiated PVG aortic allografts developed significant TA 3 months
after transplantation into AO recipient rats. * P<0.05 vs. AO isografts, Mann-Whitney U test. NS, not
significant. (B) CsA treatment (5 mg/kg/d and 10 mg/kg/d) for 28 days prevented development of TA
after aorta transplantation in the Lew to BN strain combination. * P<0.05, ** P<0.01 vs. untreated
recipients, Mann-Whitney U test. Double staining for VSM cells (α-actin) and elastin (Lawson) (C,E,F).
(C) Non-treated allograft. Note the absence of α-actin positive VSM cells in the vascular media. (D)
Neointimal lesions in non-treated allografts contained considerable numbers of ED1+ macrophages.
Treatment with 5 mg/kg/d CsA (E) and 10 mg/kg/d CsA (F) prevented development of TA 1 month after
transplantation. VSM cells were abundantly present in the vascular media. No adventitial inflammation
was observed. a, adventitia; lu, lumen; m, media; iel, internal elastic lamina; ni, neointima. Original
magnification, x400124
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was similar to nontransplanted aortic tis-
sue. Grafts from CsA-treated recipients
were characterized by a high nuclear den-
sity in the media, which appeared to be
α-actin-positive VSM cells (Figures 1, E
and F).
Origin of EC's in nontreated and CsA-
treated aorta recipients
To analyze the origin (donor vs. recipi-
ent) of EC's after allogeneic aorta trans-
plantation, MHC class I haplotype-spe-
cific immunohistochemistry was per-
formed (Figure 2). PVG allografts trans-
planted in AO recipient rats showed se-
vere neointima formation 3 months after
transplantation (Figure 1A). Presence of
EC's was confirmed by positive staining
using mAb RECA-1 (not shown). Serial
tissue sections were stained using mAb’s
OX18, OX27 and U9F4. Neointimal EC's
express MHC class I antigens as indi-
cated by intense staining with mAb OX18
(pan-class I), whereas neointimal VSM
cells do not express MHC class I antigens
sufficiently to allow detection by this
staining (Figure 2A). Note the absence of
nuclei in the media and the swollen ap-
pearance of the EC's. Staining with mAb
OX27 (donor type) was negative (Figure
2B), whereas mAb U9F4 (recipient type)
clearly showed positive staining of EC's
(Figure 2C), indicating that donor EC's
had been replaced by recipient-derived
EC's. Similar results were obtained after
haplotype-specific MHC class I staining
of PVG allografts that were 50 Gy γ-ir-
radiated prior to transplantation into AO
recipient rats (not shown).
To further analyze whether EC replace-
ment had also taken place after CsA treat-
ment, serial tissue sections from aortic
grafts transplanted in the Lew to BN strain
combination were stained using mAb’s
OX18 (pan-class I) and OX27 (recipient
type). Again, presence of EC's was con-
firmed by positive staining using mAb
RECA-1 (not shown). Neointimal EC's
from untreated animals showed abundant
MHC class I expression as indicated by
positive OX18 staining (Figure 2D). Also,
in this strain combination donor endo-
thelium had been replaced by recipient-
derived EC's as indicated by positive
OX27 staining. MHC class I staining of
aortic allografts transplanted in the recip-
rocal BN to Lew strain combination con-
firmed these results (not shown). After
CsA treatment, however, donor endothe-
lium was still covering the internal elas-
tic lamina and had not been replaced by
recipient-derived EC's. EC's express
MHC class I (positive staining using mAb
OX18) (Figure 2F), but lack positive
staining using the recipient specific mAb
OX27 (Figure 2G).
Origin of EC's in cardiac allografts
Cardiac transplantation following in-
trathymic immunomodulation resulted in
development of severe TA in the CA's30.
To study whether EC replacement by re-
cipient-derived EC's had also taken place
in these cardiac allografts, recipient and
donor MHC class I-specific staining was
performed. As control tissue, normal car-
diac AO-derived tissue was used. Repre-
sentative micrographs are shown in Fig-
ure 3. Results of normal AO cardiac tis-
sue and PVG allografts are depicted in
Figures 3, A-E and F-J, respectively. VSM
cell α-actin staining (Figure 3F) con-
firmed presence of severe neointima for-
mation and luminal narrowing in the CA's
in PVG allografts explanted 530 days af-
ter transplantation. RECA-1 staining125
Origin of endothelium and alpha-actin positive smooth muscle cells
Lew allografts transplanted into BN recipient rats also showed severe TA. (D) MHC class I expression
on EC’s (OX18-positive). (E) Donor endothelium had been replaced by recipient-derived EC’s (OX27-
positive).  After CsA treatment, no neointima formation was observed 1 month after transplantation. (F)
EC’s covering the internal elastic lamina expressed MHC class I antigens (OX18-positive). (G) How-
ever, EC’s were OX27 (recipient class I)-negative, indicating that after CsA treatment EC replacement
does not occur. Arrowheads indicate positively stained EC’s. Original magnification, x400.
Figure 2.Neointimal EC’s in aortic
allografts are of recipient origin. Im-
munohistochemical staining using
MHC class I haplotype-specific
mAb’s was performed to determine
the origin (donor vs. recipient) of
neointimal EC’s after allogeneic
aorta transplantation. PVG allografts
transplanted in AO recipients showed
severe TA. (A) MHC class I expres-
sion on EC’s (OX18-positive). Note
the absence of  VSM cells in the
media (m). (B) Donor endothelium
had disappeared (OX27-negative)
and (C) had been replaced by recipi-
ent-derived EC’s (U9F4-positive).126
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showed presence of EC's (Figure 3, B and
G). Note the swollen and activated ap-
pearance of EC's covering the neointima
in the PVG allograft. OX18 (pan-class I)
staining confirmed presence of MHC
class I expression by EC's in normal car-
diac tissue and PVG allografts (Figures
3, C and H). Neointima- infiltrating leu-
kocytes were virtually absent in the arte-
riosclerotic lesions. However, perivascu-
lar mononuclear cell infiltrates (MHC
class I-positive) were present in the PVG
allografts. Staining with recipient-specific
mAb U9F4 showed positive staining of
the mononuclear cell infiltrates (which,
as expected, are recipient-derived) (Fig-
ure 3I). However, the neointimal EC's in
the PVG allografts are negative, suggest-
ing that, in contrast to aortic allografts,
recipient EC's have not replaced donor
endothelium in CA's with severe TA. This
was confirmed by positive staining of
neointimal EC's with the donor-specific
mAb OX27 (Figure 3J). Similar findings
were obtained in CA's in PVG allografts
showing only mild TA as well as CA's
showing no TA at all (not shown).
Tap2 PCR analysis of aortic and cardiac
tissue
Since neointimal VSM cells do not ex-
press MHC class I antigens sufficiently
to allow MHC class I- specific immuno-
histochemistry to study the origin of
neointimal VSM cells in aortic and car-
diac allografts, another (PCR-based) ap-
proach was followed to define the origin
of α-actin-positive neointimal cells.
The first PCR that was used to analyze
the origin of neointimal cell types after
aortic and cardiac allografting was based
on polymorphic regions in the Tap2 gene.
Because of the relatively low sensitivity
of the Tap2 PCR, analysis was performed
on 70-￿m-thick tissue samples of aortic
allografts transplanted in the BN to Lew,
Lew to BN and Lew to BN + CsA (5 and
10 mg/kg/d CsA) combinations. Three
individual grafts from either group were
included, and of each graft four 70-￿m-
thick tissue samples were analyzed. Non-
transplanted BN and Lew aortic tissue
served as controls for specificity of this
Tap2 PCR. As shown in Figure 4A, con-
trol BN and Lew DNA resulted in DNA
fragments of 360 bp and 380 bp, respec-
tively. Restriction analysis with HindIII
showed cleavage of the Lew-derived 380-
bp fragments into 276-bp and 104-bp
Figure 3. (facing page) Neointimal EC’s in cardiac allografts are of donor origin. Immunohistochem-
ical staining was performed on nontransplanted AO cardiac tissue (A-E) and PVG allografts (F-J). (A)
Medial VSM cells are α-actin-positive in CA’s in normal, nontransplanted AO cardiac tissue. (B) EC’s
are covering the internal elastic lamina as indicated by positive RECA-1 staining. (C) MHC class I
expression on EC’s was confirmed by positive staining using OX18. (D) U9F4 is AO MHC class I
haplotype-specific and recognizes AO-derived EC’s. (E) OX27 does not recognize AO-derived EC’s.
(F) PVG cardiac allografts transplanted in AO recipients showed severe TA 530 days after transplanta-
tion. The vascular lumen is obliterated as a result of neointima formation. Neointimal tissue predomi-
nantly consists of α-actin-positive VSM cells. (G) Neointima is covered by RECA-1 positive EC’s.
Note the swollen and activated appearance of the neointimal EC’s. (H) MHC class I expression on EC’s
was confirmed by positive staining using OX18. (I) Neointimal EC’s are U9F4-negative, indicating
donor origin. (J) Positive OX27 staining confirmed donor origin of neointimal EC’s in CAs with severe
TA. Arrowheads indicate positively stained EC’s. m, media; ni, neointima. Original magnification: x400.127
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fragments, whereas the BN-derived 360-
bp fragments remained uncut, thereby
proving the specificity of this Tap2 PCR.
Subsequently, this PCR was applied to
tissue samples obtained from grafts trans-
planted from BN donor to Lew recipient
rats. Tap2 PCR followed by HindIII re-
striction showed cleavage of the DNA
fragments into two fragments, indicating
Lew (recipient) origin of the majority of
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the DNA present in these samples. This
was confirmed by analysis of tissue ob-
tained from grafts transplanted in the re-
ciprocal combination (Lew to BN). After
HindIII restriction the DNA fragments
remained uncut, indicating BN (recipient)
origin of the DNA present in these sam-
ples. Finally, the same analysis was per-
formed on tissue from Lew grafts trans-
planted into BN recipient rats followed
Figure 4.PCR analysis of 70-￿m-thick tissue samples, microdissected cell clusters, and microdissected
single nuclei of α-actin-positive neointimal VSM cells after allogeneic aorta transplantation. (A) Tap2
PCR analysis of 70-￿m-thick tissue samples from aortic allografts transplanted in the BN to Lew, Lew
to BN and Lew to BN + CsA combinations. Normal BN- and Lew- derived aortic DNA served as
controls. Lew-derived DNA is cut after HindIII restriction, whereas BN- derived DNA remains uncut.
Restriction analysis of tissue samples from untreated aortic allografts indicates recipient origin of the
tissue analysed. After CsA treatment, tissue samples show the Lew-type restriction pattern indicating
donor origin. (B) HY PCR analysis of microdissected neointimal cell clusters from allografts transplan-
ted in the female PVG to male AO strain combination. Grafts were 50 Gy γ-irradiated prior to transplan-
tation or left untreated. Representative results of first-round PCR products (549 bp) as well as nested
PCR products (128 bp) of two different irradiated and three different untreated grafts are shown. All
samples show the male-specific DNA fragments after first- round and nested PCR. (C) Micrograph
showing double staining for VSM cells (α-actin) and elastin (Lawson) on an aortic allograft after isola-
tion of single nuclei using a micromanipulator. Arrowheads indicate remaining gaps after isolation of
nuclei of three separate α-actin-positive neointimal cells. Note absence of VSM cells in the media. a,
adventitia; m, media; ni, neointima. Asterisk shows an α-actin- positive VSM cell. Original magnifica-
tion, x400. (D) HY PCR performed on eight single nuclei microdissected from two aortic allografts
transplanted from female PVG to male AO recipient rats, showing the male-specific (recipient-specific)
128-bp DNA fragment after nested PCR. bp, 100-base pair ladder; H2O, water control (i.e., no template
DNA present in the PCR reaction mixture).129
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by CsA treatment (5 mg/kg/d) for 28 days.
HindIII restriction showed cleavage of the
DNA fragments into two fragments, in-
dicating Lew (donor) origin of the ma-
jority of the DNA after CsA treatment
(Figure 4A). Similar results were obtained
from analysis of aortic allografts after
treatment with 10 mg/kg/d CsA (not
shown). These results suggest that both
neointimal EC's an VSM cells are recipi-
ent-derived in aortic allografts.
To study whether the same holds true for
neointimal cells in cardiac allografts, Tap2
PCR analysis was performed on micro-
dissected CA's showing severe TA. To
obtain sufficient DNA, microdissected
Figure 5.PCR analysis of microdissected pooled CA’s (Tap2 PCR), and of single CA’s and single nuclei
of α-actin-positive neointimal cells (HY PCR). (A) PAGE after Tap2 PCR analysis of pooled
microdissected CA’s from a PVG cardiac allograft with severe TA. AO- and PVG-derived DNA served
as specificity controls. PCR analysis of one 7-￿m tissue section showed presence of donor (PVG, 340
bp) as well as recipient (AO, 360 bp) DNA. Analysis of 11 pooled CA’s including (donor-derived)
myocardial tissue again showed presence of donor- as well as recipient-derived DNA. Analysis of 20
pooled CA’s without myocardial tissue resulted in presence of primarily recipient-derived DNA. (B) HY
PCR analysis of three single CA’s that were microdissected from three different female-derived PVG
cardiac allografts transplanted into male AO recipient rats. Female- and male-derived DNA from AO
rats served as specificity controls. All three single CA’s showed the male-specific (recipient-specific)
128-bp DNA fragment after nested PCR analysis, indicating presence of recipient-derived cells. (C) HY
PCR performed on eight single nuclei microdissected from two cardiac allografts showing the male-
specific (recipient-specific) 128-bp DNA fragment.130
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CA's from one graft were pooled prior to
PCR analysis. Since PVG- and AO-de-
rived DNA both lack the HindIII restric-
tion site in their Tap2 sequence, discrimi-
nation could only be made by difference
in size of the PCR products (340 and 360
bp, respectively). Analysis of one com-
plete 7-￿m section of a cardiac allograft
showed presence of donor-derived (PVG,
340 bp) as well as recipient-derived (AO,
360 bp) DNA fragments (Figure 5A).
Subsequent analysis of pooled microdis-
sected CA's, including donor myocardial
tissue, again showed presence of both
donor- and recipient-derived DNA frag-
ments. Finally, 20 CA's of one graft were
microdissected without contamination
with donor-derived myocardial tissue.
Again, recipient-derived (360 bp), and
now to a lesser extent donor-derived (340
bp), DNA fragments were present (Fig-
ure 5A). These results suggest that also
after cardiac allografting, neointimal tis-
sue consists, at least in major part, of re-
cipient-derived cells.
HY PCR analysis of microdissected neoin-
timal aortic tissue and CA's
Since the sensitivity of the Tap2 PCR was
not sufficient to analyze microdissected
cell clusters (~20-30 cells) and single
CA's, another, more sensitive, PCR-based
analysis was developed as described in
detail elsewhere (32). This highly sensi-
tive and specific nested PCR procedure
enabled the identification at the single-
cell level of a 128-bp Y chromosome-
associated DNA sequence and thereby of
the (male) origin of cells. Since aortic and
cardiac allografting was performed not
only between MHC-incompatible rat
strains but in a female (donor) to male
(recipient) combination as well, we could
use this HY marker as indicator for male
cellular origin.
First, this PCR was applied to microdis-
sected cell clusters derived from neointi-
mal lesions in aortic allografts with or
without 50 Gy γ-irradiation transplanted
from female PVG donor to male recipi-
ent rats. Three individual grafts of either
group were studied, and of each graft five
microdissected cell clusters were ana-
lyzed. HY PCR performed on microdis-
sected cell clusters resulted in appearance
of Y chromosome-specific DNA frag-
ments in the nonirradiated as well as the
50 Gy γ-irradiated aortic allografts (Fig-
ure 4B). First-round PCR already resul-
ted in detectable amounts of specific DNA
fragments (549 bp). Additional nested
PCR confirmed this observation by the
amplification of a 128 bp DNA fragment.
Subsequently, this PCR was applied to
microdissected single CA's obtained from
three cardiac allografts. Of either graft,
four single CA's (with severe TA) were
microdissected and analyzed individual-
ly for the presence of male-derived (re-
cipient-derived) cells. All samples ana-
lyzed showed the male-specific DNA
fragments after the first round, as well as
after nested PCR. Representative results
of the nested PCR performed on three in-
dividual CA's microdissected from three
different grafts, as well as specificity con-
trols (male- and female-derived DNA),
are shown in Figure 5B. Results obtained
with the HY-specific as well as with the
Tap2 PCR thus indicate the presence of
recipient-derived cells, both in microdis-
sected neointimal cell clusters obtained
from aortic allografts and in microdissect-
ed whole CA's showing severe TA. How-
ever, although neointimal tissue predomi-
nantly consists of α-actin- positive VSM131
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cells (Figures 1C and 3F), neointimal le-
sions can also contain an appreciable
number of recipient-derived infiltrating
leukocytes, especially macrophages43.
The neointimal lesions present in aortic
allografts in this study indeed contained
considerable numbers of ED1+ macroph-
ages (Figure 1D). Neointimal lesions in
CA's appeared to contain few if any infil-
trating inflammatory cells (Figure 3);
however, one cannot exclude the possi-
bility that such inflammatory cells were
present. Since the HY PCR is sufficiently
sensitive to detect male-derived cells on
the single-cell level, false-positive results
could be obtained by neointima-contami-
nating recipient-derived inflammatory
cells.
HY PCR analysis of microdissected sin-
gle VSM cell nuclei
To avoid contamination of the samples
with neointima-infiltrating inflammatory
cells, HY PCR analysis was performed on
microdissected single nuclei from α-ac-
tin-positive neointimal cells from aortic
and cardiac allografts. α-Actin staining
ensured positive identification of neoint-
imal VSM cells and prevented potential
contamination of our samples with inti-
ma-infiltrating inflammatory cells.
Aortic allografts.
Figure 4C shows a representative micro-
graph of an aortic allograft with TA after
isolation of three VSM cell nuclei. First,
PCR analysis was performed on nuclei
isolated from allografts exchanged be-
tween male rats for both donor and re-
cipient. As now neointimal VSM cells, by
definition, were of male origin, we could
test the efficacy of the isolation procedure
and subsequent PCR analysis. In total, 13
isolated nuclei from two grafts were ana-
lyzed, of which 12 (92.3%) showed the Y
chromosome-specific (male-specific)
128-bp DNA fragment (not shown).
Subsequently, the same procedure was
performed on nuclei isolated from female
PVG grafts transplanted into male AO
recipients. Three grafts were analyzed,
and from each graft eight nuclei were iso-
lated. PCR analysis revealed that 21/24
(87.5%) of the samples contained DNA
and, of these, 19/21 (90.5%) displayed the
male-specific 128- bp DNA fragment.
These results indicate that at least 90% of
α-actin-positive VSM cells in transplant
arteriosclerotic lesions after allogeneic
aorta transplantation are of recipient ori-
gin.
Coronary arteries .
Subsequently, this PCR was applied to
single nuclei microdissected from CA's
showing severe TA. Again, three grafts
were analyzed and from each graft eight
nuclei were isolated. After allogeneic car-
diac transplantation, neointimal α-actin-
positive VSM cells are recipient-derived.
Figures 4D and 5C show representative
results of the HY PCR applied to micro-
dissected single nuclei from aortic and
cardiac allografts, respectively.
The nucleotide sequence of the 128-bp
PCR products was determined to confirm
the Y-chromosomal nature of the ampli-
fied material. The obtained sequences
were compared with the sequence data
available from EMBL/Genbank data li-
braries, accession no. X80155 (clone
9.1ES8). The sequence data of the PCR
products were identical to the sequence
data available from the database, indicat-
ing that the 128-bp DNA fragment be-
longs to the Y chromosome (not shown).132
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Discussion
CTD is the primary cause of allograft loss
after the first perioperative year and is
today’s most important problem in clini-
cal organ transplantation. The hallmark
of CTD is development of TA; i.e., pro-
gressive intimal thickening (neointima
formation) consisting of α-actin-positive
VSM cells intermingled with recipient-
derived mononuclear cells (T cells and
macrophages)2. Current thought on the
process of TA holds that medial VSM cells
of affected arteries migrate into the sub-
endothelial space and start to proliferate,
leading to vascular narrowing and occlu-
sion2,9,10,44. In this paper, we analyzed
whether neointimal VSM cells as well as
EC's are truly donor-derived, using two
transplant models (aorta and heart) in
rats28,29. To address this question, donor
and recipient MHC class I haplotype-spe-
cific immunohistochemistry and PCR
analyses of DNA sequences allowing dis-
crimination between donor and recipient
origin were performed.
First we analyzed development of TA af-
ter transplantation of aortic grafts that
were ex vivo 50 Gy γ-irradiated (to in-
hibit proliferation and migration of me-
dial VSM cells) prior to transplantation.
It has been shown that γ-irradiation of
cultured VSM cells in vitro inhibits pro-
liferation of these cells after stimulation45.
Three months after transplantation, irra-
diated grafts showed severe TA, similar
to nonirradiated grafts, suggesting re-
cipient origin of neointimal cells. Aziz et
al. performed similar experiments using
liquid nitrogen to destroy medial VSM
cells in aortic allografts prior to transplan-
tation. These frozen allografts showed TA
to the same extent as unmodified grafts,
also suggesting recipient origin of neoin-
timal cells22.
Subsequently, aorta recipients were treat-
ed with 5 mg/kg or 10 mg/kg CsA for 28
days to study the effect of immuno-
suppressive treatment on the development
of TA. CsA treatment completely blocked
neointima formation and preserved the
vascular media, confirming that develop-
ment of TA is primarily alloimmune-me-
diated. Neointima formation is dependent
on, and proportional to, the extent of me-
dial VSM cell damage46. By suppressing
the alloimmune response by CsA treat-
ment, no medial VSM cell (and possibly
also no EC) damage occur; thereby de-
velopment of TA is prevented. How-
ever, Stoltenberg et al. showed that ad-
ministration of the same amounts of CsA,
resulting in similar 24-hour CsA trough
levels, resulted in significant inhibition,
but no prevention of neointima formation
3 and 6 months after aorta transplantation
in the ACI to Lew strain combination33.
Differences between the rat strains used
and the follow-up period might explain
the different results.
To confirm the origin (donor vs. recipi-
ent) of neointimal endothelial and VSM
cells in rat aortic allografts displaying
extensive TA, we first performed recipi-
ent MHC class I specific immunohisto-
chemistry. Results indicate that EC's in-
deed are of recipient origin in nontreated
and irradiated aortic allografts. CsA treat-
ment prevented neointima formation, and
MHC class I staining showed that EC's
layering the internal elastic lamina are still
of donor type and are not being replaced
by recipient-derived EC's. In contrast to
the aortic allografts, neointimal EC's are
still of donor type in cardiac allografts
showing severe TA 530 days after engraft-133
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ment. Similar results were found by Ha-
segawa et al.47, who showed that after
MHC-mismatched cardiac allografting in
mice EC's in CA's with neointimal lesions
are still of donor origin at 12 weeks after
transplantation by using MHC class II-
specific immunohistochemistry.
The origin of EC's (donor vs. recipient)
after organ allografting has been debated
since Woodruff48 and Medawar49 sugges-
ted that replacement of donor EC's with
recipient EC's (graft adaptation) might be
an important factor in establishing trans-
plantation tolerance in long-term allograft
survivors. Since then, several groups re-
ported data supporting11-16 and discount-
ing17-20,24 repopulation of graft vessels by
recipient-derived EC's after solid organ
transplantation (kidney, heart and lung)
(reviewed in ref. 50). Taken together, re-
sults from literature and data presented
in this paper suggest that EC replacement
is not a general phenomenon after allo-
geneic organ transplantation. In the ab-
sence of immunosuppression, donor EC's
become necrotic and disappear within 2
weeks after allogeneic aorta transplanta-
tion in rats21,22. This severe damage of
donor EC's might explain the repopula-
tion of the graft with recipient-derived
endothelium. After cardiac transplantation
following intrathymic immunomodula-
tion and short-term immunosuppression,
remaining alloreactivity against graft en-
dothelium as well as alloimmune- inde-
pendent factors do not result in sufficient
EC damage leading to EC replacement.
Recently, we reported that after intrathy-
mic immunomodulation the intragraft
cytokine profile in long-term allografts
(>200 days) has shifted from a Th1 type
(high IL-2 and IFN-γ) toward a Th3 or
Tr1 type (high IFN-γ, TGF-β and IL-10;
no IL-2) profile. This altered immune re-
sponse might preserve graft endothelium,
but it does not prevent the development
of TA30. Studying human kidney biopsies,
Lagaaij et al. recently suggested a corre-
lation between the degree of EC replace-
ment by recipient-derived endothelium
and the severity of vascular rejection16.
Replacement of donor endothelium by re-
cipient-derived EC's seems to be related
to graft dysfunction, rather than to graft
function as suggested by Woodruff and
Medawar48,49, and seems to play a role in
endothelial repair processes upon (severe)
vascular injury.
The origin of the neointimal VSM cells
in the arteriosclerotic lesions still remains
questionable. The original paradigm con-
cerning the development of TA implies
intimal hyperplasia to be derived from the
donor media8. This is supported by find-
ings of Hruban et al., who showed donor
origin of neointimal VSM cells in two
patients using fluorescence in situ hybri-
dization on tissue sections20. However,
data have also been reported indicating
recipient origin of neointimal VSM cells
in experimental transplant models21-23.
MHC class I haplotype-specific immu-
nochemistry did not allow distinction be-
tween donor and recipient origin of neoin-
timal VSM cells in our transplant mod-
els, since both neointimal and medial
α-actin-positive VSM cells do not express
sufficient amounts of MHC class I anti-
gens for detection. A similar lack of ex-
pression has been described for MHC
class II antigens on neointimal VSM
cells47.
Therefore we addressed the question
whether neointimal VSM cells are truly
graft-derived using two unrelated PCR-
based analyses (Tap2 and HY) on aortic134
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and cardiac allografts, enabling discrimi-
nation between donor and recipient-de-
rived cells.
Using both types of PCR analysis on aor-
tic allografts and microdissected CA's
with severe TA, we found that at least a
significant part of the cells in these tis-
sues displays recipient-type DNA. Simi-
lar data were obtained for irradiated aor-
tic allografts. However, neointimal lesions
have been reported to contain an appre-
ciable number of recipient-derived infil-
trating leukocytes43. Also, the aortic al-
lografts analyzed in this study contained
neointima-infiltrating mononuclear cells,
consisting predominantly of ED1+ ma-
crophages and some T cells. Such con-
taminating recipient-derived leukocytes
can account for the recipient-specific sig-
nal in our analysis of aortic allografts and
microdissected CA's, especially for the
male-specific analysis, since the HY PCR
is much more sensitive than the Tap2
PCR. Similar problems may also have
influenced the results of Plissonnier et al.21
and more recently Brazelton et al.23 on the
origin of VSM cells in vascular allografts.
These groups used allospecific immuno-
fluorescent staining of cell suspensions21
and tissue sections23 of aortic and femo-
ral arterial allografts. Although their con-
clusion, that neointimal VSM cells are of
recipient origin, in itself is probably cor-
rect, their type of analysis cannot distin-
guish between the infiltrating (recipient-
derived) leukocytes and neointimal VSM
cells.
Since our male-specific nested HY PCR
allows detection of male-derived cells at
the single-cell level32, we analyzed micro-
dissected single nuclei of neointimal VSM
cells. Nuclei were isolated from neointi-
mal lesions of both aortic allografts and
CA's with severe TA by positive selec-
tion (α-actin staining), thereby eliminat-
ing the risk of contaminating our samples
with infiltrating recipient-derived mono-
nuclear cells. HY PCR analysis of single
nuclei of α-actin-positive neointimal cells
showed that at least 90% of these cells in
neointimal lesions of both aortic allografts
and CA's from cardiac allografts are of
recipient origin.
Although Hasegawa et al. claim that VSM
cells in neointimal lesions of CA's after
cardiac transplantation in mice are prob-
ably still of donor origin at 12 weeks af-
ter transplantation, their type of analysis,
MHC class II specific immunohistochem-
istry, does not allow determination of ori-
gin of neointimal VSM cells because of
lack of MHC class II antigen expression
on these neointimal VSM cells47.
Since our data show recipient origin of
neointimal VSM cells (aortic and cardiac
allografts) and endothelium (aortic al-
lografts), the question arises: what is the
anatomical origin of these neointimal
cells? Kouchi et al. demonstrated blood-
stream origin of endothelial and α-actin-
positive smooth muscle cells present on
Dacron grafts transplanted in dogs51.
Recently, recirculating bone marrow-de-
rived CD34+ EC progenitor cells (EPC's)
have been identified in the peripheral
blood of humans52,53. The frequency of
circulating EPC's increases in response to
regional ischemia in both mice and rab-
bits. This increased frequency of circu-
lating EPC's contributes to neovasculari-
sation of ischemic regions54, indicating
that EPC's are mobilized from the bone
marrow into the circulation and subse-
quently ‘home’ to sites needing  neovas-
cularisation. Using bone marrow chi-
meric dogs, Shi et al. demonstrated do-135
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nor (bone marrow) origin of EC's attached
on implanted Dacron grafts, also indica-
ting existence of circulating bone marrow-
derived EC's55. In another study, Bhatta-
charya et al. recently showed enhanced
re-endothelialisation of Dacron grafts af-
ter seeding with bone marrow-derived
CD34+ cells prior to implantation56. Ta-
ken together, these results suggest an im-
portant role for bone marrow-derived
CD34+ progenitor cells as a source for
EC's.
The anatomical source of the neointimal
VSM cells is still unknown. One possi-
bility might be ingrowth of medial VSM
cells from the recipient side of anastomo-
sis, as suggested by Aziz et al.22. VSM
cell destruction by freezing the recipient
aortic ends at both sides near the anasto-
mosis resulted in less pronounced intimal
thickening compared with untreated aor-
tic allografts. However, the frozen re-
cipient aortic ends remained devoid of
α-actin-positive VSM cells during the ob-
servation period of 60 days. If the neoin-
timal VSM cells originate from the re-
cipi ent media, one should expect migra-
tion of α-actin-positive VSM cells along
the frozen aortic ends toward the mid-
graft region. This was, however, not clear
from the study by Aziz et al.22. A second
possibility might be transdifferentiation
from EC's into α-actin-positive VSM
cells. Studying quail embryos, de Ruiter
et al. showed transdifferentiation of em-
bryonic EC's into α-actin-expressing mes-
enchymal cells in vivo and in vitro57.
The third possibility for the anatomical
origin of neointimal VSM cells is the ex-
istence of VSM progenitor cells that dif-
ferentiate into α-actin-positive VSM cells.
Circulating VSM progenitor cells, how-
ever, have not been identified so far. Bu-
cala et al. reported the existence of a non-
bone marrow-derived circulating cell pop-
ulation with fibroblast properties that spe-
cifically enters sites of tissue injury58. In
addition, Kouchi et al. described the pres-
ence of α-actin- positive smooth muscle
cells on Dacron grafts which apparently
originated from the bloodstream51. Using
whole vessel wall organ cultures, Slomp
et al. showed migration of adventitial
myofibroblasts to the luminal surface,
where they transdifferentiated into endo-
thelial-like cells as well as into a VSM
cell phenotype in intimal thickening59.
These results suggest the existence of a
myofibroblast cell lineage that can serve
as an endothelial and smooth muscle stem
cell population. In our aortic transplant
model, sequential immunohistological
analysis of developing TA at an early stage
after transplantation indeed suggests a
blood-borne influx of regenerating VSM
cells (not shown).
In conclusion, in contrast to current
thought about the process of TA, the
α-actin-positive VSM cells in the hyper-
plastic neointima in aortic and cardiac al-
lografts are of recipient and not of donor
origin. Neointimal EC's in aortic allografts
are replaced by recipient-derived endo-
thelium, whereas in cardiac allografts
neointimal EC's are not replaced and are
still of donor origin. So, independent of
EC replacement, donor VSM cells in the
graft are replaced by VSM cells of re-
cipient origin in these two transplant mo-
dels.
We propose that the development of TA
is an attempt to restore vascular function
upon immunological injury (alloreactivi-
ty) and is essentially part of a normal heal-
ing process. Basically, as a result of the
immunological injury, medial VSM cells136
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disappear, leaving the elastin network as
a scaffold allowing restoration of the ves-
sel wall by recipient-derived cells. How-
ever, in TA this remodeling does not seem
to stop, eventually leading to total occlu-
sion of the vessels involved. According
to this concept, at least two windows in
time seem to exist that would allow thera-
peutic intervention to prevent the devel-
opment of severe TA. The first is early
after transplantation when primary vas-
cular graft damage through either  ische-
mia or alloreactivity should be prevent-
able. Perhaps current immunosuppressive
therapies should even be intensified or
adapted to suppress nonclinical rejection
episodes causing vascular damage even-
tually leading to TA. The second window
for intervention would be later, when TA
starts to develop. Our data suggest that
TA is the result of a repair process pro-
ceeding beyond the needs of functional
repair. Future intervention strategies at
this stage should aim at regaining proper
control of this dysregulated process.
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Abstract
Background. Coronary artery disease is today’s most important post-heart transplan-
tation problem after the first perioperative year. Histologically, coronary artery dis-
ease is characterized by transplant arteriosclerosis. The current view on this vascu-
lopathy is that vascular smooth muscle (VSM) cells from the media of affected arter-
ies proliferate and migrate into the subendothelial space (intima) in response to sig-
nals from inflammatory cells and damaged graft endothelium. According to this model,
the intimal VSM cells in transplant arteriosclerotic lesions should originate from do-
nor tissue. Using recipient-specific polymerase chain reaction (PCR) analysis of mi-
crodissected, single, neointimal VSM nuclei, we recently showed that after allogene-
ic aorta transplantation the neointimal VSM cells are of recipient and not of donor
origin. In this study, we analyzed whether VSM-cell replacement with recipient-de-
rived cells also takes place after allogeneic heart transplantation.
Methods. Cardiac allografts, when transplanted from female donors to male immune-
modulated recipient rats, eventually developed transplant arteriosclerosis. We micro-
dissected α-actin positive neointimal VSM cells from tissue sections and determined
the origin (donor or recipient) using-recipient (male),  single-cell, PCR analysis.
Results. In total, we analyzed 35 VSM-cell nuclei from 3 allografts, and PCR analy-
sis revealed that 30/35 (86%) of the samples displayed the male-specific 128 base
pair DNA fragment. These results indicate that after allogeneic cardiac transplanta-
tion, at least 86% of VSM cells in transplant arteriosclerotic lesions are of recipient
origin.
Conclusions. In contrast to current thought, the neointimal VSM cells in cardiac al-
lografts that show transplant arteriosclerosis are of recipient and not of donor origin.143
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Introduction
Development of chronic transplant dys-
function (CTD) is the primary cause of
allograft loss after the first perioperative
year and is today’s most important prob-
lem in clinical organ transplantation. Cur-
rent immunosuppressive protocols cannot
prevent CTD1,2. Depending on the type of
organ grafted (liver, kidney, heart or lung),
the incidence of CTD varies from 5% in
liver allografts to >50% in lung trans-
plants3-5. After clinical heart transplanta-
tion, coronary artery disease (CAD) is the
main cause of CTD. Five years after heart
transplantation, CAD is present in about
40% of transplant recipients6,7.
Coronary artery disease is characterized
by a process of vascular remodeling re-
ferred to as transplant arteriosclerosis, and
consists of ongoing perivascular inflam-
mation and progressive intimal thicken-
ing (intimal hyperplasia). This vasculo-
pathy is generally accepted as the main
cause for progressive deterioration in graft
function after heart transplantation.  Me-
chanisms involved in the development of
CAD development, however, remain ob-
scure. Risk factors appear to include al-
loantigen dependent factors (e.g., major
histocompatibility complex [MHC] dis-
parity and the number of acute rejection
episodes) as well as alloantigen indepen-
dent factors (e.g., donor age, donor hy-
pertension, cold ischemia/reperfusion in-
jury, and cytomegalovirus infection)2,7.
The current view on transplant arterioscle-
rosis is that donor-derived medial vascu-
lar smooth muscle (VSM) cells of affec-
ted arteries start to proliferate and migrate
into the sub-endothelial space (intima) in
response to signals from inflammatory
cells (perivasculitis) and damaged graft
endothelium8-11. According to this model,
intimal smooth muscle cells in transplant
arteriosclerotic lesions should originate
from donor tissue. Presently, however,
few experimental or clinical studies have
addressed the question of whether the
VSM cells in intimal lesions are indeed
graft-derived (donor), and results con-
flict12-15. Using recipient-specific poly-
merase chain reaction (PCR) analysis of
microdissected, single, neointimal VSM
cell nuclei, we recently showed that, af-
ter allogeneic aorta transplantation in rats,
neointimal VSM cells are (for the vast
majority) of recipient and not of donor
origin16. We hypothesized that develop-
ment of transplant arteriosclerosis is an
attempt to restore vascular wall function
after immunologic injury and essentially
is part of a normal healing response17. In
contrast to the normal healing response,
which stops after healing, the remodel-
ing process  in transplant arteriosclerosis
does not seem to stop, and eventually
leads to total occlusion of the vessels in-
volved.
Because transplantation of aortic al-
lografts provides a simplified model to
study pathogenesis of transplant arterio-
sclerosis18, we wondered whether VSM-
cell replacement is a general phenome-
non after transplantation and not unique
to vascular allografts. Therefore, we ana-
lyzed the origin (donor vs. recipient) of
VSM cells in cardiac allografts that were
transplanted in an MHC-incompatible rat
strain combination after intrathymic (IT)
immune modulation of the recipient rats.
Intrathymic immune modulation prevents
acute rejection and significantly prolongs
graft survival19. However, this strategy
cannot prevent transplant arteriosclerosis
development. Using recipient-specific,144
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single cell, PCR analysis of microdissec-
ted neointimal VSM-cell nuclei, we show
that also after cardiac allografting, the
neointimal VSM cells throughout the graft
are of recipient origin.
Materials and Methods
Animals
We  obtained specific pathogen-free fe-
male PVG (RT-1c) and male AO (RT-1u)
rats from the Central Animal Facility of
the Faculty of Medical Sciences of the
University of Groningen. The PVG and
AO rats were age-matched (7 to 10 weeks
of age) and used as donors and recipients,
respectively. We maintained animals un-
der clean, conventional conditions and fed
them standard rat chow and acidified
water ad libitum. All animals received
humane care in compliance with the Prin-
ciples of Laboratory Animal Care (NIH
Pub. No. 86-23, revised 1985) and the
Dutch Law on Experimental Animal Care.
Cardiac Transplantation and IT Immune
Modulation
To prevent acute rejection after cardiac
allografting in the fully MHC-incompati-
ble PVG-to-AO rat-strain combination,
we used a protocol developed in our labo-
ratory and described elsewhere19 (Group
1, n=39). Cardiac allografts thus trans-
planted eventually develop transplant
arteriosclerosis indicative of CTD.
Control groups consisted of rats that re-
ceived cardiac allografts and subsequent
treatment with rabbit anti-rat lymphocyte
serum (ALS) and cyclosporine (CsA)
(Group 2, n=8) or that received no fur-
ther treatment at all (acute rejection,
Group 3, n=9). We monitored grafts until
rejection (cessation of palpable ventricu-
lar contraction). We also transplanted AO
grafts to serve as isograft controls (Group
4, n=3). All grafts promptly started beat-
ing after revascularisation, and we regu-
larly assessed graft function by palpation.
Evaluation of Transplant Arteriosclero-
sis
To analyze presence of transplant arterio-
sclerosis after IT modulation (Group 1),
we removed functioning (beating) grafts
at various points after transplantation
(ranging from 100 to 500 days after trans-
plantation). We did not include grafts from
Group 2 (CsA and ALS treatment only)
in this histologic analysis. To study vas-
culopathy in acutely rejecting allografts,
we transplanted 3 additional grafts, gave
them no further treatment, and removed
grafts 4 days after transplantation (at this
time the grafts were still beating) (Group
3). We removed isografts (Group 4) 250
days after transplantation. We embedded
grafts in paraffin and processed them for
histologic analysis. Development of trans-
plant arteriosclerosis was evaluated on
tissue sections stained with orcein (Gurr,
BDH Chemicals Ltd.; UK) for elastin. To
confirm presence of intimal VSM cells in
neointimal lesions, we performed a dou-
ble staining for elastin and VSM-cell α-
actin20,21.
Microdissection of Single Cells from Tis-
sue Sections
To study the origin (donor vs. recipient)
of neointimal VSM cells in transplant ar-
teriosclerosis, we first microdissected cell
clusters (20 to 50 cells) from neointimal
lesions from 5 grafts (showing severe
transplant arteriosclerosis) using a micro-
manipulator (Leica, Germany). How-
ever, transplant arteriosclerotic lesions not145
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only contain α-actin-positive VSM cells,
but also (recipient derived) infiltrating
leukocytes (T cells and macrophages).
Therefore, we also microdissected single
nuclei from α-actin-positive VSM cells
to prevent potential contamination with
neointima infiltrating cells. We used
α-actin staining to ensure positive identi-
fication of VSM cells. From the 5 grafts
used for cell-cluster microdissection, we
selected 3 grafts for microdissection of
single nuclei. For each graft studied, nu-
clei were isolated from at least 2 repre-
sentative cross sections (4 nuclei/section).
Nuclei were randomly selected from
among α-actin-positive cells that had
well-visible nuclei surrounded by α-ac-
tin-positively stained cytoplasm. Isola-
ted nuclei were directly transferred into
PCR tubes containing MilliQ water and
stored at  –20￿C until PCR analysis.
Single-Cell PCR Analysis
Because we performed all transplanta-
tions in female (donor) to male (recipi-
ent) combinations, we could use sex
mark ers as indicators for cellular origin.
Therefore, we developed a highly sensi-
tive and specific, nested PCR procedure
that enabled identification at the single-
cell level of a Y-chromosome-associated
DNA sequence and thereby identification
of the (male) origin of cells. We designed
2 sets of primers (for the first- and sec-
ond-round PCR) to detect specifically
male-derived cells using the Y-chromo-
some-specific sequence as described by
Essers et al.22. These sequence data are
available from EMBL/Genbank Data Li-
braries under accession number X80155
(clone 9.1ES8). The sequences of the first-
round primers were 5’-CAGGCTG
GAAAGGCTTGTAG-3’ (forward) and
5’-CCCATGTTTGGTCCACATAG-3’ (re-
verse), and the sequences of the second-
round primers were 5’-GCTGGTGA-
TTTGCAGAGTGA-3’ (forward) and 5’-
GAATGTTCGATTCCGACTGG-3’ (re-
verse). The first and second rounds of
PCR amplification resulted in 549 base
pair (bp) and 128 bp DNA fragments, re-
spectively. Before amplification, single
nuclei were treated with proteinase K
(Boehringer Mannheim, Germany) for 1
hour at 50￿C, and thereafter proteinase K
was heat inactivated for 10 minutes at
95￿C. First and second rounds of PCR
reactions were performed in a 50 ￿l mix-
ture containing 1 U Taq polymerase (Ther-
mus aquaticus YT1), 200 ￿mol/liter
dNTP, 30 ￿mol/liter of each of the two
primers (forward and reverse), 0.05%
W-1, and 1.5 mmol/liter MgCl2 in PCR
buf- fer (Life Technologies B.V.; The
Netherlands). Temperature profile for the
first round of PCR  follows: 3 minutes
denaturation at 95￿C; 35 cycles of 60 sec-
onds at 95￿C, 60 seconds at 60￿C, and 80
sec- onds extension at 72￿C; 7 minutes
extension at 72￿C. After the first round of
PCR, 2 ￿l of the first-round reaction mix-
ture was transferred into a new reaction
tube containing second-round reaction
mixture. Temperature profile for the sec-
ond round of PCR follows: 3 minutes de-
naturation at 95￿C; 30 cycles of 60 sec-
onds at 95￿C, 60 seconds at 60￿C, and 80
seconds of extension at 72￿C; 7 minutes
extension at 72￿C. Amplifications were
carried out using an Amplitron® II Ther-
molyne thermocycler (Barnstead/Ther-
molyne, USA). After the second round of
PCR, 5 ￿l of the reaction mixture was ana-
lyzed on a 2% agarose gel. Presence of
the 128 bp fragment indicates male (re-
cipient) origin of the nucleus analyzed.146
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Statistical Analysis
To analyze differences in graft survival
rates for statistical significance, we per-
formed a 2-tailed Mann-Whitney U Test
using Graphpad Prism™ 2.0.1 for Win-
dows. Differences were considered sta-
tistically significant when P< 0.05.
Results
Graft Survival After IT Immune Modula-
tion
Intrathymic inoculation of donor spleno-
cytes followed by short-term immuno-
suppressive treatment (Group 1) resulted
in significantly prolonged graft survival
(P<0.0001) (Figure 1). Median survival
time after IT inoculation was >208 days
compared with 20 days after CsA and
ALS treatment without IT inoculation
(Group 2), and with 8 days in acute rejec-
Figure 1.Graft survival after intrathymic  immune modulation. Intrathymic inoculation of 2.5x107 donor
splenocytes and short-term immunosuppressive treatment (Group 1, n=39) results in significantly pro-
longed graft survival of MHC-incompatible cardiac allografts compared with grafts transplanted in re-
cipients treated with ALS and CsA only (Group 2, n=8) and compared with acutely rejecting grafts
(Group 3, n=9) (P<0.0001, Mann Whitney U test). Only 4 of 39 allografts were rejected, whereas the
others showed ‘indefinite’ survival and remained beating until removal. Cardiac isografts (Group 4, n=3)
showed indefinite survival and remained beating until removal 250 days post-transplantation. Open circles
represent cardiac grafts in respective groups that remained beating until removal, whereas the closed
circles represent rejected grafts. ALS, rabbit anti-rat lymphocyte serum; AR, acute rejection; CsA,
Cyclosporin A; IT inoc., intrathymic inoculation.147
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tion (Group 3). Treatment with CsA and
ALS alone resulted in significantly pro-
longed graft survival compared with acute
rejection (P<0.0001). Only 4 out of 39
cardiac allografts transplanted after IT
inoculation were rejected (at time points
comparable with animals treated with
CsA and ALS only, Group 2). Grafts that
were not rejected after IT inoculation sur-
vived ‘indefinitely’, and we removed
them for histologic analysis at several
time points (ranging from 100 to 500
days) after transplantation, still beating at
that time. Cardiac isografts also survived
indefinitely and were beating at removal
(mean survival time >250 days).
Development of Transplant Arterioscle-
rosis
Intrathymic inoculation prevented rejec-
tion of cardiac allografts in the majority
of the grafts transplanted (Figure 1). How-
ever, IT inoculation did not prevent the
development of transplant arteriosclero-
sis, indicative of CAD. In beating grafts
that were removed before 200 days after
transplantation, up to 36% – 25% of coro-
nary arteries showed moderate to severe
transplant arteriosclerosis (i.e., circum-
ferential intimal thickening with > 20%
luminal compromise). In grafts removed
between 200 and 500 days after transplan-
tation, 80% – 18% of the coronary arter-
ies showed severe transplant arterio-
sclerosis, in which the vascular lumen was
completely occluded. We observed a posi-
tive correlation between the severity of
transplant arteriosclerosis and the time of
explantation. Immunohistochemical
staining revealed large numbers of α-ac-
tin-positive VSM cells in neointimal le-
sions of coronary arteries, showing severe
transplant arteriosclerosis.
In cardiac isografts, explanted 250 days
after transplantation, coronary arteries
were virtually free from severe transplant
arteriosclerosis and generally appeared
normal. Allografts without further treat-
ment (Group 3) were rejected (cessation
of palpable ventricular contraction) within
7 days after transplantation. Therefore, we
transplanted another 3 allografts and gave
no further treatment. These remained
functional until removed 4 days after
transplantation. We used these grafts for
further histologic analysis. We observed
no transplant arteriosclerosis and blood
vessel pathology in rejecting allografts
was characterized by mononuclear-cell
infiltration of the intima (without presence
of α-actin-positive cells), often coincid-
ing with perivascular infiltration. Thus, IT
inoculation of donor splenocytes followed
by short-term immunosuppressive thera-
py prevents (acute) rejection but not de-
velopment of transplant arteriosclerosis.
Figure 2 shows representative micro-
graphs of the morphologic appearance of
coronary arteries in the various treatment
groups.
Single-cell PCR Analysis of VSM Cells
Because we performed cardiac allograft-
ing not only between MHC-incompatible
rat strains but also in a female (donor) to
male (recipient) combination, we could
use sex markers as indicators for cellular
origin. Therefore, a highly sensitive and
specific, nested PCR procedure was de-
veloped that enabled the identification, at
the single-cell level, of a 128 bp Y-chro-
mosome-associated DNA sequence and
thereby the (male) origin of cells. Speci-
ficity and sensitivity of this PCR was con-
firmed by PCR analysis on serially dilu-
ted male and female splenocyte-derived148
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Figure 2.Photomicrographs of coronary artery morphology after intrathymic immune modulation and
in the control groups. Staining for VSM-cell α-actin shows medial and neointimal α-actin-positive
VSM cells. In normal (non-transplanted) cardiac tissue as well as cardiac isografts (250 days after trans-
plantation), no blood vessel pathology was present (A en B). Acutely rejecting allografts showed vascu-
lar rejection with disruption of the vascular media, but without transplant arteriosclerosis (C). After
intrathymic immune modulation (>200 days after transplantation), the vast majority of blood vessels
showed severe transplant arteriosclerosis with (nearly) complete luminal occlusion. The neointimal le-
sions mainly consisted of α-actin-positive cells (D). IEL, internal elastic lamina; LU, lumen; M, media;
NI, neointima (original magnification, x400).149
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DNA as well as PCR analysis on single-
cell sorted (using a FACS® cell sorter)
male and female thymocytes. In both ana-
lyses, the PCR proved to be male speci-
fic and sufficiently sensitive to detect
male-derived cells at the single-cell level
(not shown). We first performed PCR
analysis on cell clusters that we micro-
dissected from neointimal lesions from 5
grafts that showed severe transplant arte-
riosclerosis (majority of the coronary ar-
teries completely obliterated), explanted
436, 469, 469, 481 and 481 days after
transplantation. Polymerase chain reac-
tion analysis showed that recipient-de-
rived cells were present in the cell clus-
ters (not shown). To prevent potential
contamination with neointima infiltrating
recipient-derived leukocytes, we subse-
quently performed single-cell PCR ana-
lysis on VSM-cell nuclei microdissected
from 3 selected grafts, which were ex-
A 30 µm
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Figure 3.Vascular smooth muscle (VSM) cells in neointimal lesions are of recipient origin. (A) Micro-
photograph shows double staining for VSM cells (α-actin) and elastin (Lawson) of a coronary artery
with severe transplant arteriosclerosis after microdissection of single, VSM cell nuclei using a micro-
manipulator. White arrowheads indicate α-actin- positive VSM cells, whereas black arrowheads indi-
cate remaining gaps after dissection of nuclei of 2 α-actin-positive VSM cells (original magnification
x400). (B) Eight samples, representing 8 single nuclei from α-actin-positive cells dissected from 2
cardiac allografts transplanted from female-donor to male-recipient rats, showing the Y-chromosome-
specific (recipient) 128 bp DNA fragment. bp ladder, 100 base pair ladder; H2O, water control (i.e. no
nucleus present). NI, neointima; IEL, internal elastic lamina.150
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planted 436, 469 and 481 days after
transplantation.
α-Actin staining ensured positive identi-
fication of smooth muscle cells. Figure
3A shows a representative micrograph of
a cardiac allograft with severe transplant
arteriosclerosis after microdissection of 2
VSM-cell nuclei (black arrowheads).
We tested the efficacy of the microdissec-
tion procedure and subsequent PCR ana-
lysis on male-derived tissue sections,
which turned out to be about 90%. From
each graft, we microdissected at least 8
nuclei. In total, 35 individual nuclei were
isolated and analyzed. Polymerase chain
reaction analysis revealed that 30 of 35
nuclei analyzed displayed the male-spe-
cific 128 bp DNA fragment, whereas 5
(DNA containing) samples were negative
for the male-specific 128 bp DNA frag-
ment. This high frequency of positive
samples indicates that at least 86% of
VSM cells in (severe) transplant arterio-
sclerotic lesions after allogeneic cardiac
transplantation are of recipient origin.
Because the efficacy of the microdissec-
tion procedure and subsequent PCR ana-
lysis was about 90%, the results indicate
that virtually all neointimal α-actin posi-
tive cells are of recipient origin. We dis-
sected nuclei from neointimal lesions
from large (primary) coronary arteries as
well as from small coronary arteries deep
in the myocardial tissue, indicating that
not only VSM cells near the site of ana-
stomosis but that all VSM cells through-
out the cardiac graft are of recipient ori-
gin. Figure 3B shows representative re-
sults of the Y-chromosome-specific, sin-
gle-cell PCR analysis performed on mi-
crodissected VSM-cell nuclei from 2
different cardiac allografts.
Discussion
Coronary artery disease is the main cause
of long-term transplant dysfunction and
affects up to 40% of heart transplant re-
cipients 5 years after transplantation6,7.
This vasculopathy is characterized by
perivascular inflammation, disappearance
of medial VSM cells, and a generalized
concentric intimal thickening (transplant
arteriosclerosis), consisting of vascular
smooth muscle (VSM) cells intermingled
with some T cells and macrophages2.
Current thought on the process of trans-
plant arteriosclerosis holds that medial
VSM cells of affected arteries in the graft
proliferate and migrate into the sub-en-
dothelial space (intima) and therefore are
donor derived8-11. Presently, however, few
studies have addressed the question of
whether the VSM cells in intimal lesions
are indeed graft-derived and results con-
flict12-15. Using specific immunohis-
tochemistry and recipient-specific, single-
cell PCR analysis, we recently showed
that after allogeneic aorta transplantation
in rats, the endothelial cells as well as
neointimal VSM cells are of recipient and
not of donor origin16. These observations
are in line with results reported by oth-
ers, who also used models in which allo-
geneic vascular grafts were transplanted
to study the origin of neointimal cells13,14.
Because transplantation of a vascular al-
lograft provides a simplified model to
study the pathogenesis of transplant
arteriosclerosis, we wondered whether
VSM-cell replacement with recipient de-
rived cells is a general phenomenon after
allogeneic transplantation or is strictly
related to vascular remodeling after trans-
plantation of (large) vascular allografts.
Recipient origin of VSM cells after solid151
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organ transplantation has not been repor-
ted so far. Using another rat model, we
analyzed the origin (donor vs. recipient)
of neointimal VSM cells in cardiac al-
lografts showing severe transplant arte-
riosclerosis. In this model, IT immune
modulation prevented acute rejection,
eventually resulting, however, in the de-
velopment of transplant arteriosclerosis19.
Using recipient-specific, single-cell PCR
analysis of microdissected neointimal
VSM-cell nuclei, we, for the first time,
show that also after solid-organ transplan-
tation (cardiac allograft) the neointimal
VSM cells are of recipient origin. Cardi-
ac allografts surviving >200 days dis-
played severe transplant arteriosclerosis
and 86% of the microdissected neointi-
mal VSM cells were of recipient origin.
Because the efficacy of the microdissec-
tion procedure and subsequent PCR ana-
lysis was about 90%, the results indicate
that neointimal VSM cells are essentially
recipient- derived.
Thus, not only in vascular transplantation
but also in solid-organ transplantation, the
VSM cells in neointimal lesions are pre-
dominantly and most likely entirely of
recipient origin, indicating VSM-cell re-
placement during the development of
transplant arteriosclerosis in such grafts.
Whether VSM-cell replacement by re-
cipient cells is a general phenomenon af-
ter solid-organ transplantation needs fur-
ther investigation. We propose that suffi-
cient initial damage to the graft endothe-
lium has to occur (as a result of allo-
reactivity but also as a result of ischemia/
reperfusion injury) before replacement of
graft endothelial and as well as VSM cells
will take place23. This might explain why
Hruban et al15 and Bittmann et al12 study-
ing human cardiac and renal allografts
respectively, reported donor origin of
neointimal VSM cells and endothelium in
grafts that showed transplant arterioscle-
rosis. Perhaps in these grafts, endothelial
and VSM-cell replacement did not occur
because of a lack of severe initial vascu-
lar damage. In the absence of severe dam-
age of donor endothelium, endothelial
cells will not be replaced by recipient-
derived endothelial cells. However, pre-
vention of donor endothelial-cell replace-
ment does not automatically prevent de-
velopment of transplant arteriosclerosis.
Hruban et al15 and Bittmann et al12 clear-
ly observed arteriosclerotic blood vessels
that contained donor-derived VSM cells.
Taken together, these results suggest that
in the absence of donor endothelial-cell
replacement, transplant arteriosclerosis,
containing donor-derived (possibly me-
dia) VSM cells, can still develop.
In allogeneic aorta transplantation, on the
other hand, donor endothelium disappears
within 15 days after transplantation and
is replaced by recipient endothelial cells
at day 18 13. Also medial (donor) VSM
cells have disappeared within 25 days af-
ter transplantation. These observations
suggest severe damage of donor endo-
thelial cells as well as VSM cells, lead-
ing to replacement with recipient-derived
endothelial cells and neointimal VSM
cells. Also in our model of allogeneic car-
diac transplantation, graft endothelium
and VSM cells are probably damaged to
such an extent that eventually recipient-
derived cells replace them.
Because this study shows neointimal
VSM cells are recipient-derived, the ques-
tion arises of the anatomic origin of these
cells. Using combinations of MHC and
gender-different bone marrow chimeric
rats, we are presently investigating whet-152
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her these cells originate from the recipi-
ent side of anastomosis or from recircu-
lating (possibly bone marrow- derived) re-
cipient VSM progenitor cells. Recently,
recirculating, bone marrow-derived en-
dothelial progenitor cells have been iden-
tified in human peripheral blood24,25, and
seem to contribute to neovascularisation
of ischemic regions26. Circulating VSM
progenitor cells have not been identified
so far. However, Bucala et al reported the
existence of a non-bone marrow derived
circulating-cell population with fibro-
blast-like properties that specifically en-
ters sites of tissue injury27. These results
strengthen the possibility that after severe
donor endothelial damage, the endotheli-
um as well as intimal VSM cells will be
replaced by recipient-derived recirculat-
ing progenitor cells.
In conclusion, this study shows that also
after solid-organ transplantation, the VSM
cells in the hyperplastic neointima are of
recipient and not of donor origin. We pro-
pose that development of allograft arte-
riosclerosis is an attempt to restore vas-
cular wall function after immunologic
injury (alloreactivity), and is essentially
part of the normal healing process18. Ba-
sically, as a result of the immunologic
injury, graft endothelium as well as me-
dial VSM cells disappear, leaving the elas-
tin network as a scaffold that allows res-
toration of the vessel wall by recipient-
derived cells. In contrast to remodeling
during normal healing, however, the pro-
cess of vessel wall rebuilding after allo-
geneic grafting is obviously not  properly
controlled, resulting in luminal occlusion
and graft dysfunction.
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Abstract
Neointimal lesions in chronic transplant dysfunction consist of vascular smooth muscle
(VSM) cells intermingled with inflammatory cells, and are covered with endothelial
cells (EC’s). The graft EC’s of a transplanted organ are thought to be the major target
for graft rejection. The origin of EC’s after transplantation has been studied for several
decades, and both donor-origin and host-origin have been described. EC replacement
appears to be correlated to vascular injury. We recently showed complete EC
replacement by host-derived endothelium in aortic allografts transplanted in rats. The
source of those host-derived EC’s contributing to re-endothelialization of graft’s vessels
is still a matter of debate. Here we used aortic allografts transplanted in MHC-
mismatched bone marrow chimeric rats to determine the contribution of bone marrow
(BM)-derived and non-BM-derived host-EC’s in the development of TA. Confocal
laser scanning microscopy demonstrated that the neointimal EC’s (and VSM cells)
are predominantly non-BM-derived.157
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Introduction
Long-term survival of solid-organ
transplants is limited as a result of chronic
transplant dysfunction (CTD) which is
histologically characterized by progres-
sive concentric intimal thickening (trans-
plant arteriosclerosis, TA). Intimal lesions
consist of vascular smooth muscle (VSM)
cells intermingled with inflammatory
cells1,2. Persistent alloreactivity against the
graft seems to be the predominant factor
in the development of TA, however,
precise mechanisms involved in the
pathogenesis of TA still remain obscure.
Current thinking on the process of TA
holds that in response to signals from
inflammatory cells and activated/dam-
aged graft endothelium (cytokines,
growth factors), medial VSM cells mi-
grate into the subendothelial space
beneath the graft endothelium3,4. Neo-
intimal endothelial cells (EC’s) and VSM
cells are therefore generally presumed to
originate from the donor. In 1959, Wood-
ruff5, and later expanded by Medawar6,
proposed that replacement of graft
endothelium with host-derived EC’s
results in graft adaptation, thereby reduc-
ing the immunogenicity of the graft.
According to this hypothesis, graft
adaptation should result in improved long-
term graft survival. Since then, the origin
of EC’s after transplan-tation has been
studied extensively, and both data
supporting donor-origin7-10 and host-
origin11-15 have been described. The
proposed beneficial effect of EC replace-
ment by host-derived cells, however, was
not demonstrated in these studies. In
contrast, Lagaaij et al. recently showed
that donor EC replacement with host-
derived endothelium was correlated with
the severity of vascular rejection in human
kidney allografts, suggesting that EC
replacement occurs in response to
vascular damage16. Whether EC replace-
ment influences the development of TA
is unclear, however, a worse prog-nosis
instead of graft adaptation is not un rea-
sonable.
We showed complete EC replacement by
host-derived endothelium in aortic allo-
grafts transplanted in non-immuno sup-
pressed rats, whereas in cardiac allografts
transplanted in immune modulated rats
graft endothelium was not replaced by
host-derived EC’s17,18. Data on the origin
of EC’s reported so far thus indicate that
EC replacement might occur after
allogeneic organ transplantation and that
replacement seems to be a repair-mecha-
nism upon vascular injury. Whether or not
donor endothelium will be replaced by
host-derived EC’s seems to depend on the
extent of the vascular injury.
The anatomical source of the host-derived
EC’s which replace donor endothelium in
the graft upon injury is still unknown.
Circulating EC progenitor cells (EPC’s)
recruited from the bone marrow (BM)
would be suitable candidates, since recir-
culating BM derived CD34+ endothelial
cell progenitors have been identified in
the peripheral blood of human indi-
viduals19. Moreover, it was recently
demonstrated that Flk-1 positive cells
derived from embryonic stem cells can
differentiate into both EC’s and VSM
cells20. However, also cells which are not
recruited from the BM, such as circulating
endothelial cells (CEC’s), may give rise
to the neointimal EC’s in TA21.
Here we used MHC-mismatched aortic
allografts transplanted in allogeneic bone
marrow chimeric rats to determine158
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whether neointimal EC’s are BM or non-
BM-derived. Using MHC-class I haplo-
type specific staining and confocal laser
scanning microscopy we demonstrate that
the neointimal EC’s in advanced intimal
lesions are predominantly non-BM
derived. However, in developing lesions,
in which the donor EC’s had partly
disappeared, we observed among the
scattered distributed host-derived EC’s
some EC’s which originated from the
BM-compartment. These data indicate
that BM-derived EC’s may contribute to
the re-endothelialization process during
the early stages of TA development. How-
ever, the overall contribution of those cells
to EC replacement in intimal lesions is
probably minimal since BM-derived EC’s
can not be detected in advanced TA.
Methods
Rats
Specific-pathogen free male Lew (RT-1l)
and BN (RT-1n) were used as BM donors
or recipients and as aorta recipients. Male
DA (RT-1avl) rats were used as aortic
allograft donors. All rats were aged 7-10
wk and were purchased from Harlan
(Zeist, The Netherlands). Animals were
maintained under clean conventional
conditions and fed standard rat chow and
acidified water ad libitum. All animals
received humane care in compliance with
the ‘’Principles of Laboratory Animal
Care’’ (NIH Publication No.86-23,
revised 1985) and the Dutch Law on
Experimental Animal Care.
Bone marrow transplantation
Both femora and tibiae of the donor rats
were excised and surrounding muscle and
connective tissue were removed. Both
ends were removed with small pincers,
and the BM was flushed with RPMI 1640
(Life Technologies) using a syringe with
a needle. Clusters were disaggregated by
vigorous pipetting and the cell suspension
was filtered using nylon gauze. BM cells
were washed, counted and set to a
concentration of 2x108 cells/ml. Male
recipient rats aged 7-10 wk were lethally
γ-irradiated (BN 8.5 Gy and Lew 9.5 Gy)
using a 137Cesium source (IBL 673, CIS
Bio International). Irradiated BN and Lew
hosts received 1x108 Lew and BN BM
cells respectively by tail vein injection.
Four to six weeks after bone marrow
transplantation, chimerism was deter-
mined in the peripheral blood by flow-
cytometry. If complete chimerism was
observed aortic transplantation of DA
allografts into the chimeric hosts was
performed.
Aortic transplantation
Aortic allografts (10-12 mm) were
transplanted orthotopically as described
previously22. Total ischemic time was
consistently less than 30 min. Transplan-
tations were performed in the DA to
LewBM->BN and DA to BNBM->Lew
strain combinations.
Flowcytometry
To determine the level of chimerism at
the time of aortic transplantation (4-6
weeks after BM transplantation), 0.5 ml
of heparinized blood was obtained from
the BM transplant recipients by cardiac
puncture. The blood samples were 1:1
diluted with PBS and subsequently
centrifuged (2500 rpm, 20 min). Buffy
coat mononuclear cells (MNC’s) were
isolated and remaining erythrocytes were159
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lysed in NH4Cl lysis-buffer. After
centrifugation (1200 rpm, 10 min) the
cells were resuspended in PBS and
counted. At the time of sacrifice three
months after aortic transplantation, aortic
allografts were explanted and processed
for histology. Moreover, to determine the
level of chimerism in the BM compart-
ment, BM cells were isolated as described
above. MNC’s and BM cells (0.5x106/
sample) were centrifuged in a 96-well
microtiter plate (1050 rpm, 3 min at 4￿C)
and resuspended in PBS containing 2%
newborn calf serum, 0.01% NaN3, and a
mixture of monoclonal antibodies
(mAb’s). The following mAb’s were used:
OX18 (pan MHC class I)23, OX27 (BN
[RT-1n] MHC class I haplotype)24, and
OX7 (CD90, Thy-1)25.
Cells were analyzed on an Elite flow-
cytometer (Coulter), and data analysis
was conducted with FlowJo (for Mac-
intosh, release 3.4 software package).
Within the forward and side scatter
diagram the lymphocyte population was
gated and within this population, the
expression of Thy-1 (among others ex-
pressed on hematopoietic stem cells, early
myeloid and erythroid cells, and im-
mature B cells), OX18 and OX27 was
analyzed. Positive OX18 staining
confirmed MHC class I expression,
whereas positive OX27 staining indicated
BN origin of these cells.
Confocal laser scanning microscopy
Three months after transplantation, the
aortic grafts were explanted and
immediately frozen in liquid nitrogen and
stored at -80￿C for cryostat sections. To
analyze the development of TA, an
indirect immunofluorescence double
staining was performed using mAb’s
asm-1 (IgG2a, VSM cell α-actin)26,27 and
RECA-1 (IgG1, endothelium)28. The
origin of neointimal EC’s in grafts trans-
planted in the BM chimeric rats was
analyzed using the following mAb’s:
OX18 (IgG1, pan MHC class I)23, OX27
(IgG2a, BN [RT-1n] class I)24, and MN4-
91-6 (IgG1, DA [RT-1a] MHC class I
haplotype)29. The following combinations
of antibodies were used for double-
staining: asm-1 & OX18, asm-1 & MN4-
91-6, and OX27 & RECA-1. Second-step
antibodies consisted of FITC conjugated
goat-anti-mouse IgG2a and TRITC conju-
gated goat-anti-mouse IgG1 antibodies
(Southern Biotechnologies). Sections
were DAPI (Molecular Probes) counter-
stained, embedded in Vectashield (Vector
Laboratories), and subsequently analyzed
with a confocal laser scanning microscope
(Leica).
Results
Chimerism after bone marrow trans-
plantation
Four to six weeks after BM transplan-
tation, we analyzed the level of chimerism
in the peripheral blood by MHC class I
haplotype specific flowcytometry. In all
BN hosts transplanted with Lew derived
BM cells (LewBM->BN) (n=4), <1% of the
OX18+ leukocytes was OX27+ which was
identical to Lew control rats, thus
indicating that the peripheral blood was
completely repopulated with BM-donor
(Lew, OX27-) derived cells. Moreover, the
total number of lymphocytes and subset
distribution was normal compared to age-
matched BN controls (not shown). In the
Lew hosts transplanted with BN BM cells
(BNBM->Lew) (n=4) peripheral blood160
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cellularity had also restored to normal
levels at six weeks after irradiation and
BM transplantation. However, only one
animal displayed complete chimerism,
e.g. all OX18+ cells showing the OX27+
BN-phenotype, whereas the other rats
displayed split-chimerism. These latter
animals were not used for further analysis.
Stable bone marrow chimerism was
confirmed by performing the same
flowcytometric analysis on BM cells
isolated from the chimeric aortic allograft
recipients at the time of sacrifice, three
months after aortic transplantation. In
normal BN BM, all cells were OX27+
(Fig. 1A), whereas in normal Lew BM,
all cells were OX27- (Fig. 1B). Although
OX27-, Lew BM cells clearly expressed
MHC class I antigens as indicated by
positive OX18 staining (not shown). Also
in the BM chimeric rats, MHC class I
expression was present on BM cells as
indicated by positive OX18 staining (not
shown). However, LewBM->BN rats
contained no BN-derived (OX27+) cells
in the BM compartment, indicating that
stable chimerism was established (Fig.
1C). In the BNBM->Lew rat, all cells in
the BM compartment were BN-derived
(OX27+) indicating that also in this
combination stable chimerism was
established (Fig. 1D).
Origin of neointimal EC’s and VSM cells
At 3 months after DA aortic allografting
the LewBM->BN rats had developed
OX27 
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Figure 1.Allogeneic bone marrow (BM) transplantation resulted in the establishment of   complete
stable chimerism. The level of chimerism was determined three months after aortic transplantation by
FACS analysis of BM cells. BM transplantation was performed in the Lew to BN (LewBM->BN) and BN
to Lew (BNBM->Lew) strain combinations. Fluochrome labeled mAb’s OX7 (PE) and OX27 (FITC)
were used to detect lymphoid and myeloid cells, and BN MHC class I, respectively. Normal BN (A) and
Lew (B) BM cells were used as controls. OX27+ cells were only detected in BN BM cells, whereas Lew
BM cells were OX27-. BM cells in LewBM->BN rats (C) were OX27-, indicating that no residual BN-
derived cells were present and complete stable chimerism had been established. BM cells in BNBM ->
Lew rat (D) were OX27+, indicating that also in this combination complete stable chimerism had been
established161
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marked TA consisting of a thick layer of
α-actin positive VSM cells, which was
covered with endothelium at the luminal
surface (Fig. 2A). The amount of neoin-
tima formation in the chimeric rats did not
differ significantly from that observed in
DA allografts transplanted in normal, non-
chimeric, BN hosts (not shown). The
neointimal EC’s (and VSM cells) were not
of donor origin since they did not stain
with the antibody MN4-91-6, which is
specific for DA (donor-type) MHC class
I (Fig. 2B).  Surprisingly, some residual
medial VSM cells showed weak but
positive staining indicating graft origin of
these cells. Medial VSM cells do normally
not express MHC class I antigens (not
shown). The negative staining of neo-
intimal EC’s in Fig. 2B was not due to a
lack of MHC class I expression on these
cells, since staining with the pan MHC
class I antibody OX18 gave a clear signal
on EC’s, as well as on residual medial
VSM cells, thus confirming the obser-
vation with mAb MN4-91-6 (Fig. 2C and
2D). Again to our surprise also some
neointimal VSM cells displayed low but
positive MHC class I expression. Neo-
intimal VSM cells (Fig. 2E) and EC’s
(Fig. 2F) were of host-origin as evidenced
by positive OX27 (host-type) staining.
Staining for α-actin and MHC class I on
serial tissue sections revealed co-loca-
lization of these markers thus ensuring
that the OX27+ neointimal cells were
indeed VSM cells (not shown). Since the
bone marrow of these LewBM->BN rats
was completely replaced with OX27- cells
(see above), such OX27+ neointimal EC’s
and VSM cells must be non-marrow
derived.
Although the majority of the neointimal
EC’s (and VSM cells) appeared to origi -
nate from the host’s non-marrow compart-
ment, we could not exclude that also some
BM-derived EC’s were part of the EC
layer covering the neointimal lesion.
Therefore, we performed the same type
of analysis on a DA aortic allograft
transplanted in a BM-chimeric Lew host
reconstituted with BN BM-cells
(BNBM->Lew). Although at 3 months after
transplantation the gross morphology of
the aortic allograft appeared to be
relatively normal, large parts of the
internal elastic lamina were devoid of
EC’s, while other parts were covered with
stretches of EC’s (Fig. 3A). Moreover,
also clusters of EC’s adhering to the
internal elastic lamina were present (Fig.
3B) which are absent in normal, non-
transplanted, aortic tissue. Staining for
donor-type MHC class I using antibody
MN4-91-6 revealed that positive cells
(graft-origin) were still present, indicating
that not all donor EC’s had been destroyed
yet in this aortic allograft (Fig. 3C). More-
over, intermingled with the remaining
graft-derived EC’s, also MN4-91-6
negative cells, suggesting host-origin,
were present (Fig. 3C). The EC’s localized
in clusters tended to be MN4-91-6
negative, suggesting host-origin of these
cells (not shown). RECA-1 staining on
serial sections confirmed that both cells
shown in Fig. 3C are EC’s (Fig. 3D). The
negative MN4-91-6 staining of one of the
EC’s in Fig. 3C was not due to a lack of
MHC class I expression, since staining
with the pan MHC class I antibody OX18
gave a clear signal on all EC’s (Fig. 3E).
These results further indicate host-origin
of the MN4-91-6 negative EC’s. RECA-
1 and OX27 (BM origin) double staining
revealed that among the host-derived EC’s
some double positive cells were present,162
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Figure 2.Confocal laser scanning microscopy indicated host-origin of neointimal EC’s and VSM cells
in DA aortic allografts transplanted in LewBM->BN rats and analyzed 3 months after transplantation. (A)
Staining for α-actin [asm-1, green] and EC’s [RECA-1, red]. Arrowheads indicate RECA-1 positive
EC’s and the asterisk indicates α-actin positive neointimal VSM cells (magn. x2520). (B) Staining for
α-actin [asm-1, green] and aorta donor (DA) MHC class I [MN4-91-6, red]. Asterisk indicates remaining
medial VSM cells which are donor MHC class I positive. Double asterisks indicate α-actin positive,
MN4-91-6 negative, neointimal VSM cells, indicating host-origin (magn. x1260). (C) Staining for α-
actin [asm-1, green] and MHC class I [OX18, red]. Asterisk indicate MHC class I positive, α-actin
negative, remaining medial VSM cells. Double asterisks indicate MHC class I positive, α-actin positive,
neointimal VSM cells (magn. x1260). (D) High power magnification of (C). Arrowheads indicate MHC
class I positive EC’s and the asterisk indicates MHC class I expression by α-actin positive neointimal
VSM cells (magn. x2520). (E) Staining for host (BN) MHC class I [OX27, green] and EC’s [RECA-1,
red]. Asterisk indicates OX27 positive neointimal VSM cells, indicating host, non-BM, origin (magn.
x630). (F) High power magnification of (E). Arrowheads indicate RECA-1 positive, OX27 positive,
EC’s, indicating host, non-BM, origin (magn. x2520). Abbreviations: a, adventitia; m, media; ni,
neointima.163
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Figure 3.Confocal laser scanning microscopy of a DA aortic allograft transplanted in the BNBM->Lew
rat and analyzed 3 months after transplantation revealed bone-marrow origin of EC’s. (A) Staining for
α-actin [asm-1, green] and EC’s [RECA-1, red]. Asterisk indicates α-actin positive medial VSM cells.
Arrowheads indicate stretches of RECA-1 positive EC’s, whereas the arrow indicates a cluster of RECA-
1 positive EC’s attached to the internal elastic lamina. Note that other parts of the internal elastic lamina
are devoid of EC’s (magn. x1260). (B) High power maginification of (A). Arrow indicates a cluster of
RECA-1 positive EC’s attached to the internal elastic lamina. Asterisk indicates α-actin positive medial
VSM cells (magn. x2520). (C) Staining for α-actin [asm-1, green] and aorta donor (DA) MHC class I
[MN4-91-6, red]. Arrowhead indicates a donor MHC class I positive EC, indicating graft-origin. Arrow
indicates a MN4-91-6 negative cell, suggesting host-origin. Asterisk indicates the nucleus of an α-actin
positive medial VSM cell (magn. x5670). (D) Staining for α-actin [asm-1, green] and EC’s [RECA-1,
red] on a serial section of (C). Arrowheads indicate RECA-1 positive staining, thereby confirming that
the cells depicted in (C) are EC’s (magn. x5670). (E) Staining for α-actin [asm-1, green] and MHC class
I [OX18, red]. Arrowheads indicate MHC class I positive EC’s. Asterisk indicates α-actin positive medial
VSM cells (magn. x2520). (F) Staining for BM-donor (BN) MHC class I [OX27, green] and EC’s
[RECA-1, red]. Arrowheads indicate RECA-1 positive EC’s, which are also OX27 positive (arrows),
indicating that these EC’s are BM-derived (magn. x5040). Abbreviations: a, adventitia; iel, internal
elastic lamina; m, media.164
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representing BM-derived endothelial cells
(Fig. 3F).
Discussion
Several decades ago, EC replacement of
graft endothelium was proposed to result
in graft adaptation leading to improved
long-term clinical outcome of solid organ
transplants5,6. Replacement of graft endo-
thelium by host-derived EC’s indeed has
been reported by several groups, however,
instead of  improving long-term clinical
outcome, EC replacement seems to be
related to the severity of rejection and
vascular damage11-16. These observations
are in line with our own data in experi-
mental transplant models in rats, in which
we showed complete EC replacement of
graft endothelium in aortic allografts
transplanted in non-immunosuppressed
rats whereas in immune modulated
cardiac allograft recipients graft endothe-
lium was preserved18.
To date, long-term survival of solid-organ
transplants is limited as a result of chronic
transplant dysfunction (CTD) which is
histologically characterized by progres-
sive concentric intimal thickening (trans-
plant arteriosclerosis, TA)1,2. Although the
role of EC replacement on the develop-
ment of TA in clinical organ transplan-
tation is unknown, our results clearly
indicate that whether or not the graft is
repopulated by host-derived EC’s, the
development of TA proceeds18. This
suggests that EC replacement is a respon-
se to vascular-damage, but is not neces-
sary for the formation of a hyperplastic
neointima per se.
The source of host-derived EC’s repo-
pulating the graft’s blood vessels upon
vascular injury is still a matter of debate
and several possibilities have been
proposed30,31. Circulating EC’s, derived
from the vascular bed, could be recruited
to sites in need of re-endothelialization,
i.e. the damaged vascular wall. A similar
role has been suggested for BM-derived
endothelial precursor cells (EPC’s).
Recirculating BM-derived EPC’s have
been identified in the peripheral blood of
humans32,33. Moreover, in animal models
it has been shown that the frequency of
such circulating EPC’s increases in
response to regional ischemia, thereby
contributing to neovascularization of
ischemic regions34,35.
Here we analyzed the contribution of BM-
derived and non-BM-derived EC’s in the
re-endothelialization process and devel-
opment of TA in aortic allografts trans-
planted in MHC-incompatible BM-
chimeric recipient rats. Using MHC class
I haplotype specific immunofluoresence
and confocal laser scanning microscopy
we showed that virtually all EC’s covering
the neointimal lesions in advanced TA are
host-derived, but do not originate from the
BM. Most likely, the host-derived
neointimal EC’s are recruited from a pool
of CEC’s which have been shown to be
present in human blood in a low frequen-
cy21. In contrast to advanced neointimal
lesions, characterized by a thick layer of
α-actin positive and MHC class I negative
VSM cells, some BM-derived EC’s were
detected in an aortic allograft in which the
neointima had not yet developed. In this
particular allograft, the vascular media
still contained α-actin positive VSM cells
which had not disappeared as a result of
medial VSM cell necrosis. The graft
endothelium covering the internal elastic
lamina was injured and partly replaced by
host-derived EC’s. Although not many,165
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some BM-derived EC’s were identified.
Jackson et al. recently demonstrated
regeneration of vascular endothelium by
BM-derived adult stem cells in ische-
mically injured hearts in mice36. Although
BM-derived EC’s were detected in the
ischemic regions, the prevalence of those
cells was about 3%.
In aortic allografts with advanced TA, the
vascular media had become acellular or
only contained some remaining graft-
derived VSM cells which had lost their
α-actin expression. Using a PCR-based
analysis we previously demonstrated
host-origin of neointimal VSM cells in TA
in aortic and cardiac allografts17,18 and
these results were now confirmed in the
aortic allografts by confocal laser
scanning microscopy. Moreover, similar
to the origin of host-derived EC’s, also
the neointimal VSM cells were primarily
non-BM-derived. Two recent papers by
Shimizu et al.37 and Li et al.38 analyzed
the contribution of BM-derived VSM
cells in the development of TA in mouse
aortic allografts. Using BM-chimeric
mice reconstituted with β-galactosidase-
expressing BM-cells, Shimizu et al. de-
monstrated that up to 10% of the
neointimal VSM cells were BM-derived.
In contrast, Li et al. were not able to detect
BM-derived neointimal VSM cells using
Y-chromosome specific in situ hybridi-
zation. Although also in the aortic trans-
plant model in mice graft endothelium is
completely replaced by host-derived EC’s
at 30 days after transplantation (S.M.
Ensminger, personal communication), the
issue of the origin of neointimal EC’s was
not addressed in these studies37,38,
probably due to technical reasons.
So, results from the literature and data
presented in this paper thus indicate that
neointimal VSM cells and EC’s are
primarily derived from the non-BM-
compartment. Migration of host-derived
EC’s and VSM cells from the recipient
side of anastomosis might be a possible
source of these cells as suggested by Aziz
et al.39. Alternatively, CEC’s detached
from host blood vessels can provide a
source of EC’s contributing to the re-
endothelialization process of allografts.
Circulating VSM progenitor cells have
not been identified so far. However
Bucala et al. reported the existence of a
non-BM-derived circulating cell popu-
lation that specifically enters sites of tissue
injury40. Moreover, Kouchi et al. des-
cribed the existence of bloodstream
originated α-actin positive VSM cells41.
In the developing neointima in aortic
allografts, a scattered distribution of
α-actin positive cells adhering to the de-
veloping neointima was observed,
suggesting bloodstream origin of these
cells42. Moreover, the scattered adherence
of host-derived EC’s to the internal elastic
lamina in the developing lesion as
mentioned in this paper also suggests
bloodstream origin of the EC’s. We
therefore propose bloodstream origin of
neointimal EC’s and VSM cells derived
from a non-BM source in the host.
In conclusion, although the BM can
provide EC and VSM cell progenitor
cells, the contribution of those cells in the
development of TA and probably also
other vascular repair processes, seems to
be minimal. Therefore, the biological
importance and the functional relevance
of BM-derived EC and VSM cell
progenitor cells in vascular wall repair
processes is questionable. Non-BM-
derived host EC’s and VSM cells seem to
be more important in these processes. One166
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should focus therefore on these cells when
trying to unravel the pathogenesis of TA
and to develop new therapeutic inter-
ventions to prevent or treat TA after solid
organ transplantation.
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Introduction
During the last decades, solid organ trans-
plantation has increasingly become a suc-
cessful therapy for patients suffering from
end-stage organ failure, which is primar-
ily due to the introduction of new immu-
nosuppressive agents preventing acute
rejection of the graft. To date, however,
clinical transplantation has not achieved
its goals as a long-term treatment, and
development of chronic transplant dys-
function (CTD) is now recognized as the
most important cause of graft loss after
the first year after transplantation1,2. CTD
can be defined as the progressive irrevers-
ible loss of graft function that occurs late
in the post transplant period3. The most
characteristic histologic feature of CTD
is transplant arteriosclerosis (TA) which
is characterized by a generalized, concen-
tric intimal thickening predominantly con-
sisting of vascular smooth muscle (VSM)
cells intermingled with some T cells and
macrophages4. Pathogenesis of TA seems
to be multifactorial, and both alloantigen-
dependent (e.g., acute rejection and his-
toincompatibility) as well as alloanti gen-
independent factors (e.g., donor brain
death, ischemia and cytomegalovirus in-
fection) have been identified as probable
risk factors for the development of TA5.
The etiology of TA, however, is largely
unknown and precise mechanisms in-
volved in the development of this remod-
eling process still remain obscure.
The aim of this thesis was to analyze the
contribution of several risk factors (allore-
activity, CMV infection and host genet-
ics) on the pathogenesis of TA, as well as
to gain more insight in the precise mech-
anism leading to vascular narrowing (ori-
gin of neointimal cells).
The data described in this thesis have been
summarized in a scheme (Figure 1, see
spread out figure on page 182) in which a
sequence of events is proposed before (I),
during (II) and after (III) solid organ trans-
plantation that lead to the development
of TA and subsequent CTD.
A central element in the development of
TA is injury of the graft vascular tree. As
described in detail in Chapter 1 (General
Introduction), damage of the graft vascu-
lature may already occur even before graft
retrieval. Especially donor brain death and
ischemia after graft retrieval, are the main
causes of EC activation thereby creating
a proinflammatory milieu in the graft dur-
ing the pre-transplant period (see Figure
1, I). During the actual transplantation,
graft endothelium is further activated and
may loose function mainly as a result of
reperfusion injury to the graft (see Figure
1, II).
In this thesis, we focused on vascular
damage inflicted after transplantation, i.e.
injury of the graft vasculature as a result
of an alloreactive response of the host
against the graft, and several factors in-
fluencing this process (see Figure 1, III).
In the next part of this chapter, the key
events leading to TA and CTD will be
highlighted in sequence of appearance (as
shown in Figure 1) and will be placed in
the context of the experimental data de-
scribed in this thesis. Moreover, possible
targets of therapeutic intervention will be
discussed.
Alloreactivity and transplant arterio-
sclerosis (III.a)
Although alloantigen-independent factors
may induce damage to the graft before and
after transplantation, it has become clear
that alloreactivity is the main cause of TA
development6. Since alloreactivity seems171
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to be the key player in the development
of TA, deletion of the alloreactive re-
sponse would be a possible strategy to
prevent development of TA. Previously,
we and others showed that intrathymic
(IT) immune modulation is effective in
preventing acute rejection of allografts in
rodents7. Though preventing acute rejec-
tion and prolonging graft survival, IT
immune modulation did not prevent the
development of TA in allogeneic cardiac
allografts (Chapter 2). TA started to de-
velop several weeks after transplantation
and an increase in the number of arterio-
sclerotic coronary arteries as well as in
the severity of the neointimal lesions was
observed. These histologic changes were
associated with an altered intragraft im-
mune response. IT immune modulation
did not completely abolish alloreactivity
against the graft, and the observed intra-
graft cytokine profile suggested the pres-
ence of Th3 or Tr1 cells in long-term sur-
viving grafts with severe TA. Most toler-
ance inducing protocols, like our IT im-
mune modulation protocol, mainly part-
ly suppress or alter the alloreactive re-
sponse (thereby preventing acute rejec-
tion), and induction of true tolerance with
complete absence of alloreactivity is sel-
dom achieved. Probably all tolerance in-
ducing protocols will fail in preventing
TA when alloreactivity is not completely
abolished. Most likely, only those proto-
cols will be successful in preventing TA
development in which true tolerance is
achieved by e.g. donor-specific bone mar-
row transplantation. Future studies on tol-
erance induction should therefore aim at
developing protocols that induce true tol-
erance rather than alter the alloreactive
immune response.
That complete suppression of alloreactiv-
ity for a prolonged period of time may
indeed be effective in prevention of TA
was clear from data described in Chapter
6. Daily treatment with high dosages of
cyclosporin A completely prevented de-
velopment of TA in aortic allografts.
Long-term treatment using high dosages
of currently available immunosuppressive
agents, however, is not applicable to
clinical transplantation because of serious
(nephrotoxic) side-effects.
One of the alloantigen-independent risk
factors suggested to be involved in the
development of TA is cytomegalovirus
(CMV) infection. Although positive cor-
relations between CMV infection and TA
development have been shown in clini-
cal transplantation8,9 as well as experimen-
tal transplant models in rats10,11, also data
have been described suggesting that
CMV does not contribute to TA develop-
ment12,13. The mechanism by which CMV
could be involved in the pathogenesis of
TA is unclear. In Chapter 4 we showed
that infection with Rat CMV indeed can
enhance the development of TA in aortic
allografts, however, this effect seems to
be rather the exception than the rule after
allogeneic aorta transplantation. Timing
of viral infection appeared to be an im-
portant factor in whether or not CMV will
enhance the development of TA. Only
infection during the developing acute re-
jection phase resulted in enhanced TA,
suggesting that CMV strengthens and pro-
longs the alloreactive response, thereby
increasing vascular damage in the graft.
However, CMV-enhanced TA was only
observed in one specific weak TA re-
sponder rat strain combination, whereas
in other weak combinations this effect was
not present. These results suggest that al-172
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though CMV can enhance the develop-
ment of TA, this effect is dependent on
host characteristics influencing TA which
may be genetically determined (Chapter
5).
Endothelial cell replacement and trans-
plant arteriosclerosis (III.b)
Several decades ago it was postulated by
Woodruff and Medawar14,15 that replace-
ment of graft endothelium by host-derived
EC’s (‘graft adaptation’) would be bene-
ficial for long-term graft survival. In
Chapter 6 we showed that graft endothe-
lium in non-immunosuppressed aortic al-
lografts is indeed replaced by host-derived
EC’s. Previously, it has been shown in this
model that graft endothelium disappears
within 2 weeks after transplantation16, and
we now showed complete replacement
with host-derived EC’s in this model.
In contrast to aortic allografts, in IT im-
mune modulated cardiac allograft recipi-
ents, in which alloreactivity was de-
creased though not completely abolished,
graft endothelium was preserved. These
results indicate that whether or not graft
endothelium will be replaced by host-de-
rived EC’s depends on the severity of graft
vascular damage. This was recently con-
firmed by a study from Lagaaij et al. dem-
onstrating that the level of EC replace-
ment in human kidney allografts is corre-
lated with the severity of vascular rejec-
tion17.
Since EC replacement of graft endotheli-
um with host-derived EC’s may occur
upon vascular injury, it is of interest to
know what the anatomical origin of these
EC’s is. In Chapter 8 we showed that the
host-derived EC’s in advanced neointimal
lesions in aortic allografts are primarily
non-bone marrow derived, indicating that
a non-marrow source provides these cells.
Although migration of EC’s from the re-
cipient side of anastomosis can not be
excluded, we propose that a pool of cir-
culating endothelial cells (CEC’s) is the
main source of the neointimal host-de-
rived EC’s.
It is unlikely that EC replacement will
improve long-term graft survival as sug-
gested by Woodruff and Medawar14,15,
since both in aortic allografts (EC replace-
ment) as well as cardiac allografts (no EC
replacement) development of severe TA
was observed (Chapter 2 and Chapter 6).
Consequently, it appears that replacement
of graft endothelium with host-derived
cells is an indicator for severe vascular
damage but is not a prerequisite for the
subsequent development of TA per se.
Vessel wall morphology and transplant
arteriosclerosis (III.c)
Transplant arteriosclerosis can be ob-
served in all intragraft arteries and arteri-
oles, whereas capillaries and veins seem
to be protected from these lesions5. Ar-
teries and arterioles consist of a three layer
structure: tunica adventitia (fibrous tis-
sue), tunica media (elastin laminae and
VSM cells) and the tunica intima (suben-
dothelial fibrous tissue and EC’s). The
presence of a pronounced vascular me-
dia in arteries and arterioles, which plays
an important role in regulating blood flow
and blood pressure, appears to be a pre-
dominant factor in determining whether
vascular structures are prone or resistant
to the development of TA. In Chapter 3
we showed that cardiac tissue transplan-
ted subcutaneously following IT immune
modulation was characterized by the ap-
pearance of graft-derived large veins (neo-
angiogenesis). Although persistent allore-173
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activity against graft parenchyma and
graft EC’s was present, development of
TA in these newly formed veins was not
observed. These results suggest that only
vessels with a medial architecture consist-
ing of elastin laminae and VSM cells are
prone to TA development (like coronary
arteries in cardiac allografts (Chapter 2)
and aortic allografts (Chapter 4 and Chap-
ter 6)), whereas veins and capillaries with-
out a clear medial architecture are resis-
tant to TA. Also in vascularized cardiac
allografts neo-angiogenesis with presum-
ably graft-derived veins was observed,
which were free of TA, whereas the coro-
nary arteries and arterioles suffered from
severe TA (Chapter 2). Since neo-angio-
genesis with vascular structures which
remain free of TA occurs in transplanted
allografts, this might be a possible site of
therapeutic intervention to treat CTD with
established TA. However, these newly
formed blood vessels should be capable
of taking over function of the obliterated
vessels which is unlikely.
Response-to-injury hypothesis revisit-
ed (III.d)
Despite discrepancies in histopathology
between ordinary atherosclerosis and TA,
the ‘response-to-injury’ hypothesis appli-
cable to atherosclerosis and originally
proposed by Ross et al.18,19 has been ac-
cepted widely for the development of TA.
This hypothesis implies that in response
to transplant-related trauma (e.g., brain
death, ischemia/ reperfusion, alloreactiv-
ity), which induces EC damage, a gen-
eralized vascular repair process is initia-
ted resulting in replication and migration
of medial VSM cells into the subendo-
thelial space (schematically represented
in Figure 2, Chapter 1). According to this
hypothesis, the neointimal VSM cells are
of graft-origin and therefore donor-de-
rived. In Chapter 6 and Chapter 7, how-
ever, we showed that the neointimal VSM
cells both in aortic and cardiac allografts
are not of donor but of host-origin. Our
findings have recently been confirmed by
others also showing contribution of host-
derived VSM cells in the process of TA
development in femoral artery allografts20
in rats and aortic allografts in mice21-23.
Moreover we showed that these host-de-
rived VSM cells are predominantly, if not
all, derived from a non-bone marrow
source (Chapter 8). This latter observa-
tion is in line with some recent observa-
tions in aortic transplant models in mice
demonstrating that, though bone marrow-
derived VSM cells contribute to the de-
velopment of TA, the percentage of these
cells is rather low22,23. Although derived
from a non-marrow source, the precise
anatomical origin of the host-derived
neointimal VSM cells is as yet unknown.
At least two possibilities arise from which
anatomical origin the VSM cells are de-
rived: ingrowth from the recipient side of
anastomosis or recruitment of VSM (pro-
genitor) cells from the circulation. Al-
though the first possibility may take place,
our data suggest that the bulk of VSM
cells are blood-borne since a scattered
distribution of α-actin positive cells ad-
hering to the developing neointima in
aortic allografts was observed (Figure 2).
Taken together, TA indeed seems to be a
response-to-injury, however, not VSM
cells and EC’s from the injured graft but
host-derived cells are the key players in
this remodeling process.
The data described in Chapter 6, Chap-
ter 7 and Chapter 8 have led to the hypo-174
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thetical sequence of events in the aortic
and coronary artery vascular wall lead-
ing to TA as schematically depicted in
Figure 3. The process of TA development
can be divided in 5 phases, starting from
the transplantation procedure (phase 1) to
end-stage TA (phase 5) and will be dis-
cussed below. Although this scheme is
based on our observations in the aortic and
cardiac transplant models in the rat, this
sequence of events may also apply to sol-
id organ transplants in clinical transplan-
tation.
Phase 1. At the time of transplantation
an anastomosis (e) is made between re-
cipient and donor blood vessels both hav-
ing a regular 3-layer microscopic anato-
my consisting of a tunica adventitia (a),
tunica media (b) and tunica intima (c). The
vasa vasorum (d) provide nutrition to the
outer part of the vascular wall. VSM cells
are located between the elastic laminae
in the media. At the luminal side the ves-
sel wall is covered with EC’s. At this ear-
ly time point after transplantation, the
graft endothelium may already be acti-
vated or damaged as a result donor brain
death, ischemia and reperfusion.
Phase 2. The early phase of tissue dam-
age after transplantation is primarily due
to host alloreactivity directed against the
graft. This is characterized by ingrowth
of recipient derived vasa vasorum in the
graft adventitia (a) and extensive perivas-
culitis around these small vessels (b).
Moreover, graft endothelium is attacked
by recipient inflammatory cells leading
to destruction of the EC-lining of the graft
(c). As a result of this alloreactive re-
sponse, medial VSM cells start to disap-
pear as a result of apoptosis (d).
lu
ni m
a
Figure 2.Micrograph showing double staining for smooth muscle cell α-actin and elastin on an aortic
allograft (28 days after engraftment) transplanted in the Lew to BN rat strain combination. Arrowheads
indicate α-actin positive cells adhering to the surface of the developing neointima, suggesting blood-
borne origin of these cells (original magnification, x400). The insert shows a higher magnification of the
adhering α-actin positive smooth muscle cells. Abbreviations: a, adventitia; lu, lumen; m, media; ni,
neointima. (Reprinted with permission from Sage Science Press, Graft 4(8), 2001)175
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Phase 3. Due to the ongoing inflamma-
tion in the adventitia (a) and/or the lack
of ingrowth of new recipient derived vasa
vasorum into the media (thereby causing
a severe nutritional deficiency for that
area) complete necrosis disappearance of
the medial VSM cells is observed, with
only the elastin scaffold remaining (b).
Phase 4. Rebuilding of the damaged ves-
sel wall, which has lost appropriate func-
tion, starts: a new EC-layer of recipient
origin (re-endothelialization) is built both
by ingrowth of recipient EC’s over the
denuded intima starting at the side of anas-
tomosis (a) as well as derived from circu-
lating EC’s which may originate from a
non-bone marrow source such as the host
vascular wall (b & c).
 Phase 5. Like for EC recovery, VSM cell
replacement starts either through in-
growth of recipient VSM cells into the
graft intimal space starting at the side of
the anastomosis (a), or from circulating
recipient VSM (progenitor) cells (b). Ini-
tial appearance of VSM cells is followed
by intimal hyperplasia caused by uncon-
trolled proliferation of VSM cells, result-
ing in luminal occlusion eventually (c).
Genetic predisposition and transplant
arteriosclerosis (III.e)
Besides the aforementioned alloantigen
dependent and independent factors in-
volved in TA, other host determined ge-
netic factors may modulate the rate and
severity of the development of TA24. In
the literature, several data have been re-
ported indicating that development of TA
is influenced by genetic variation in the
regulation of cytokine gene expression,
in particular variation in the expression
levels of TGF-β25-27.
In Chapter 5 we showed that besides ge-
netic differences in the immunological
responder status of the host also other non-
MHC encoded determinants influence the
rate of development of TA in aortic al-
lografts. These results indicate that the
rate of TA development is indeed geneti-
cally controlled, however which factors
are responsible for this effect remains
unclear. Since neointimal lesions pre-
dominantly consist of host-derived VSM
cells and EC’s (Chapter 6 and Chapter
7), it is tempting to speculate that these
neointimal VSM cells and EC’s intrinsi-
cally determine the rate and severity of
neointima formation. Possible candidates
for VSM cell or EC produced factors
which may be involved in the develop-
ment of TA are enzymes (e.g., elastase28)
and vasoactive peptides (e.g., endothelin-
129). Also the proliferative capacity of
VSM cells may be genetically determined
30, and differences in proliferative capa-
city may influence the rate and severity
of TA development.
Since genetic differences between organ
transplant recipients may determine the
rate of TA development, identification of
the gene products responsible for this
phenomenon will be essential both in trac-
ing patients who are at risk (genetically
predisposed) to develop TA rapidly, as
well as in developing new strategies to
prevent or treat TA.
Transplant arteriosclerosis: a normal
vascular repair process beyond con-
trol?
We propose that the development of TA
is a repair process initiated from the host
attempting to restore vascular wall func-
tion of vessels in which the medial archi-
tecture has been destroyed by an allore-
active inflammatory response31. The ques-176
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Normal vessel wall morphology
at the time of  transplantation
consisting of the adventitia (a),
media (b), intima (c) and vasa
vasorum (d). Anastomosis (e).
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Phase 2.
Ingrowth of recipient-derived
vasa vasorum (a).
Alloreactive response directed
against advential tissue (b) and
EC's (c) results in medial VSM
cell apoptosis (d).
Phase 4.
Re-endothelialization with host-
EC's via ingrowth from the side
of anastomosis (a) and/or from a
pool of CEC's (b & c). 
Phase 3.
Ongoing inflammation (a) results
in complete disappearance of
medial VSM cells (b) and
graft EC's.
Phase 5.
Recruitment of host-derived
VSM cells via ingrowth from the
side of anastomosis (a) and/or
from the circulation (b), resulting
in intimal thickening (c). 
Figure 3.Schematic representation of events in the vascular wall after allogeneic organ transplantation
leading to transplant arteriosclerosis. The different phases are described in detail in the text. Abbrevia-
tions: CEC, circulating endothelial cell; EC, endothelial cell; IC, inflammatory cell; VSM cell, vascular
smooth muscle cell.177
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tion remains why a healing process, that
normally is self-limiting once function is
fully restored, in TA does not stop and
eventually will lead to occlusion of the
vessel lumen. One explanation is that as
a result of the ongoing perivascular in-
flammatory response, activation and dam-
age of vascular wall cells persist and mi-
togenic factors like PDGF and bFGF will
be produced continuously. Alternatively,
physiologic shortcomings of the neointi-
ma to restore vascular wall function may
be the driving force behind the ongoing
intimal thickening observed in TA. This
explanation is founded by observations
made in biodegradable vascular grafts,
which have been developed to replace
diseased vessels (e.g., in cardiac coronary
surgery). Experiments in rats have shown
that these grafts should be biocompatible,
microporous, compliant, and biodegrad-
able32,33. Essentially, the graft functions as
a temporary scaffold allowing de novo
formation of a new vessel wall in parallel
with the biodegradation process. With
time a neointima and neomedia were
found to develop inside the lumen of the
graft. The process leading to TA may es-
sentially be the same as the process ob-
served in the biodegradable compliant
vascular grafts: as a results of the rejec-
tion process medial VSM cells are de-
stroyed leaving the now condensed lay-
ers of elastic laminae as a scaffold facili-
tating regeneration of a new vessel wall.
Major difference between TA and biode-
gradable vascular grafts is that in the lat-
ter within the neomedia new elastic lami-
nae developed with circularly oriented
VSM cells34,35. In TA, however, neointi-
mal VSM cells are randomly oriented and
newly formed elastin is hardly present.
Since a well organized neomedia in bio-
degradable vascular grafts may restore
graft function, the random organization
of neointimal VSM cells without elastic
laminae in TA does not.
Possible targets for therapeutic inter-
vention to prevent of treat transplant
arteriosclerosis
Based on the observations described in
this thesis several possible targets of thera-
peutic intervention could be identified,
which may be helpful in developing new
strategies to prevent or treat TA in the fu-
ture. To our opinion, most profit can be
made by strategies which are directed on
prevention of TA rather than treatment of
established TA. The key events leading
to TA which can be used as a point of ap-
plication are shown in gray boxes in Fig-
ure 1 and will be discussed below.
Suppression of the alloreactive response
Damage induced by the alloreactive re-
sponse appeared to be the most important
factor for TA development. Therefore,
deletion of host’s alloreactivity against the
graft should be the obvious solution to
prevent TA after organ transplantation.
New immunosuppressive drugs which
abolish any degree of alloreactivity but
have not the toxic side-effects of today’s
immunosuppressive agents may be effec-
tive in preventing TA. Also tolerance in-
duction protocols which induce true tol-
erance rather than alter or diminish allore-
activity (Chapter 2) should be effective
in preventing allo-mediated vascular dam-
age, thereby also preventing the develop-
ment of TA. True tolerance might be
achieved by donor-specific bone marrow
transplantation, and experimental data in
rodents indicate that bone marrow trans-
plantation indeed can prevent develop-178
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ment of TA36,37. However, bone marrow
transplantation is still a risky procedure,
particularly when the transplantation is
performed across one or more MHC in-
compatibilities, and today these risks do
not counterbalance the risk of TA devel-
opment after organ transplantation.
Anti-cytomegalovirus prophylaxis
CMV-infection may enhance the devel-
opment of TA in susceptible patients, in
particular when active CMV infection
coincides with acute rejection episodes
(Chapter 4). Active CMV infection
should therefore be prevented and this can
be achieved by prophylaxis with anti-vi-
ral agents (e.g., ganciclovir). Today, some
transplantation-centers already incorpo-
rate anti-CMV prophylaxis in their stan-
dard treatment regimens. Although anti-
CMV prophylaxis by itself will not pre-
vent development of TA, it may be effec-
tive in reducing the rate and severity of
TA development.
Prevention of medial VSM cell apoptosis
and uncontrolled neointimal proliferation
We proposed that loosing vascular wall
function as a result of disappearance of
medial VSM cells is the key element in
inducing TA. Preservation of the vascu-
lar media should retain vascular wall func-
tion, thereby preventing development of
TA. Recently, it has been shown that me-
dial VSM cells disappear as a result of
apoptosis. Therapies directed at preven-
tion of medial VSM cell apoptosis  de-
spite the presence of persisting alloreac-
tivity might therefore be effective in the
prevention of TA.
Once the medial VSM cells have disap-
peared and host-derived VSM cells have
been recruited to form the neointima, a
possible way of intervention is preven-
tion of VSM cell proliferation beyond the
stage of functional repair. However, to do
so we first need to identify the precise
(possibly autocrine) factors which regu-
late proliferation of neointimal VSM cells.
Identification of high-risk patients
Since genetic differences between organ
transplant recipients will determine the
rate of TA development, identification of
the gene products, possibly produced by
host-derived VSM cells, responsible for
this phenomenon will be essential in trac-
ing patients who are genetically predis-
posed to develop TA rapidly and may pro-
vide new tools for therapeutic interven-
tion. Immunosuppressive regimens could
be adjusted for such high TA responder
patients.
Concluding remarks
In this thesis we have identified the con-
tribution of several risk factors in the
pathogenesis of TA. Moreover, we ac-
quired a better understanding in the pre-
cise mechanisms leading to vascular nar-
rowing, and showed that in contrast to the
current dogma, neointimal EC’s and VSM
cells are not of donor-origin but of host-
origin. Putting the data described in this
thesis together, we propose that instead
of looking at TA as an undesirable ele-
ment in chronic transplant dysfunction,
the process leading to TA is basically part
of a normal healing process and as such
should be welcomed. However, this “heal-
ing process’’, which may be genetically
controlled, does not seem to stop, even-
tually leading to total occlusion of the
vessels involved. This revised view on the
development of TA has led to the identi-
fication of possible new sites for thera-179
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peutic intervention to prevent TA and pro-
vides a basis for future studies in the strug-
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Pathogenesis of transplant arteriosclerosis (TA) and possible targets of therapeutic intervention
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Figure 1.Scheme of the proposed sequential events before and after solid organ transplantation that
lead to the development of transplant arteriosclerosis and chronic transplant dysfunction. Key events
addressed in this thesis are highlighted and the chapters in which the regarding data are described  are
given. Possible targets of therapeutic intervention to prevent transplant arteriosclerosis are shown in
gray boxes.183
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Chronic transplant dysfunction, histolo-
gically characterized by obliterative vas-
culopathy referred to as transplant arte-
riosclerosis (TA), is today’s most impor-
tant cause of long-term graft loss after
solid organ transplantation. Although sev-
eral risk factors have been identified, the
etiology of TA is largely unknown and
precise pathogenetic mechanisms still re-
main obscure. Aim of this thesis was to
analyze the contribution of several risk
factors supposedly involved in the devel-
opment of TA, namely alloreactivity di-
rected against the graft (Chapter 2 &
Chapter 3), cytomegalovirus (CMV) in-
fection (Chapter 4) and host genetics
(Chapter 5). Moreover, we aimed at gain-
ing more insight in the precise patho-
genetic mechanisms leading to vascular
narrowing by focusing on the origin (do-
nor vs. recipient) of neointimal vascular
smooth muscle (VSM) cells and endo-
thelial cells (EC’s) (Chapter 6, Chapter 7
& Chapter 8).
Chapter 1 gives an overview of the
clinical and histopathological hallmarks
of CTD after solid organ transplantation.
Moreover, risk factors for the develop-
ment of TA and subsequent CTD are de-
scribed. The current paradigm of the de-
velopment of TA is discussed and the sup-
posed cascade of pathological events lead-
ing to TA is presented. Finally, the aim of
this thesis is formulated.
Alloreactivity of the host immune sys-
tem against the graft seems to be one of
the key factors in the pathogenesis of TA.
Eliminating this alloreactive response af-
ter transplantation by induction of trans-
plant tolerance would therefore be a pos-
sible solution to prevent development of
TA. In the course of a series of studies on
tolerance induction against cardiac al-
lografts, several years ago a model was
developed using intrathymic (IT) immune
modulation and a short course of immun-
osuppression. IT immune modulation is
effective in preventing acute rejection of
MHC-incompatible vascularized cardiac
allografts transplanted in rats, suggesting
that transplant tolerance was achieved.
However, experiments described in Chap-
ter 2 clearly demonstrated that the devel-
opment of TA was not prevented: TA start-
ed to develop several weeks after trans-
plantation and an increase in the severity
of TA and the number of affected graft
coronary arteries was observed with time.
In vitro mixed lymphocyte reactions and
immunohistochemical analysis revealed
that IT immune modulation did not com-
pletely abolish alloreactivity, but rather
altered the type of immune response
against the graft. Intragraft cytokine
mRNA expression, as analyzed with semi-
quantitative RT-PCR, showed decreased
IL-2 and IFN-γ expression indicative of
a down-regulated Th1-type cytokine re-
sponse two weeks after transplantation.
In long-term surviving allografts, high
intragraft mRNA expression levels of
IL-10, IFN-γ and TGF-β were measured.
In conclusion, despite induction of long-
lasting graft-survival, IT immune modu-
lation did not prevent the development of
TA.
Using the same IT immune modula-
tion protocol as in Chapter 2, in Chapter
3 it was studied whether IT immune mo-
dulation was effective in prolonging graft
survival after non-vascularized allogene-
ic tissue transplantation. In contrast to
vascularized cardiac allografts, IT im-
mune modulation did not prolong survival
of MHC-incompatible skin grafts which
may be caused by tissue-specific antigens185
Summary
which are presumably not expressed on
splenocytes. Survival of allogeneic neo-
natal cardiac tissue transplanted subcuta-
neously in the ear-pinnae of recipient rats
was significantly prolonged after IT im-
mune modulation. Long-term surviving
neonatal cardiac tissue was characterized
by the appearance of large-cavernous like
blood vessel structures which appeared to
originate from the graft (neo-angiogene-
sis). In contrast to the coronary arteries
in vascularized cardiac allografts, newly
formed blood vessels in long-term surviv-
ing neonatal cardiac tissue did not devel-
op TA.
One of the factors supposed to be in-
volved in the process of TA development
is CMV infection. In Chapter 4 the effect
was analyzed of recipient genotype and
timing of infection on the severity of TA
development in aortic allografts trans-
planted in rats. Development of TA dif-
fered among different rat strain combina-
tions, in which the Lew to BN combina-
tion appeared to be a high TA responder
combination. The effect of timing of CMV
infection was analyzed in the BN to Lew
combination, since this appeared to be a
low TA responder combination. Infection
with  Rat CMV (RCMV) only enhanced
the development of TA when the devel-
oping acute rejection episode and acute
infection occurred simultaneously, i.e.
when the allograft recipients were infec-
ted with RCMV 1-5 days after transplan-
tation. The enhancing effect of RCMV
infection on TA development could not
be generalized since, in other weak TA
responder combinations, RCMV infection
did not enhance the development of TA.
Obviously there are more factors than tim-
ing of infection and weakness of TA de-
velopment that determine the CMV-en-
hanced development of TA.
In Chapter 4 it was already shown that
differences exist in the severity of TA de-
velopment between different rat strain
combination after aortic transplantation.
This observation was further analyzed in
Chapter 5, in which the contribution of
recipient encoded MHC and non-MHC
determinants on the rate of TA develop-
ment was studied. The high TA respon-
siveness of BN rats appeared to be deter-
mined by non-MHC encoded determi-
nants, since also MHC congenic BN.1L
rats still showed the high TA responder
phenotype. Which non-MHC encoded
determinants precisely determine the high
TA responsiveness remained unclear from
this study, however, data indicated that it
is at least unlikely that the immunologic
responder status of the host (Th1 vs. Th2
status) plays an important role.
A central element in the process of TA
development is uncontrolled proliferation
of neointimal VSM cells, resulting in
obliteration of intragraft arteries. Current
thinking on the process of TA holds that,
in response to cytokines, growth factors
and other inflammatory mediators, medial
VSM cells start to migrate and prolifer-
ate into the subendothelial space. Accord-
ing to this generally applied working hy-
pothesis, neointimal VSM cells and EC’s
are graft (donor)-derived. In Chapter 6
and Chapter 7 it was analyzed whether
the neointimal VSM cells and EC’s are
truly graft-derived. MHC class I haplo-
type specific immunohistochemistry re-
vealed that neointimal EC’s in aortic al-
lografts transplanted in non-immuno-
suppressed recipients were of host- and
not of donor-origin, indicating that EC-
replacement had taken place (Chapter 6).
However, in cardiac allografts transplan-186
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ted following IT immune modulation (see
also Chapter 2), neointimal EC’s were
still of graft origin indicating that in car-
diac allografts no EC-replacement oc-
curred (Chapter 6). In both aortic and
cardiac allografts severe TA developed,
indicating that EC replacement is not a
prerequisite for eventual TA development.
Immunosuppressive treatment with high
dosages of cyclosporin A for a period of
4 weeks completely prevented EC de-
struction and TA development in aortic
allografts indicating that adequate immu-
nosuppression in the short run is effec-
tive in preventing development of TA.
To further analyze the origin (donor vs.
recipient) of neointimal VSM cells a
male-specific nested PCR procedure was
developed, based on the genomic se-
quence of the Y-chromosome, which was
sufficiently sensitive to detect male-de-
rived cells at the single cell level. Since
all transplantations were performed using
female donor and male recipient rats, a
positive PCR signal indicated recipient-
origin of the regarding cell. PCR analysis
of single nuclei of α-actin positive neoin-
timal VSM cells microdissected from both
aortic allografts (Chapter 6) and cardiac
allografts (Chapter 7) revealed that these
VSM cells were of recipient and not of
donor origin. These results were con-
firmed by another PCR which was based
on polymorphisms present in the geno-
mic sequence encoding the Tap2-gene.
So, in contrast to current thinking we feel
these data to indicate that neointimal VSM
cells are of recipient- and not of donor-
origin.
As in Chapter 6 it was shown that in
aortic allografts with TA neointimal EC’s
and VSM cells were recipient-derived, in
Chapter 8 the anatomical origin (bone
marrow [BM] vs. non-BM derived) of
host-derived neointimal cells was ana-
lyzed. Confocal laserscanning microsco-
py on DA aortic allografts transplanted
in LewBM->BN and BNBM->Lew chi-
meric rats revealed that in advanced TA
EC’s were primarily non-BM derived, al-
though BM-derived EC’s can contribute
to the development of TA in developing
lesions. Also neointimal VSM cells were
most-likely non-BM derived. These re-
sults indicate that a non-marrow source
provides the neointimal EC’s and VSM
cells in TA.
In Chapter 9 the results described in
this thesis are discussed at large and, based
on the findings, a sequence of events lead-
ing to the development of TA and subse-
quent CTD is proposed. Instead of look-
ing at TA as an undesirable element in
CTD, we propose that the process lead-
ing to TA is basically part of a normal
healing response which proceeds, how-
ever, beyond the needs of functional re-
pair. This view on the development of TA
has led to the identification of possible
new targets of therapeutic intervention to
prevent or treat TA.187
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Inleiding
Orgaantransplantatie
In de afgelopen decennia is het transplan-
teren van organen (hart, lever, nier of long)
in toenemende mate een succesvolle the-
rapie geworden voor patiënten die lijden
aan een ernstige vorm van orgaan-disfunc-
tie. Alleen in de uitzonderlijke situatie
waarbij de donor en de ontvanger gene-
tisch niet van elkaar verschillen (een zgn.
syngene transplantatie), zoals het geval is
bij een eeneiige tweeling, kan dit min of
meer ongestraft plaatsvinden. In de kli-
nische praktijk komen dergelijke trans-
plantaties echter weinig voor en worden
de meeste organen getransplanteerd tus-
sen individuen die wel genetisch van el-
kaar verschillen (een zgn. allogene trans-
plantatie). Een allogene transplantatie zal
leiden tot een afstotingsreactie: het af-
weersysteem van de ontvanger zal pro-
beren het ‘lichaamsvreemde’ getransplan-
teerde orgaan te vernietigen. Om deze af-
stotingsreactie te voorkomen of in ieder
geval te onderdrukken, zijn er sinds de
zestiger jaren verschillende medicijnen
ontwikkeld met afweeronderdrukkende
eigenschappen (zgn. immuunsuppres-
siva). Aanvankelijk waren deze medi-
cijnen niet krachtig genoeg om de afsto-
tingsreactie te onderdrukken, maar aan het
einde van de jaren ’70 kwam er een grote
doorbraak met het beschikbaar komen van
cyclosporine A (CsA). CsA is een eiwit
dat geproduceerd wordt door schimmels
en dat met name de activering en vermeer-
dering van T-cellen remt. T-cellen vormen
de belangrijkste cellen binnen het af-
weersysteem, die verantwoordelijk zijn
voor de afstoting van getransplanteerde
organen. Sinds het gebruik van CsA heeft
er een aanzienlijke verbetering plaatsge-
vonden in met name de korte termijn (<1
jaar) transplantaatoverleving. Echter, on-
danks het gebruik van CsA en meer re-
cent ontwikkelde afweeronderdrukkende
medicijnen (bv. FK506 en rapamycine) is
de transplantaatoverleving op de langere
termijn (>1 jaar) niet of nauwelijks ver-
beterd. Heden ten dage is de ontwikke-
ling van chronische transplantaatdisfunc-
tie (CTD) de belangrijkste oorzaak van
transplantaatfalen in de periode >1 jaar
na transplantatie. Op dit moment kan CTD
niet voorkómen of behandeld worden met
de afweeronderdrukkende medicijnen die
vandaag de dag gebruikt worden om af-
stoting in de vroege fase (zgn. acute af-
stoting) te voorkomen.
Chronische transplantaatdisfunctie
(CTD)
CTD kan gedefinieerd worden als een
voortdurende, onomkeerbare achteruit-
gang van de functie van het getransplan-
teerde orgaan, wat uiteindelijk resulteert
in de noodzaak om over te stappen op ver-
vangende therapie indien dit mogelijk is,
of om te gaan hertransplanteren. Alleen
in het geval van CTD na een niertrans-
plantatie kan er teruggevallen wor-den op
een vervangende therapie (haemodialyse).
In geval van CTD in getransplanteerde
harten en longen is er géén vervangende
therapie voorhanden en zal de patiënt ge-
hertransplanteerd moeten worden om
vroegtijdig overlijden te voorkomen.
Transplantaat arteriosclerose
De reden waarom CTD zich uiteindelijk
ontwikkelt is niet geheel duidelijk, maar
de algemene gedachte is dat veranderin-
gen in de bloedvaten in het getransplan-
teerde orgaan hier een belangrijke rol bij
spelen. Wanneer er op microscopisch ni-189
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veau naar het weefsel van organen met
CTD gekeken wordt, dan blijkt dat er niet
alleen orgaangebonden veranderingen
aanwezig zijn, maar ook een verandering
die in alle organen voorkomt. In alle ge-
transplanteerde organen (hart, nier en
long) worden namelijk vernauwingen in
de bloedvaten aangetroffen, een kenmerk
dat transplantaat-arteriosclerose (TA) ge-
noemd wordt. De algemene gedachte is,
dat als gevolg van de vaatvernauwingen
er onvoldoende zuurstof en voedings-
stoffen in de achter de vernauwing gele-
gen gebieden komen (ischemie), wat
uiteindelijk zal resulteren in weef-
selschade en dus het ontstaan van CTD.
Figuur 1A toont een foto van een normale
kransslagader (zgn. coronair arterie), ter-
wijl Figuur 1B een typisch voorbeeld laat
zien van TA in een kransslagader zoals
die aangetroffen kan worden in een
getransplanteerd hart. Het is duidelijk te
zien dat het gezonde vat mooi open is en
voor het bloed doorgankelijk, terwijl in
het vat met TA de holte, waar het bloed
doorheen stroomt, helemaal verdwenen is.
Kransslagader
gezond (normaal)
A
M
EI
Kransslagader met
transplantaat-arteriosclerose
B
EI
NI
MC
AC
Figuur 1. Microscopische opname van een normale, gezonde, kransslagader (A) en een kransslagader
met een ernstige vorm van transplantaat-arteriosclerose (B). Deze opnames zijn gemaakt van respec-
tievelijk gezond hartspierweefsel en een getransplanteerd hart (rat). De aanwezigheid van een ernstig
verdikte intima (neointima) is karakteristiek voor transplantaat arteriosclerose. De neointima bestaat
met name uit α-actine positieve spiercellen die in dit preparaat met een α-actine specifieke kleuring zijn
aangekleurd. Tevens wordt transplantaat-arteriosclerose gekenmerkt door de continue aanwezigheid
van afweercellen rondom de bloedvaten. Afkortingen: EI, elastica interna (binnenste elastinemembraan
op de grens van media naar intima); M, media (elastine membranen met daartussen de α-actine posi-
tieve gladde spiercellen); MC, myocard (hartspierweefsel); AC, afweercellen. Vergroting: x200190
Deze vernauwing in het bloedvat wordt
een neointima genoemd: een nieuw ge-
vormde cellaag die zich in de binnenste
laag van het bloedvat, de intima, heeft
ontwikkeld. Hoewel Figuur 1 foto’s laat
zien van hartweefsel van een rat, vertonen
de getoonde bloedvatafwijkingen zeer
grote gelijkenis met de afwijkingen in
menselijk hartweefsel.
Oorzaken en mechanisme van de
ontwikkeling van transplantaat-arterio-
sclerose
Hoewel er in de afgelopen jaren verschil-
lende factoren geïdentificeerd zijn die een
risico vormen voor de ontwikkeling van
TA, is het precieze mechanisme, dat ten
grondslag ligt aan TA, nog grotendeels
onbekend. De risicofactoren voor TA kun-
nen grofweg in 4 groepen worden onder-
verdeeld:
1. alloantigeen afhankelijke factoren (o.a.
weefselincompatibiliteit [mate van
‘vreemdheid’] tussen donor en ont
vanger, aantal en ernst van acute
afstotingsreacties)
2. donor-afhankelijke factoren (o.a. mate
van weefselbeschadiging als gevolg
van ischemie [zuurstof/voedingsstof
tekort] vóór transplantatie, hersendood
en leeftijd)
3. ontvanger-afhankelijke factoren (o.a.
hoge bloeddruk, hyperlipidemie [hoog
cholesterol])
4. virale infecties (met name cytomega-
lovirus [CMV])
Hoewel het precieze mechanisme, dat ten
grondslag ligt aan TA ontwikkeling nog
voor een belangrijk deel onbekend is, lijkt
het centrale element ‘schade’ aan de
bloedvaten in het transplantaat te zijn. Het
veronderstelde mechanisme, dat uiteinde-
lijk leidt tot de ontwikkeling van TA en
CTD zal hieronder nader worden toege-
licht.
Zelfs vóórdat het te transplanteren orgaan
uit de potentiële donor is verwijderd, kan
er als gevolg van hersendood van de do-
nor al activatie en schade van de binnen-
bekleding van het bloedvat (zgn. endo-
theelcellen) hebben plaatsgevonden. Ver-
volgens wordt het orgaan verwijderd en
zal het naar de kliniek getransporteerd
moeten worden, waar de werkelijke trans-
plantatie wordt uitgevoerd. Gedurende
deze periode wordt het orgaan gekoeld
bewaard in een speciale vloeistof (preser-
vatievloeistof). Deze procedure dient er
toe om de schade als gevolg van ische-
mie (zuurstof/voedingsstoffen tekort van
het weefsel) te beperken. Desondanks
veroorzaakt deze ischemische periode, die
enkele uren kan duren, verdere schade aan
de binnenbekleding van het bloedvat. Na
de transplantatie wordt het getransplan-
teerde orgaan op de bloedcirculatie van
de ontvanger aangesloten (reperfusie),
waarbij verdere schade kan optreden.
De belangrijkste schade wordt echter
toegebracht in de periode na de transplan-
tatie als gevolg van de afstotingsreactie
van het afweersysteem van de ontvanger,
die gericht is tegen het ‘lichaamsvreemde’
getransplanteerde orgaan. Naast een al-
gehele ontstekingsreactie in het weefsel
van het getransplanteerde orgaan wordt
deze afstotingsreactie met name geken-
merkt door een ontsteking in het gebied
rond de bloedvaten (perivasculitis) en een
reactie gericht tegen de endotheelcellen
(binnenbekleding van het bloedvat).191
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In Figuur 2 staat de tot nu toe geldende
gedachte over de ontwikkeling van TA
schematisch weergegeven. Als gevolg van
de perivasculitis (ontsteking van de
buitenwand van de bloedvaten [adventi-
tia]), alsmede door activatie en bescha-
diging van het endotheel, raken de spier-
cellen (Engels: Vascular Smooth Muscle
cells [VSM cells]) in de spierwand van
het bloedvat [media] beschadigd. Deze
spiercellen, tezamen met de elastinemem-
branen waar ze tussen liggen in de spier-
wand van het bloedvat, vervullen een be-
langrijke functie bij de regulatie van de
bloeddruk en mate van doorstroming van
het vat. De hypothese luidt, dat, als ge-
volg van de ontstekingsreactie, de spier-
cellen in de spierwand gedeeltelijk dood-
gaan en verdwijnen. Onder invloed van
verschillende groeifactoren worden de
resterende spiercellen aangezet tot ver-
plaatsing en deling in de subendotheliale
ruimte (het deel van de intima net onder
het endotheel). Dit heeft tot gevolg dat
de spierwand nu alleen nog bestaat uit
elastinemembranen, terwijl er in de inti-
ma nu spiercellen zitten die ongecon-
troleerd gaan delen, hetgeen uiteindelijk
leidt tot neointima-vorming en resulte-
rend in vernauwing van de bloeddoor-
stromende holte van het bloedvat en ver-
volgens functieverlies van het getrans-
planteerde orgaan. Een belangrijk punt in
dit proces is, dat, volgens deze hypo-
these, de spiercellen in de neointima dus
uit de bloedvatwand zelf afkomstig zijn,
hetgeen betekent dat ze van de donor
afkomstig zijn.
Dit proefschrift
De doelstelling van het onderzoek be-
schreven in dit proefschrift was, zoals de
titel al zegt, het verkrijgen van meer in-
zicht in de manier waarop verschillende
risicofactoren de ontwikkeling van TA
beïnvloeden. Daarnaast is getracht meer
ontstekings/afweercellen
spiercellen (VSM cellen)
endotheelcellen (EC's)
Verondersteld mechanisme van de ontwikkeling van
transplantaat-arteriosclerose na orgaantransplantatie
transplantaat
arteriosclerose
voor transplantatie na transplantatie
tunica adventitia
tunica media
tunica intima
lumen
perivasculitis (ontsteking
van de adventitia)
neointima vorming
(spiercellen en macrofagen)
afsterven van spier-
cellen in de media
en migratie naar de 
subendotheliale ruimte
Figuur 2. Verondersteld mechanisme waarvan  men tegenwoordig denkt dat transplantaat-arteriosclero-
se zich na orgaantransplantatie ontwikkelt.192
inzicht te krijgen in de precieze mecha-
nismen die uiteindelijk leiden tot de ver-
nauwing van de bloedvaten. Daarbij is met
name de herkomst van de belangrijkste
cellen in de neointima, de spiercellen
(VSM cellen) en endotheel cellen (EC’s),
bestudeerd: zijn deze inderdaad afkomstig
van de donor (huidige hypothese) of mis-
schien van de ontvanger?
Om deze vraagstellingen te kunnen beant-
woorden, zijn experimenten uitgevoerd in
verschillende transplantatiemodellen in de
rat. Aan de hand van de resultaten zijn er
nieuwe inzichten verkregen in het mecha-
nisme, dat ten grondslag ligt aan de
ontwikkeling van TA en de manier waarop
de verschillende risicofactoren hierop
zouden kunnen aangrijpen.
De onderstaande tekst geeft een samen-
vatting van de inhoud van de verschil-
lende hoofdstukken, zoals die in het proef-
schrift beschreven staan.
In Hoofdstuk 1 staat een algemene in-
leiding beschreven, waarin de klinische
en microscopisch zichtbare kenmerken
van CTD de revue passeren. Daarnaast
wor-den de tot nu toe bekende risico-
factoren voor de ontwikkeling van TA en
CTD uitvoerig besproken en wordt het
alom geaccepteerde, hypothetische me-
chanisme dat ten grondslag ligt aan de
ontwikkeling van TA, gepresenteerd. Het
hoofdstuk besluit met een beschrijving
van de verschillende onderzoeksvragen
die de basis gevormd hebben voor dit
proefschrift.
Zoals reeds eerder naar voren is ge-
bracht, is de afstotingsreactie (alloreactivi-
teit) van de ontvanger tegen het transplan-
taat de grootste boosdoener in het ontstaan
van TA. Een manier om TA te voorkomen
zou dus het wegnemen van deze afsto-
tingsreactie zijn. Het volledig onderdruk-
ken van het afweersysteem m.b.v. af-
weer onderdrukkende medicijnen blijkt in
de klinische praktijk niet mogelijk. Deze
medicijnen hebben bij langdurig gebruik
in hoge concentraties schadelijke bij-
werkingen. Een andere manier om de af-
stotingsreactie weg te nemen, is het op-
wekken van tolerantie tegen het getrans-
planteerde orgaan; m.a.w. het afweer-
systeem van de ontvanger herkent het ge-
transplanteerde orgaan niet meer als li-
chaamsvreemd. Enkele jaren geleden is
er op ons laboratorium een protocol
ontwikkeld waarbij door middel van het
in de thymus [zwezerik] aanbrengen van
donor-afkomstige cellen en een kort-
durende behandeling met afweeronder-
drukkende medicijnen, acute afstoting van
‘lichaamsvreemde’ harten voorkomen kan
worden. In Hoofdstuk 2 is echter aange-
toond, dat, ondanks het feit dat deze be-
handeling acute afstoting voorkomt, het
de ontwikkeling van TA niet voorkomen
kan. Bij microscopische analyse van de
morfologie van kransslagaders in hart-
weefsel op verschillende tijdstippen na
transplantatie, bleek, dat er al vanaf en-
kele weken na transplantatie een begin
van TA in deze vaten kon worden waar-
genomen. Het aantal vaten met TA en de
ernst van TA namen toe naarmate het
transplantaat langer bleef zitten. Experi-
menten die in het laboratorium zijn uit-
gevoerd toonden aan dat de afweercellen
van de ontvangerratten na toediening van
donorcellen in de thymus nog steeds een
afweerreactie vertoonden tegen cellen van
de donor. Analyse van de productie van
verschillende eiwitten, die betrokken zijn
bij de werking van het afweersysteem (cy-
tokines) in het getransplanteerde
hartweefsel, toonde aan dat met name het193
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type afstotingsreactie tegen het transplan-
taat veranderd was als gevolg van de be-
handeling. De ontwikkeling van TA wordt
dus niet voorkomen door toediening van
donorcellen in de thymus en zou zelfs,
door verandering van het type afstotings-
reactie tegen het transplantaat, de ont-
wikkeling van TA kunnen bevorderen.
In Hoofdstuk 3 is gebruik gemaakt van
hetzelfde protocol als in Hoofdstuk 2, al-
leen is er nu geen orgaan (hart) getrans-
planteerd dat aangesloten werd op de
bloedcirculatie van de ontvanger, maar
zijn er weefsels (huid en neonataal hart-
spierweefsel) getransplanteerd, die niet op
de circulatie werden aangesloten. In
tegenstelling tot de op de circulatie aan-
gesloten harten bleek toediening van do-
norcellen in de thymus de overleving van
‘lichaamsvreemde’ huidtransplantaten
niet te verlengen. De overleving van neo-
nataal hartspierweefsel, dat in een pocket
onder de huid boven op het oor werd ge-
ïmplanteerd, werd wel significant ver-
lengd als gevolg van deze behandeling.
Microscopische analyse van dit neonatale
hartspierweefsel toonde aan, dat de oor-
spronkelijke kransslagaders niet meer
aanwezig waren, terwijl er wel nieuw ge-
vormde grote bloedvatstructuren (aderen)
zichtbaar waren. Deze nieuw gevormde
vaten zijn ontstaan in en uit het neonatale
hartspierweefsel zélf. In tegenstelling tot
de kransslagaders in op de circulatie
aangesloten harten, vertoonden de nieuw
gevormde vaatstructuren in neonataal
hartspierweefsel geen tekenen van TA.
Deze resultaten suggereren, dat het type
bloedvat en de functie daarvan (krans-
slagader versus  ader) bepalend is voor
het wel of niet ontwikkelen van TA.
Naast het feit dat de afstotingsreactie
van de ontvanger tegen het transplantaat
de belangrijkste factor in de ontwikke-
ling van TA lijkt te zijn, is er ook nog een
aantal andere risicofactoren, dat mogelijk
betrokken is bij de ontwikkeling van TA.
Een van deze factoren is infectie met cy-
tomegalovirus (CMV). In Hoofdstuk 4 is
het effect van timing van Rat CMV
(RCMV)-infectie op de ontwikkeling van
TA in allogene aorta-transplantaten onder-
zocht. Na ‘lichaamsvreemde’ aorta-trans-
plantatie bleek de snelheid van TA
ontwikkeling afhankelijk te zijn van de
rattenstamcombinatie die gebruikt werd.
Brown Norway (BN) ontvanger-ratten
ontwikkelden veel sneller TA dan Lewis
(Lew) ontvanger-ratten. BN-ratten kun-
nen daarom ‘fast TA responders’ genoemd
worden, terwijl Lew-ratten ‘slow TA re-
sponders’ zijn. Omdat er verondersteld
wordt dat CMV de ontwikkeling van TA
versnelt, is het effect van timing van in-
fectie onderzocht in Lew ontvanger-rat-
ten. Infectie met RCMV bleek alleen de
ontwikkeling van TA te versterken, in-
dien de ontvanger ratten kort na transplan-
tatie (1-5 dagen) geïnfecteerd werden. In-
fectie 3 weken vóór of na transplantatie
bleek de ontwikkeling van TA niet te beïn-
vloeden. Deze resultaten suggereren, dat
de acute virus infectie en de acute afsto-
tingsreactie tegelijkertijd moeten plaats-
vinden. Dit zou kunnen betekenen, dat
RCMV de ontwikkeling van TA bevordert
door verheviging van de op gang ko-
mende acute afstotingsreactie tegen het
transplantaat. Dit effect van RCMV kan
echter niet gegeneraliseerd worden, aan-
gezien RCMV de ontwikkeling van TA
niet beïnvloedt in andere ‘slow TA-re-
sponder’ stamcombinaties. Klaarblijke-
lijk zijn er nog andere factoren dan de ti-
ming van infectie en de mate van aan-
vankelijke TA ont-wikkeling, die bepalen194
of RCMV de ontwikkeling van TA al dan
niet versterkt.
In Hoofdstuk 4 was reeds aangetoond
dat er verschillen bestaan in de snelheid
waarmee TA tot ontwikkeling komt in
verschillende stamcombinaties. In Hoofd-
stuk 5 is verder onderzocht welke factoren
voor dit verschil verantwoordelijk zijn,
waarbij er onderscheid is gemaakt tussen
MHC (Engels: Major Histocompatibility
Complex)- en niet-MHC gecodeerde de-
terminanten in de ontvanger-rat. Het
MHC omvat een groep genen, die teza-
men coderen voor een eiwitcomplex, dat
voor ieder individu uniek is en om-
schreven kan worden als een zgn.
Vreemdheids Bepalend Eiwit (VBE).
Deze VBE’s zijn de belangrijkste eiwit-
ten, die verantwoorde-lijk zijn voor het
opwekken van een af-stotingsreactie na
transplantatie. Echter binnen het MHC
liggen ook genen die voor andere eiwit-
ten dan de VBE’s coderen en die mogelijk
betrokken zijn bij de ontwikkeling van
TA. Alle overige genen, die niet binnen
het MHC vallen kunnen als niet-MHC
omschreven worden.
Het bleek dat de snelle ontwikkeling van
TA in BN ratten bepaald wordt door niet-
MHC gecodeerde factoren aangezien
MHC-congene BN.1L ontvanger-ratten
(BN ratten met het Lew MHC i.p.v. het
BN MHC) waarin een bloedvat van een
BN of Lew rat werd getransplanteerd, ook
dezelfde snelle TA ontwikkeling lieten
zien. Welke niet-MHC gecodeerde fac-
toren hier precies voor verantwoordelijk
zijn is nog onduidelijk.
Ongecontroleerde celdeling van spier-
cellen in de neointima wordt gezien als
de centrale gebeurtenis gedurende de
ontwikkeling van TA, wat uiteindelijk re-
sulteert in volledige afsluiting van de
bloedvaten in het transplantaat. Zoals in
de inleiding van dit hoofdstuk reeds naar
voren is gebracht, is de algemeen geac-
cepteerde en toegepaste werkhypothese
dat de spiercellen in de neointima afkom-
stig zijn uit de spierwand (media) van het
betreffende bloedvat. Volgens deze hy-
pothese zijn zowel de spiercellen (VSM
cellen), als de endotheelcellen (EC’s) in
de neointima van de donor afkomstig (zie
ook Figuur 2).
In Hoofdstuk 6 en Hoofdstuk 7 is deze
hypothese getoetst en is onderzocht of de
endotheelcellen en spiercellen in de neo-
intima in aorta- en harttransplantaten in-
derdaad van de donor afkomstig zijn.
Door middel van specifieke kleuringen
gericht tegen de stamspecifieke Vreemd-
heids Bepalende Eiwitten (VBE’s) van de
donor en de ontvanger is echter aange-
toond, dat de endotheelcellen in aorta-
transplantaten niet van de donor, maar van
de ontvanger afkomstig zijn. Dit bete-
kent dat er in deze transplantaten dus ver-
vanging heeft plaatsgevonden van het oor-
spronkelijke endotheel met endotheel-
cellen, die uit de ontvanger-rat afkomstig
zijn. In tegenstelling tot de aorta-trans-
plantaten zijn de endotheelcellen in ge-
transplanteerde harten nog steeds van de
donor afkomstig, wat aangeeft dat er in
deze harten géén vervanging van het en-
dotheel heeft plaatsgevonden. Dit verschil
tussen aorta- en harttransplantaten heeft
mogelijk te maken met het feit, dat in het
geval van aortatransplantatie niet behan-
deld wordt met afweeronderdrukkende
medicijnen, terwijl in het geval van
harttransplantatie de afstotingsreactie
wordt beïnvloed door de toediening van
donorcellen in de thymus en kortdurende
behandeling met afweeronderdrukkende
medicijnen (zie ook Hoofdstuk 2). De195
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door de afstotingsreactie toegebrachte
schade aan de vaatwand in het transplan-
taat zou daardoor groter kunnen zijn in
aorta’s dan in de harten, met als gevolg,
dat in de aorta’s het endotheel vervangen
moet worden en in de harten niet. Ver-
vanging van donor endotheelcellen met
ontvanger endotheel lijkt dan ook een
maat te zijn voor de ernst van de primair
aangerichte vaatschade.
In zowel de getransplanteerde aorta’s
(Hoofdstuk 6) als de getransplanteerde
harten (Hoofdstuk 2 & Hoofdstuk 6)
ontwikkelde er zich ernstige TA, wat aan-
geeft, dat vervanging van het endotheel
niet een directe vereiste is voor de uitein-
delijke ontwikkeling van TA.
Met behulp van een specifieke analyse
van het DNA, dat in de celkernen van de
spiercellen in de neointima zit werd ver-
volgens de afkomst (donor versus ont-
vanger) van deze cellen in de neointima
van getransplanteerde aorta’s (Hoofdstuk
6) en getransplanteerde harten (Hoofdstuk
7) onderzocht. Daartoe werd een me-
thode ontwikkeld die het mogelijk maakte
specifiek een deel van het Y-chromosoom,
dat alleen bij mannen aanwezig is, aan te
tonen. Aangezien alle transplantaties
waren uitgevoerd met vrouwelijke do-
noren en mannelijke ontvangers was het
mogelijk specifiek mannelijke, en dus
ontvanger-cellen aan te tonen. In zowel
de getransplanteerde aorta’s als de harten
bleken de spiercellen in de neointima niet
van de donor (vrouwelijke rat) maar van
de ontvanger (mannelijke rat) afkomstig
te zijn, en deze resultaten werden beves-
tigd door een soortgelijke methode, die
gebaseerd was op een ander verschil tus-
sen donor en ontvanger dan het man/
vrouw verschil.
Aangezien in Hoofdstuk 6 werd aange-
toond, dat zowel de endotheelcellen als
de spiercellen in de neointima in aor-
tatransplantaten van de ontvanger afko-
mstig zijn, werd in Hoofdstuk 8 onder-
zocht waar deze cellen dan precies van-
daan komen: zijn ze afkomstig uit het
beenmerg (bron van alle bloedcellen) of
niet. Om deze vraag te beantwoorden
werd er gebruik gemaakt van ontvanger-
ratten die 6 weken voor de aortatransplan-
tatie een beenmergtransplantatie hadden
ondergaan. Confocale laserscanning mi-
croscopie toonde aan, dat in reeds gevor-
derde TA de endotheelcellen in hoofdzaak
niet uit het beenmerg afkomstig zijn. En-
kele beenmergafkomstige endotheelcellen
werden echter aangetoond in het begin
stadium van TA ontwikkeling, wat aan-
geeft, dat deze beenmergafkomstige en-
dotheelcellen wel een rol zouden kunnen
spelen in deze beginfase. Ook de spier-
cellen in de neointima zijn voor het me-
rendeel niet afkomstig uit het beenmerg.
Deze resultaten suggereren dat met name
een niet-beenmerg afhankelijke bron de
endotheelcellen en spiercellen levert ge-
durende de ontwikkeling van TA. De be-
vindingen die staan beschreven in de
Hoofdstukken 6, 7 en 8, te weten dat de
endotheelcellen en spiercellen in de neo-
intima niet van de donor afkomstig zijn
(zie Figuur 2), maar van de ontvanger,
staan schematisch weergegeven in Figuur
3. In tegenstelling tot de algemeen gehan-
teerde werkhypothese, dat de endotheel-
cellen en spiercellen afkomstig zijn van
de donor, suggereren de resultaten bes-
chreven in dit proefschrift dat deze cellen
afkomstig zijn vanuit de bloedcirculatie
van de ontvanger.
In Hoofdstuk 9 worden de resultaten
zoals die staan beschreven in dit proef-
schrift bediscussieerd en wordt de onder-196
linge samenhang tussen de verschillende
hoofdstukken weergegeven. Aan de hand
van de verkregen resultaten wordt er een
reeks van gebeurtenissen van voor, tijdens
en na de transplantatie geopperd, die
uiteindelijk leidt tot het ontstaan van TA
en dus CTD. Gebaseerd op deze opeen-
volging van gebeurtenissen is er een aan-
tal mogelijke aangrijpingspunten naar
voren gekomen, waarop zich nieuwe the-
rapeutische strategieën kunnen richten,
om TA in de toekomst te voorkomen dan
wel te behandelen.
Tot slot wordt er een nieuwe zienswijze
op de ontwikkeling van TA naar voren ge-
bracht welke inhoudt dat, in plaats van
TA te beschouwen als een ongewenste ge-
beurtenis na orgaantransplantatie, het
proces, dat hieraan ten grondslag ligt, in
Herzien mechanisme van de ontwikkeling van
transplantaat-arteriosclerose na orgaantransplantatie
ontstekings/afweercellen
spiercellen (VSM cellen)
endotheelcellen (EC's)
perivasculitis (ontsteking
van de adventitia)
afsterven van donor-
spiercellen in de media
vervanging van donor-endotheel
met ontvanger (voorloper) cellen
vanuit het bloed
neointima vorming met
ontvanger (voorloper)-spiercellen
afkomstig vanuit het bloed
beginsel juist gewenst is. Dit proces, dat
uiteindelijk leidt tot TA, is in principe
onderdeel van een ‘normaal’ herstelme-
chanisme in een poging de functie van het
beschadigde bloedvat (functie van de
spierwand [media] is verdwenen) te her-
stellen. Echter, in het geval van TA loopt
dit herstelproces uiteindelijk volledig uit
de hand met de ontwikkeling van CTD
tot gevolg. Onderzoek gericht op het
ontwikkelen van nieuwe behandelings-
strategieën zou zich derhalve voorna-
melijk moeten richten op het voorkomen
van het afsterven van de spiercellen in de
media, en het identificeren van de factoren
die verantwoordelijk zijn voor de onge-
controleerde deling van de spiercellen in
de neointima.
Figuur 3. Herzien mechanisme van de ontwikkeling van transplantaat-arteriosclerose, opgesteld aan de
hand van de bevindingen, zoals die staan beschreven in dit proefschrift. Belangrijk verschil met de tot
dusver gehanteerde hypothese (zie ook Figuur 2) is dat zowel het endotheel, als de spiercellen in de
neointima vanuit het bloed van de ontvanger afkomstig zijn.197
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